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ACN: acetonitrile  
DCM: dichloromethane  
DIC: N,N’-diisopropylcarbodimide  
DIPEA: ethyldiisopropilamine  
DMF: N,N’-dimethylformamide  
Fmoc: 9-fluorenylmethoxycarbonyl  
HATU:aO-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
hexafluorophosphate  
HFIP: hexafluoroisopropanol  
TIS: triisopropylsilane 
RP-HPLC: reversed-phase high-performance liquid chromatography
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1 INTRODUCTION  
 
1.1  Cyclopeptides 
1.1.1 Importance of cyclopeptides 
Cyclopeptides are a class of molecules which assume a 
great importance in the role of host defense molecules in 
many natural organisms (e.g. plants, marine species).
1
 
Notably, men have used cyclopeptides as leading molecules 
in the therapeutic field due to the fact that they have 
significantly contributed  to combat widespread and common 
diseases. For istance, vancomycin (1) and cyclosporin A (2) 
are classic therapeutic cyclopeptides (figure 1.1). The greater 
therapeutic importance of cyclopeptides with respect to linear 
peptides can be explained making reference to their higher 
resistance to in vivo enzymatic degradation, enhanced 
bioactivity, higher conformational stability which confers a 




In general, cyclopeptides are very versatile and 
promising molecules which are characterized by wide-ranging 
                                                 
1 D. J. Craik, N. L. Daly, I. Saska, M. Trabi, K. Rosengren J. Bacteriol., 2003, 185, 4011-
4021. 
2 M. Katsara, T. Tselios, S. Deraos, G. Deraos, M. T. Matsoukas, E. Lazoura, J. Matsoukas, 
V. Apostolopoulos Current Medicinal Chemistry, 2006, 13, 2221-2232. 




applications in the field of biomedicine and in 
nanotechnology. 
 With respect to the biomedical applications, 
cyclopeptides are currently used in the clinic as antibacterials, 
analgesics, ionophores, chemioterapics.
3
 In addition, studies 
in connection with the use of  these compounds as 
immunotherapeutic vaccines for diabetes and autoimmune 
diseases, therapeutic agents for skin disorders, modulators of 
protein-protein interactions, and molecular scaffolds for the 



































































Figure 1.1: Structure of vancomycin (1) and cyclosporin A (2). 
1.1.2 Biologically active cyclopeptides 
Taking into account the above considerations there is a 
significant number of cyclopeptides presenting different 
biological activities and some of them find use in 
                                                 
3 H. K. Kruger, F. Albericio Future Med. Chem., 2012, 4, 1527-1531. 
4 S. Namyoshi, H. A. Benson Biopolymers, 2010, 94, 673-680; D. J. Craik, S. Simonsen, N. 
L. Daly Current Opinion in Drug Discovery & Development, 2002, 5, 251-260. 




pharmaceutical industry. Some intriguing examples are 
reported below. 
Azumamides A- E, five cyclotetrapeptides isolated by 
Fusetani et al. from the marine sponge Mycale izuensis, 




Histone deacetylases (HDACs) are a family of 
metalloenzymes regulating transcriptional processes, 
apoptosis, cell-cycle progression, and angiogenesis.
6
 
The modulation of histone modifying enzymes is recognized 
as a crucial factor for the epigenetic control of oncogene 
transcription and the activation of tumor repressors.
7
 These 
synergic effects can induce growth arrest of cancer cells 
rendering HDAC inhibitors promising candidates for the 
development of specific, noncytotoxic antitumor compounds. 
HDAC inhibitors are divided in six distinct groups of zinc 
chelators.
8
 Amongst them, azumamides belong to the small 
family of hydrophobic cyclotetrapeptides. Structurally, they 
include four nonribosomal amino acid residues, three of 
which are α-amino acids of the D series (D-Phe, D-Tyr, D-
Ala, D-Val), while the fourth one is a unique β-amino acid, 
assigned as (Z)-(2S,3R)-3-amino-2-methyl-5-nonenedioic acid 
                                                 
5 Y. Nakao, S. Yoshida, S. Matsunaga, N. Shindoh, Y. Terada, K. Nagai, J. K. Yamashita, A. 
Ganesan, R. W. M.  van Soest, N. Fusetani Angew. Chem. Int. Ed., 2006, 45, 7553-7557. 
6 F. Guo, C. Sigua, J. Tao, P. Bali, P. Gorge, Y. Li, S. Wittmann, L. Moscinski, P. Atadja, K. 
Bhalla Cancer Res., 2004, 64, 2580-2589. 
7 M. Biel, V. Washolowski, A. Giannis, Angew. Chem. Int. Ed., 2005,  44, 3186 – 3216. 
8 T. A. Miller, D. J. Witter, S. J. Belvedere Med. Chem., 2003, 46, 5097-5116.  




9-amide (Amnaa) in azumamides A (3), B (4), and D (6), and 
as (Z)-(2S,3R)-3-amino-2-methyl-5-nonendioic acid (Amnda) 










Figure 1.2: Structures of azumamides A-E.
 
 
The total synthesis of azumamides A and E was 
successful performed by De Riccardis et al. in 2006, allowing 




 Recently, the bicyclic depsipeptide romidepsin, a 
natural HDAC inhibitor obtained from Chromobacterium 
violaceum bacterium and isolated from a Japanese soil 
sample, was approved for the treatment of cutaneous T-cell 
lymphoma.
10
 It contains one proteinogenic (L-Val) and three 
non-proteinogenic aminoacids (D-Val, D-Cys, Z-
dehydrobutyrine) in combination with a hydroxy-heptenoic 
                                                 
9 I. Izzo, N. Maulucci, G. Bifulco, F. De Riccardis Angew. Chem. Int. Ed., 2006, 45, 7557-
7560. 
10 V. Baeriswyl, C. Heinis Chem. Med. Chem., 2013, 8, 377-384. 
 
 
R1 R2 R3 
   
A (3) NH2  H CH3 
B (4)                NH2 OH CH3 
C (5)                    OH OH CH3 
D (6)                    NH2 H H 















acid moiety bearing the second thiol group (figure 1.3). The 
mechanism of action of romidepsin consists in the initial 
reduction of its disulfide bond by glutathione in the cell so 
that a zinc binding thiol is produced. Finally, the thiol 
interacts with a zinc ion in the active site of class I and II 

















Figure 1.3: Structure of romidepsin. 
 An interesting class of cyclopeptides with biological 
activities are head-to-side chain cyclodepsipeptides. These 
peptides are characterized by a special structural arrangement 
in which the cyclization is realized through an ester bond 
between the C-terminus and a β-hydroxyl group. 
In 2013 Albericio et. al. reported the first total synthesis of 
pipecolidepsin A (figure 1.4), an head-to-side chain 
cyclodepsipeptide isolated from the marine sponge 
Homophymia lamellose, which exhibits good cytotoxic 
properties in vitro against specific lung, colon and breast 




human tumour cell lines.
11
  This compound contains many 
unnatural amminoacids and the most intriguing residue is the 
bulky γ-branched β-hydroxy-α-aminoacid D-allo-(2R,3R,4R)-
2-amino-3-hydroxy-4,5-dimethylhexanoic acid (AHDMHA). 
The β-hydroxyl group of AHDMHA residue allows the 











































Figure 1.4: Structure of pipecolidepsin A. 
Another intriguing class of biologically active 
cyclopeptides are cyclotides, a novel class of polycyclic 
peptides of vegetal origin which have drawn a great interest 
due to their potential application in drug design. 
Cyclotides are small (~30 amino acids), disulfide-rich 
peptides that were originally discovered in plants of the 
                                                 
11 M. Pelay-Gimeno, Y. Garcia-Ramos, M. J. Martin, J. Sprengler, J. M. Molina-Guijarro, S. 
Munt, A. M. Francesch, C. Cuevas, J. Tulla-Puche, F. Albericio Nature Comm., 2013, DOI: 
10.1038/ncomms3352. 




Rubiaceae (coffee) and Violaceae (violet) families.
12
 The 
archetype cyclotide, kalata B1, is just one member of a very 
large family. The feature that combines all cyclotides is their 
head-to-tail cyclic backbone and three conserved disulfide 
bonds that form a special knotted motif, formally defined as 
‘cyclic cystine knot’ (CCK). In particular, the CCK topology 
is characterized by the presence of an embedded ring, formed 
by two disulfide bridges and their connecting backbone 
segments, which is threaded by a third disulfide bond. Figure 
1.5 shows the structure of kalata B1 (10), highlighting the 
CCK motif. The backbone segments between successive 
cysteine residues are named loops (numbered 1-6), and 
generally the loop sequences are amenable to substitution.  
                   
10 
Figure 1.5: Structure of kalata B1 (10). Panel A shows the NMR structure 
and panel B illustrates a schematic representation of the topology of the 
cyclic cystine knot (CCK) motif characteristic of cyclotides. The 
framework also incorporates a triple-stranded β-sheet, indicated by the 
arrows. 
  Cyclotides in turn fall into three subfamilies, known as 
Möbius, bracelet and trypsin inhibitor subfamilies (figure 
1.6). Anyway, a common feature of cyclotides from all three 
                                                 
12 D. J. Craik, N. L. Daly, T. Bond, C. Waine J. Mol. Biol., 1999, 294, 1327-1336. 




subfamilies is their excellent stability. For example, a 
cyclotide solution can be boiled without the peptide being 
denatured. This stability is ascribed to the CCK core.   
 
Figure 1.6: Subfamilies of cyclotides. The Möbius and bracelet 
subfamilies are defined on the basis of the presence (Möbius) or absence 
(bracelet) of a conceptual twist in the circular backbone deriving from a 
cis-peptide bond, preceding a Pro residue in loop 5. The trypsin inhibitor 
subfamily was named as so after that was discovered a trypsin inhibiting 




Cyclotides exhibit a wide range of biological 
activities, including antiviral, antifungal and antibacterial 
activities. However, most interest in cyclotides has derived 
from their usability in drug design as robust molecular 
scaffolds. 
 Recently, it was proposed the strategy of grafting 
small bioactive peptide epitopes into turns in the CCK 
framework in order to stabilize them.
14
 In this way it is 
possible to overcome the problem of the poor bioavailability 
of peptides, which limits their development as oral 
therapeutics.  
                                                 
13 N. L. Daly, D. J. Craik J. Biomol. Chem., 2001, 276, 22875-22882. 
14 D. J. Craik, J. S. Mylne, N. L. Daly Cell. Mol. Life Sci., 2010, 67, 9-16. 




 There are many recent examples of grafting in 
cylotides reported from Craik and other groups.
15
 These 
include applications in the field of cancer, cardiovascular 
disease, wound healing, infectious disease and inflammatory 
pain.  An intrigous grafting study involved the insertion of a 
tetrapeptide sequence from the hormone α-MSH into kalata 
B1.
16
 The resultant mutant peptide was characterized by a 
melanocortin-4 agonist activity, and therefore it might 
represent an effective model molecule for the development of 
anti-obesity drugs. 
1.1.3 Complexation and transport of metal 
ions 
A common feature of cyclopeptides, often related to 
their biological activity, is the ability of complexing ions.  
Molecular recognition is of fundamental importance in 
biochemistry and chemistry, and antibiotic ionophores are 
small biological molecules that recognize ions and transport 
them across cell membranes.
17
 A classic cyclopeptide capable 
of forming transmembrane ion channels is valynomicin, an 
antibiotic obtained from the cells of several Streptomyces 
strains, which acts as a highly selective potassium 
ionophore.
18,19 
In particular, it has long been studied for its 
                                                 
15 D. J. Craik J. Pept. Sci., 2013, 19, 393-407. 
16 R. Eliasen, N. L. Daly, B. S. Wulff, T. L. Andresen, K. W. Conde-Frieboes, D. J. Craik J. 
Biomol. Chem., 2012,  287, 40493-40501.   
17 M. Dobler Ionophores and Their Structures; John Wiley and Sons: New York, 1981. 
18 T. R. Forester, W. Smith, J.H.R. Clarke J. Chem. Soc. Faraday  Trans., 1997, 93, 613-619. 
19 T. J. Marrone, K. N. Jr. Merz J. Am. Chem. Soc., 1995, 117, 779–791. 








. For example, valinomycin binds 
K
+ 
more strongly than Na
+
 by ~5 kcal/mol in methanol.
20
 This 
high selectivity is intriguing because the molecule is known to 
be conformationally flexible in methanol. On the contrary, 
synthetic ionophores tipically achieve selectivity through 
rigidity ensuring that the ion fits perfectly into the central 
cavity. Moreover, in the case of valinomycin, the selectivity is 
strangely espoused to conformation flexibility. 
Structurally, valinomycin is an hydrophobic 
cyclodepsipeptide consisting of 12 alternating monomers of 
amino acid and hydroxy acid residues (figure 1.7). It has the 
formula (D-Val-L-lactic acid- L-Val-D-hydroxyvaleric acid)3.  
 It is interesting to report that the excellent ionophoric 
properties of valynomicin were more recently exploited 
through the design of a chemical microsensor of K
+
 for 
biomedical and clinical applications. This microsensor is a 
CHEMFET device, namely it was builded by a 
photolitographic deposition on the gate area of ISFET (ion-
selective field effect transistor) chips of a biocompatible 
polymeric membrane (acrylated urethane) which included a 
ionophore sensor element (2.2% valynomicin).
21
 
                                                 
20 R. M. Izatt, J. S. Bradshaw, S. A. Nielson, J. D. Lamb, J. J. Christensen, D. Sen, Chem. 
Rev,. 1985, 85, 271-339. 
21 J. Munoz, C. Jimenez, A. Bratov, J. Bartroli, S. Alegret, C. Dominguez Biosensors & 
Bioelectronics, 1997, 12, 577-585. 






























Figure 1.7: Structure of valynomicin. 
Another example of cyclopeptides with ionophoric 
properties is the family of enniatins. Enniatins are 
cyclohexadepsipeptides made of alternated residues of three 
L-N-methyl aminoacids, typically valine, leucine, isoleucine, 
and three hydroxy acids, usually D-α-hydroxyisovaleric acid. 
These molecules are mainly isolated from Fusarium species 
of fungi, and are characterized by a large range of biological 




The antimicrobial activity stems from the ability of enniatins 









 They penetrate into the cell 
membrane forming cation selective channels. 
In figure 1.8 it is reported the X-ray structure of an enniatin B 
potassium 1:1 complex (12). In the central cavity of enniatin 
                                                 
22 A. A. Sy-Corderom, C. J. Pearce, N. H. Oberlies J. Antibio., 2012, 65, 541-549. 




B is placed the metal ion, which is coordinated to six amide 
carbonyls via ion-dipole interactions.
23
 










Figure 1.8: X-ray structure of enniatin B potassium1:1 complex (left) and 
chemical structure of the same compound (right). 
 
In the same way as valynomicin and enniatins, other 
natural cyclopeptides were recognized as suitable molecules 
for metal complexation and transport, for example some 
azole-based cyclopeptides of marine origin, secreted as 
secondary metabolites from ascidians (‘sea squirts’) of the 
genus Lissoclinum.
24
 These organisms are a prolific source of 
rare cyclic peptides with both D- and L-amino acids, many 
modified in the form of thiazole, oxazole, thiazoline or 
oxazoline ring (the heterocycle comes between the terminal 
carbonyl of the acidic function and the α-carbon). There is  
currently a vast literature which demonstrates that these 
                                                 
23 M. Dobler, J. D. Dunitz, J. Krajewski J. Mol. Biol., 1969, 42, 603-606; Y. A. Ovchinnikov, 
V. T. Ivanov, A. V. Evstratov, I. I. Mikhaleva, V. F. Bystrov, S. L. Portnova, T. A.  
Balashova, E. N. Meshcheryakova, V. M. Tulchinsky Int. J. Peptide Protein Res., 1974, 6, 
465–498. 



















marine metabolites, specifically, are characterized by an high 
attitude to chelate metal ions. 
A significative example is represented by the 
compound ascidiacyclamide isolated from the sea squirt 
Lissoclinum patella.
24
 In 1994 Gahan et al. characterized a 
bis-copper(II) complex of ascidiacyclamide via X-ray 
crystallography.
24
 This complex (13, figure 1.9) contains two 
copper ions each one coordinated to two nitrogens from 
thiazole and oxazoline unit, a deprotonated amine and a water 
molecule. In addition, is present a carbonate anion in a bridge 












Figure 1.9: Bis-copper(II) complex of ascidiacyclamide (left) and ORTEP 






























Cyclic peptides are of interest also in nanotechnology, 
and in this regard Ghadiri and co-workers discovered in 1993 
that noncovalently bonded nanotubes are formed by the 
stacking of cyclopeptides via hydrogen bonds.
25
 Specifically, 
in order to form the nanotubes was prepared the octapeptide 
cyclo-[(L-Gln-D-Ala-L-Glu-D-Ala)2-], (14). The presence of 
glutamic acid in deprotonated form in basic aqueous solution  
prevents the uncontrolled stacking of the subunits through 
coulombic repulsion. Controlled acidification generates 
microcrystalline aggregates that were extensively 
characterized by electron diffraction, electron microscopy and 
FT-IR spectroscopy. 
These analyses firmly demonstrated that the structure was 
constituted from the cyclic units stacked through antiparallel 
β-sheet hydrogen bonding. By this way were formed hollow 
tubes with internal diameter of 7.5 Å and distances between 
ring-shaped units of 4.73 Å (figure 1.10).   
 In order to better understand nanotube structure, 






                                                 
25 M.R. Ghadiri, J.R. Granja, R.A. Milligan, D.E. McRee, N. Khazanovich Nature, 1993, 
366, 324-327. 
26 J. Hartgerink, J. R. Granja, R. A. Milligan, M. R. Ghadiri J. Am. Chem. Soc., 1996, 118, 
43-50. 













Figure 1.10: Proton-controlled self-assembly process for the preparation 
of microcrystalline aggregates of nanotubes composed of cyclo-[(L-Gln-
D-Ala-L-Glu-D-Ala)2-] (14). 
 
The nanotubes above described present some 
advantages with respect to the covalently bonded 
nanostructures (zeolites, graphite etc.) due to the fact that are 
very modulable: the diameter of the nanotube can be 
controlled by varying the number of amino acid residues in 
each ring and, secondly, the properties of the outer surface of 
the nanotube can easily be modified by varying the amino 
acid side chains. Indeed, the tunability of these materials has 




A recent application of the cyclopeptide nanotubes 
(CPs) has been the preparation of peptide-polymer 
nanotubular hybrids using CPs in the role of templates (figure 
                                                 






























 The synthetic strategy consisted in the self-assembly 
of  CPs with polymerization initiator groups on distint side 
chains (15, figure 1.11) to form a peptide nanotube that 
possessed the initiator groups only on the outer surface. A 
furher polymerization reaction coated the peptide core with a 















 Peptoids are oligomers of N-substituted glycine and 
were devoleped by Bartlett and co-workers in the early 
                                                 
28 J. Couet, J. D. J. S. Samuel, A. Kopyshev, S. Santer, M. Biesalski, Angew. Chem. Int. Ed., 


































 Structurally, the placement of the monomer side 
chains on the amide nitrogen (as opposed to the α-carbon in α-
peptides, figure 1.12) confers achirality to the peptoid 
backbone, and contemporary the presence of tertiary amide 
bonds (rapidly isomerizing between cis and trans 
conformation) and the absence of hydrogen donors lead to a 
flexible structure, hydrogen bond deficient. As a consequence, 
the design of a well-defined secondary structures in peptoids, 
which is very important for peptoid-target protein interactions 
and for the general understanding of structure-function 
relationships, is a complex outcome, achievable making use 















                                                          
                                Peptide 16                       Peptoid 17                 
 
        Figure 1.12: General structure of peptides and peptoids. 
Anyway, these peptido-mimetic compounds present 
many advantages with respect to peptides such as an higher 
resistance to enzymatic proteases (enhanced oral 
                                                 
29 R.J. Simon, R.S. Kania, R.N. Zuckermann, V.D. Huebner, D.A. Jewell, S. Banville, S.L. 
Wang, S. Rosenberg, C.K. Marlowe, P. A. Bartlett  Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 
9367-9371. 




bioavailability and half-life in the body), an increased cellular 
permeability due to the more hydrophobic backbone, absence 
of immunogenic properties. In addition,  they can be 
synthesized using a straightforward, modular synthesis that 
allows the incorporation of a plethora of amide side chains. 
Indeed, peptoids have being developed as mimics of 
biologically active peptides, as replacements of small 
molecule drugs, as versatile biomolecular tools in order to 
study complex biomolecular interactions, and have becoming 
attractive candidates in nanotechnology, catalysis, and for 
therapeutic and diagnostic applications.
30,31
 
Ultimately, peptoids represent a very challenging 
research field as indicated by the graphic in figure 1.13, which 




                                                 
30 M. T. Dohm, R. Kapoor, A. E. Barron Current Pharmaceutical Design, 2011, 17, 2732-
2747. 
31 S. A. Fowler, H. E. Blackwell Org. Biomol. Chem., 2009, 7, 1508-1524. 
32 A. S. Culf, R. J. Ouellette Molecules, 2010, 15, 5282-5335. 





Figure 1.13: Primary research articles, reviews and patents on peptoids 
published from 1992 to 2010. 
 
1.2.2  Synthesis 
Peptoids are normally synthesized making use of the 
solid-phase monomer or submonomer approach. 
Monomer method was developed by Merrifield
33
 in 
relation to peptide synthesis (scheme 1.1). Typically, in the 
monomer synthesis of peptides the most common α-amino-
protecting groups are Fmoc and Boc groups used in the 
Fmoc/tert-butyl (tBu) and Boc/benzyl (Bn) strategies, 
respectively.  
                                                 
33 R. B. Merrifield, J. Am. Chem. Soc, 1964, 86, 2149–2154. 




















repeat to desired chain length
 
Scheme 1.1: Monomer synthesis of peptoids. 
 
Peptoids can be synthesized by coupling N-substituted 
glycines using standard α-peptide synthesis methods. 
Nevertheless, the mean drawback of using the monomer 
approach in the case of peptoids consists in the synthetic 
effort required to prepare a suitable set of chemically diverse 
monomers.
4
 In addition, the secondary N-terminal amine in 
peptoid oligomers is more bulky than primary amine of an 
amino acid, leading to slower coupling reactions. 
The favourite synthetic method for peptoids is the 




                                                 
34 R. N. Zuckermann, J. M. Kerr, B. H. Kent, W. H. Moos, J. Am. Chem. Soc., 1992, 114, 
10646-10647.  
 














repeat to desired chain length
Br
Br RNH2
                               
Scheme 1.2: Submonomer synthesis of peptoids. 
 
This method is called as so because each cycle of monomer 
addition is divided in  
two steps, an acylation step with bromoacetic acid and a 
nucleophilic displacement step with a primary amine.  
In general, it is the reference method for peptoid synthesis 
because it is very straightforward and efficient. Futhermore, 
there is no need to use protecting groups in elongating the 
main chain and the availability of a large number of primary 
amines permits the simple preparation of a vast peptoid 
library. 
1.2.3  Conformationally constrained peptoid 
oligomers 
The question of generating stable secondary structures 
in peptoids is very challenging  because, as aforementioned, 
the peptoid backbone exhibits an intrinsic flexibility due to 
the absence of hydrogen bond donors and to the cis-trans 
isomerization of tertiary amide bonds. This causes a 
substantial conformational heterogeneity of the peptoid 
backbone. 




However, researchers have developed strategies to 
stabilize helical, loop and turn motifs in peptoids by 
incorporating amide side chains that reduce conformational 
fluxionality. Specifically, several side chains have been 
individuated which effectively control the cis-trans geometry 




The peptoid helix and threaded loop constitute the first 
peptoid secondary structural topology to be discovered, and 
are formed in presence of α-chiral amide side chains such as 
N(S)-(1-phenylethyl)glycine (Nspe), N(S)-(sec-butyl)glycine 
(Nssb), N(S)-(1-cyclohexylethyl)glycine (Nsch), N-(S)-(1-









Nspe Nssb Nsch Nsnpe  
Figure 1.14: Common bulky aliphatic and aromatic α-chiral monomers 
used to induce helical conformations in peptoids. 
 
These bulky residues produce steric repulsion between 
side chains, and in addition establish hydrophobic and n→ Π* 
interactions. In this way, it is favoured a polyproline type I 
helical conformation, totally composed of cis amide bonds 
(figure 1.15). The helical structures of different homo-
                                                 
35 J. Sun, R. N. Zuckermann ACS NANO, 2013, 7, 4715-4732. 




oligopeptoids containing α-chiral amide side chains were 
analyzed by circular dicroism, 2D NMR, molecular modeling 
studies, and X-ray crystallography.
36
 Clearly, the handedness 
of the helix is determined by the handedness of the α-chiral 










Figure 1.15: The peptoid helix, shown here as the structure of (Nspe)10 
(left). Structure generated by molecular mechanics from the calculated 
structure of (Nspe)8. X-ray crystal structure of Ac-(Nsnpe)4-COOtBu 
(right), which shows the so called “naphtoid” helix. Atom designations: 
red = oxygen; blue = nitrogen; gray = carbon.  
 
Interestingly, the highest stabilization of cis backbone 
conformation was reached using  Nsnpe side chains (Kcis/trans = 
9.7), due to the fact that n→ Π* interactions between the lone 
pair on the carbonyl oxygen of the backbone and the Π* 
orbital of an adjacent aromatic side chain were demonstrated 
to enforce cis geometry. Moreover, the “naphtoid” helix ( 
                                                 
36 C. W. Wu, K. Kirshenbaum, T. J. Sanborn, K. A. Dill, R. N. Zuckermann, A E. Barron J. 
Am. Chem. Soc., 2003, 125, 13525-13530. 








Barron and co-workers investigated the effect of 
peptoid sequence on helix stability, and in the end established 
that the minimum chain length to observe an helix is five 
residues with stability increasing with chain length up to 15 
residues, and a minimum of 50% α-chiral side chains are 
required to form a stable helix.
38
 
Accidentally, during the analysis of the peptoid helix, 
they also discovered a second peptoid structure, the threaded 
loop. This unusual structure is unique to peptoid nonamers 
with α-chiral side chains, and was first found in (Nspe)9 TFA 
salt (18, figure 1.16).
39
  It is stabilized via multiple 
intramolecular hydrogen bonds between the protonated amino 
terminus and three backbone carbonyls as highlighted by 2D 
NMR study in CD3CN (figure 1.16). Curiously, the loop 
conformation converts into the classic peptoid helix in 
presence of a solvent with hydrogen bond potential (e.g.. 50% 
methanol in acetonitrile), which is able to destroy the 
intramolecular hydrogen bonds. 
                                                 
37 J. R. Stringer, J. A. Crapster, I. A. Guzei, H. E. Blackwell J. Am. Chem. Soc., 2011, 133, 
15559-15567. 
38 C. W. Wu, T. J. Sanborn, K. Huang, R. N. Zuckermann, A. E. Barron J. Am. Chem. Soc., 
2001, 123, 6778-6784. 
39 K. Huang, C. W. Wu, T. J. Sanborn, J. A. Patch, K. Kirshenbaum, R. N. Zuckermann, A. 
E. Barron J. Am. Chem. Soc., 2006, 128, 1733-1738. 






Figure 1.16: Solution structure of (Nspe)9 TFA salt  in CD3CN containing 
the hydrogen bond interactions. Residues from the N- to the C-terminus in 
the peptoid chain are color-ramped from blue to red following the rainbow 
pattern. Atom designations: red = oxygen; blue = nitrogen; gray = carbon. 
Substituents were omitted for clarity. 
Anyway, it was also intriguing to favour trans-amide 
bonds in the peptoid backbone. In particular, Kirshenbaum 
and co-workers demonstrated the stabilization of the trans-
amide conformer with more than 90% by making use of N-
aryl side chains.
40
 Notably, in their work was predicted a 
polyproline type II helix for N-aryl peptoid oligomers. 
 In the wake of Kirshenbaum’s discover, Blackwell’s 
group demonstrated a special acyclic peptoid reverse-turn 
conformation with an all-trans amide backbone through the 
incorporation of ortho-hydroxy N-aryl side chains capable of 
hydrogen bonding in the backbone of a tripeptoid (19, figure 
1.17).
41
 Specifically, X-ray crystallography and 2D NMR 
indicate the presence of two intramolecular 8-membered-ring 
                                                 
40 N. H. Shah, G. L. Butterfoss, K. Nguyen, B. Yoo, R. Bonneau, K. Kirshenbaum J. Am. 
Chem. Soc., 2008, 130, 16622-16632. 
41 J. R. Stringer, J. A. Crapster, I. A. Guzei, H. E. Blackwell J. Org. Chem., 2010, 75, 6068-
6078. 




hydrogen bonds in which are involved the side chain hydroxyl 











Figure 1.17: Chemical structure of tripeptoid 19 with 8-membered-ring 
hydrogen bonds depicted in red (left) and X-ray crystal structure of the 
same compound with hydrogen bonds indicated as solid green lines 
(right). Atom designations: red = oxygen; blue = nitrogen; gray = carbon.  
 
Later, Blackwell and co-workers discovered a special 
sheet-like secondary structure making use of N-hydroxy side 
chains in a dipeptoid structure (figure 1.18).
42
 In particular, in 
the crystal structure individual peptoid backbones are 
arranged  in an antiparallel fashion and are linked through 




                                                 



























Figure 1.18: Chemical structure of dipeptoid 20 (left) and X-ray crystal 
structure of the same compound with hydrogen bonds indicated as solid 
green lines (right). Atom designations: red = oxygen; blue = nitrogen; gray 
= carbon.  
 
More recently, the same Blackwell’s group found that, 
alternating substituted N-aryl side chains and Nsnpe side 
chains in the backbone of an hexapeptoid, a ribbon-like 
structure hydrogen bond deficient (figure 1.19) is induced.
43
 
The peptoid ribbon can be described as a succession of turn 
units, in analogy with β-bend ribbon folds in α-peptides. 
Anyway, while in peptide ribbons all amide bonds are in the 
trans configuration, in the case of peptoid ribbon is present an 
alternating cis/trans geometry, due to the contemporary use of 
trans- and cis- inducing residues. In addition, the ribbon fold 
is largely stabilized by the steric demands of the bulky Nsnpe 
side chains. 
 
                                                 




















Figure 1.19: Chemical structure of hexapeptoid 21 (left) and an ensemble 
of 10 superimposed low-energy structures of 21 determined via 2D NMR 
in CDCl3 (right). Atom designations: red = oxygen; blue = nitrogen; gray 
= carbon.  
1.2.4  Cyclopeptoids 
The flexible nature of peptoids may limit the 
development of peptoid-based protein ligands with high 
affinity and specificity. So a potentially promising way to 
overcome this limitation, in addition to the use of specific 
amide side chains in the peptoid backbone, is the effective 
and straightforward macrocylization of peptoids, which 
reduces conformational freedom, simply producing 
conformationally constrained structures. 
Therefore, in the same manner as peptides, cyclization 
is of great importance also for peptoids and in this context 
cyclopeptoids represent an intriguing class of 
peptidomimetics. 
Specifically, it is possible to synthesize cyclopeptoids 
through a direct head-to-tail cyclization reaction (e.g. scheme 




































       Scheme 1.3: Head-to-tail macrocyclization of peptoids. 
 
The latter can be performed according to different 
approaches as following illustrated.  
The first strategy used to form intramolecular covalent 
constraints between the side chains of a peptoid oligomer was 
the Cu
I
-catalyzed azide/alkyne cycloaddition, a classic “click 
chemistry” reaction. For example, Kirshenbaum and co-
workers made use of this reaction in order to successfully 
constrain helical peptoid conformations (figure 1.20) 






Figure 1.20: Positioning of azide and alkyne groups on an idealized 
polyproline type I helix. A helical template may pre-organize reactive 
functional groups at positions i and i +3 for optimum product formation. 
 
                                                 
44J. M. Holub, H. Jang, K. Kirshenbaum Org. Lett., 2007, 9, 3275-3278. 




 Later, intramolecular lactam bridges were installed 
between peptoid side chains with the aim of enhancing 
conformational stability. This strategy was effectively tried in 
the case of helical peptoid structures.
45
 
 More recently, triazine-linked bicyclic peptoids were 
synthesized directly on the resin via a specific 
macrocyclization reaction (figure 1.21).
46
 
The macrocyclization reaction was accomplished through a 
nucleophilic attack by the cysteine sulfhydryl group on a 
reactive chloride on the triazine ring, as shown for compound 
22. 
Notably, bicyclic peptoids possess an enhanced 
conformational rigidity in comparation with monocyclic 
peptoids and, as a consequence, should be able to bind more 
tightly and specifically to target proteins. 
                                                 
45 B. Vaz, L. Brunsveld Org. Biomol. Chem., 2008, 6, 2988-2994. 
46 J. H. Lee, H. S. Kim, H. S. Lim Org. Lett., 2011, 13, 5012-5015. 





























































Figure 1.21: On-resin macrocyclization for a triazine-bridged bicyclic 
peptoid 22. 
Cyclopeptoids have permitted a structural 
investigation by X-ray crystallography a far more vast than in 
the case of peptoid oligomers.
47
 This is clearly ascribable to 
the increase of the conformational order realized in 
macrocylic peptoids.  
Interestingly, the first rigorous structural studies 
reported the X-ray crystallographic investigation on the cyclic 
oligopeptides of sarcosine (N-methyl glycine).
48
 In addition, 
the first X-ray crystal structure of a cyclic peptoid hetero-
                                                 
47 B. Yoo, S. B. Y. Shin, M. L. Huang, K. Kirshenbaum Chem. Eur. J., 2010, 16, 5528-5537. 
48 P. Groth Acta Chem. Scand., 1976, 30, 838-840.  




oligomer to date was obtained from a cyclohexapeptoid (24) 













Figure 1.22: Chemical structure of cyclohexapeptoid 24 (left) containing 
alternated residues of benzylamine and methoxyethylamine. X-ray crystal 
structure of the same compound (right) showing segregation of polar and 
apolar side chains on opposite faces of the macrocycle and the peptide 
bond pattern of backbone. Purple - residue 1, yellow - residue 2, red - 
residue 3, green - residue 4, blue - residue 5, gray - residue 6, c - cis, t – 
trans. 
The discussed structure turned out to be very 
interesting. Specifically, the crystal is triclinic and the 
backbone is characterized by a combination of  four cis and 
two trans amide bonds according to a pattern tcctcc, with the 
cis amide bonds located at the corners of a roughly 
rectangular structure. More interestingly, the orientation of 
the side chains is such that is produced a partitioning of 
                                                 






















hydrophobic and polar side chains groups on either face of the 
macrocycle. This feature may be very useful for the prediction 
of the spatial arrangements of different side chain types in a 
cyclopeptoid alike to 24. 
Additionally, superposition of 24 with the idealized 
peptide β-turn type-I and type-III showed a RMSD  (root 
mean square deviation of backbone C-α atoms) of  0.397 Å 
and 0.301 Å respectively, as a demonstration of the analogy 




 Figure 1.23: Superposition of the backbone atoms in cyclic peptoid 
hexamer 24 (blue) with canonical: (A) type I β-turn (yellow); (B) type III 
β-turn (yellow). 
1.2.5 Complexation and transport of metal 
ions 
Similarly to peptides, also peptoids can selectively 
complex and transport metal ions. In 2008 De Riccardis and 
co-workers synthesized two N-benzyloxyethyl cyclopeptoids 
(25, 26) (figure 1.24) which are characterized by a good 




affinity towards alkali metals (table 1.1).
50
 Specifically, the 
complex association constant host-ion (Ka) were determined 
by picrate extraction technique in H2O/CHCl3, as described 
by Cram and co-workers,
51
 and highlighted a good degree of 
selectivity towards Na
+
 for 25. In addition, the bigger 
macrocycle 26 resulted to be selective to Cs
+















































Figure 1.24: N-benzyloxyethyl cyclohexapeptoids synthesized from De 






                                                 
50 N. Maulucci, I. Izzo, G. Bifulco, A. Aliberti, C. De Cola, D. Comegna, C. Gaeta, A. 
Napolitano, C. Pizza, C. Tedesco, D. Flot, F. De Riccardis Chem. Commun., 2008, 3927-
3929; C. De Cola, S. Licen, D. Comegna, E. Cafaro, G. Bifulco, I. Izzo, P. Tecilla, F. De 
Riccardis Org. Biomol. Chem., 2009, 7, 2851-2854. 
51 K. E. Koenig, G. M. Lein, P. Stuckler, T. Kaneda, D. J. Cram J. Am. Chem. Soc., 1979, 
101, 3553. 




Table 1.1: Parametres for association between hosts and picrate salts in 



























 0.29 1.5 8.4 
 
a)
 [Guest]/[Host] in CHCl3 layer at equilibrium obtained by direct 




The NMR spectrum of cycle 25 was very complicated due 
to the   contemporary presence of more than one conformer in 
slow exchange on the NMR time scale. The conformational 
disorder in solution was seen as a propitious auspice for the 
complexation studies. Indeed, the stepwise addition of sodium 
picrate to 25 induced the formation of a new chemical species 
(the sodium complex), whose concentration increased with 
the gradual addition of the guest (figure 1.25 b and c). Finally, 
with an excess of guest, a simplified NMR spectrum was 
obtained, reflecting the formation of a 6-fold symmetric 
species (figure 1.25 c). 
 





 Figure 1.25: 
1
H NMR spectra of free 25 (a) (CD3CN–CDCl3 9:1 solution, 
25 
°
C, [25] = 4.0 mM, 400 MHz) and in the presence of 0.5 eq. (b) or 1.5 
eq. (c) of sodium picrate. Residual solvent peaks are labelled with *. 
The first structure of a cyclopeptoid metal complex to 
be solved was obtained for a zwitterionic complex of 25 with 
strontium picrate (252.[Sr(picr)2]3). 
Interestingly, the crystal was monoclinic and the backbone 
was characterized by a unique all-trans peptoid bond pattern, 
with the carbonyl groups alternatively pointing toward the 
strontium cations so that the N-linked side chains are made to 
adopt a pseudo-equatorial arrangement (figure 1.26). In 
addition, picrate anion behaves as a bidentate ligand 
interacting with the cation so that three picrates bind two 
external Sr cations. The presence of picrate in the complex 




















. Atom designations 
(right figure): red = oxygen; blue = nitrogen; gray = carbon, magenta = 
strontium. In the left figure picrate anions are depicted in green, strontium 
ions in magenta and cyclopeptoid molecules in gray. 
 
 Later, the compounds 25, 26 were subjected to ion 
transport studies with the HPTS assay, demonstrating a size 
dependent selectivity for the first group alkali metals with 





to a carrier based mechanism.
50
 
These results clearly indicate that cyclopeptoids 
represent novel motifs for the design of ionophoric antibiotics 
similarly to the peptide valynomicin. 
1.2.6  Biologically active peptoids 
Peptoids, exactly as peptides, can show some specific 
biological activities. In particular, amphiphilic cyclopeptoids 
have drawn interest in the role of antibacterial agents due to 
the fact that they contain both hydrophobic side chains, which 
make them soluble in bacterial membranes increasing the cell 
membrane permeability, and positive charged side chains 
interacting electrostatically with negative groups of bacterial 
porins.  




  In 2010 the antifungal and antibacterial properties of 
some new cationic hexacyclopeptoids correlating their 
efficacy with the linear cationic and cyclic neutral 
counterparts were evaluated by De Riccardis and co-workers. 
Specifically, the compounds  contained a variable number of 
N-benzyloxyethyl/N-benzyl residues and protonated N-lysine 
residues.
52
  This investigation was inspired by the analogy 
between the afore mentioned N-benzyloxyethyl 
hexacyclopeptoid, an efficient ionophore agent for Na
+
, and 




The purpose of this study was to explore the biological 
effects of the cyclization on the antimicrobial properties of 
positively charged oligomeric N-alkylglycines, in order to 
mimic the natural amphiphilic peptide antibiotics. Moreover, 
the modular peptoid backbone was very suitable for the 
appropriate design of novel antimicrobial compounds. 
Experimentally, all the molecules analyzed were more 
active against fungi than bacteria. In addition, cyclic 
molecules exhibited better antifungal properties with respect 
to  the linear ones. Finally, within the cyclic compounds, the 
antifungal potency increased with the net positive charge, as 
indicated by the fact that compounds 27 and 28 (figure 1.27) 
possessed the highest net positive charge amongst the 
peptoids tested and were also the most effective ones. 
                                                 
52 D. Comegna, M. Benincasa, R. Gennaro, I. Izzo, F. De Riccardis Biorg. Med. Chem., 2010,  
18, 2010-2018. 
















































Figure 1.27: Amphiphilic cyclopeptoids resulted to be the most active 
against fungi in a recent study carried out by De Riccardis and co-workers. 
 Kirshenbaum and co-workers recently patented some 
cyclopeptoids with antibacterial activity
53
 (figure 1.28) and 
more recently in 2013 reported some novel amphiphilic 
cyclopeptoids, exhibiting a strong antibacterial activity 
against Staphylococcus aureus, a multi-drug resistant 
bacterium.
54
 One of the most active cyclopeptoids tested is 
illustrated in figure 1.29.  
  
                                                 
53 U.S.A. Patent Application Pubblication  2010/0222255. 
54 M. L. Huang, M. A. Benson, S. B. Y. Shin, V. J. Torres, K. Kirshenbaum Eur. J. Org. 
Chem., 2013, 17, 3560-3566. 

















































































Figure 1.29: Amphiphilic cyclopeptoid resulted to be one of the most 
active against Staphylococcus aureus  in a very recent study carried out by 
Kirshenbaum and co-workers. 




In conclusion, these results strongly encourage the research 
on amphiphilic peptidomimetics with antibiotic properties. 
1.2.7  Catalytic properties  
In literature there is only one example of peptoids in 




synthesized a set of helical 
peptoid oligomers catalyzing the oxidative kinetic resolution 








Figure 1.30: Oxidative kinetic resolution of 1-phenylethanol. 
TEMPO, a well-known catalyst for oxidative transformations, 
was covalently linked at various sites along properly designed 
chiral peptoid backbones which were used as asymmetric 
catalysts in the oxidative resolution.  
It was demonstrated that the enantioselectivity of the 
process essentially depended on three factors: 1) the 
handedness of the asymmetric environment derived from the 
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helical scaffold, 2) the position of the catalytic centre TEMPO 
along the peptoid backbone, and 3) the degree of 
conformational ordering of the peptoid scaffold. For istance, 
the highest activity in the OKR (e.e. > 99%) was observed for 
the catalytic peptoids with the TEMPO group attached at the 
N-terminus, as in the case of peptoids 38, 39 (figure 1.31). 
These results revealed that the selectivity of the OKR was 
dictated by the global structure of the catalyst and not solely 





















































39, left-handed helix (e.e. > 99% (S))  
 
Figure 1.31: Catalytic peptoid oligomers 38 and 39. 
 
1.2.8 Nanostructures                   
Peptoids can also form nanotubular structures as in the 
case of peptide nanotubes described before.  




In 2013 Kirshenbaum’s group reported a cyclo-
octapeptoid (40) which is able to storage and release water 
molecules from the central channels of a nanotubular 
structure, realizing the first single-crystal-to-single-crystal 














Figure 1.32: Chemical structure of cyclo-octapeptoid 40 (left) and X-ray 
crystal structure of the same compound with view along b axis (right). 
Atom designations: red = oxygen; blue = nitrogen; gray = carbon. 
Single crystal X-ray determination demonstrated the 
formation of a monoclinic crystal with C2 symmetry derived 
from the backbone sequence. The backbone adopts a planar 
geometry, and there is a central cavity in the macrocycle. In 
the crystal lattice, the macrocycle units stack along the b axis 
                                                 























and in this way the inner macrocycle cavities generate a 
nanotube structure. 
In addition, the crystal contained water molecules 
within the central channel, which sum up to 19% mol relative 
to the peptoid. Furhermore, in order to evaluate the possibility 
to uptake and release water molecules from the nanotubular 
structure in a cyclic way, a peptoid single-crystal was firstly 
full dehydrated under ambient conditions with total retention 
of the single crystalline morphology, and afterwards was 
effectively rehydrated in a humid environment up to 44% 
mol.     
 In conclusion, the nanotubular structure of peptoid 40 
is a valid starting point for the future design of new peptoid-
based crystalline materials capable of undergoing unusual 
single-crystal-to-single-crystal transformations. 
1.3 The research project 
 Aim of the research project has been the synthesis of 
cyclopeptides and cyclopeptoids in order to investigate their 
structural properties and catalytic activities. 
In particular, studies of the arrangement and the 
cyclopeptoids organization in the crystal structure have been 
realized. Moreover, the influence of some aminoacidic 
residues on conformational control of peptoid skeleton was 
evaluated.  In this context, the effect of proline, an 
aminoacid with an important role in the formation of 






 and of a pseudo-proline 
residue on the crystal structure and conformational equilibria 
of some cyclopeptoids was evaluated. In particular, N-
methoxyethyl cyclic peptoids containing proline and N-
methoxyethyl hexacyclopeptoid (proline-free) in complexed 
and uncomplexed form (41-43, figure 1.33) were successfully 
synthesized and characterized by X-ray diffraction. In 
addition, the synthesis of a cyclohexapeptoid containing a 
pseudo-proline residue was obtained (44, figure 1.33).   
Furthermore, two isomeric amphiphilic peptoids (45, 
46, figure 1.33) were synthesized in order to investigate the 
effect of amphiphilicity on the crystal frame.  
 All that will be described in the following two sections. 
 Moreover, considering the well documented 
complexation properties of cyclopeptoids towards alkaline 
metals,
50
 the ability of some cyclohexapeptoids to work as 
phase-transfer catalysts was investigated in a benchmark SN2 
reaction. In particular, the cyclopeptoid which revealed to be 
the most active was the N-[2-(2-methoxyethoxy)ethyl] side 
chain cyclohexapeptoid (47, figure 1.34). Therefore, we also 
tested some proline-rich cyclopeptoids in asymmetric phase 
transfer catalysis and the most promising demonstrated to be 
the cyclopeptoid 48 (figure 1.34) alternating N-3,5-dimethyl 
benzylamine glycine and proline residues.  
                                                 
57 M. Mutter, G. G. Tuchscherer, C. Miller, K. H. Altmann, R. I. Carey, D. F. Wyss, A. M. 
Labhardt, J. E. Rivier, J. Am. Chem. Soc., 1992, 114, 1463 –1470. 




The catalytic studies mentioned will be illustrated in section 
4. 
 Finally, in section 5 is reported a novel synthetic 
strategy for the synthesis of the biologically active cyclotide 
kalata B1 (10, figure 1.35), based on Fmoc/t-Bu solid phase 






































































































Figure 1.33: Cyclopeptoids synthesized for structural studies. 
 










































Figure 1.34: Cyclopeptoids resulted to be the most active in the phase-
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2 PROLINE-RICH CYCLOPEPTOIDS 
2.1 The role of proline in peptoid conformation 
  In the last years many efforts have been devoted to 
restrict backbone conformation for linear and cyclic 
peptoids,
58
 considering that a decreased conformational 
entropy and a well defined structure could be useful for 
biological applications such as interaction peptoid-biological 
target. 
  Proline is unique among the aminoacids, having the 
side chain linked to amide nitrogen atom. Its five membered 
ring imposes rigid constraints on the N-C
α
 bond rotation, 
playing important role in peptide loops and turns, and 
confering unique conformational properties to the peptide or 
protein backbone when compared to the common 
proteinogenic aminoacids.
47
 For example, the structural 
elements induced by proline are necessary for the formation 
of compact globular structures in proteins.
57
 Futhermore, 
proline residues lead to cis-trans isomerization of the imidic 
bond formed with the preceding residue (Xaa-Pro) due to the 
characteristic low activation barrier for isomerization, 
combined with the small free energy differences between the 
two peptide bond isomers. This isomerization can produce 
conformational changes involved in many biological 
processes such as protein folding and various aspects of 
                                                 
58 S. A. Fowler, H. E. Blackwell Org. Biomol. Chem., 2009, 7, 1508-1524. 
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The biological importance of proline-rich peptides has 
caused the development of several substituted-proline 
analogues in order to control the peptoid backbone or to 
modify the imide cis-trans ratio.
60
 In this regard, it was 
recently reported that 2,2-dimethyl-1,3-oxazolidine-4-
carboxylic acid and 2,2-dimethyl-1,3-thiazolidine-4-
carboxylic acid, named pseudo-prolines (Ψ
Me,Me
Pro) (49 and 
50, figure 2.1), significantly control the peptide backbone, 
inducing preferentially the cis conformation in the Xaa-ΨPro 
bond, due to unfavorable steric interactions between the 
methyl groups and the α-proton of Xaa in the trans-
conformation.
60









49 50  
Figure 2.1: 2,2-dimethyl-1,3-thiazolidine-4-carboxylic acid (49) and 2,2-




 An intriguing example of pseudo-proline analogue of a 
biologically active peptide deals with the synthesis of a 
mimetic of peptide hormone oxytocine (51, figure 2.2): a 
cyclic nonapeptide containing a disulfide bond between two 
                                                 
59 P. Craveur, A. P. Joseph, P. Poulain, A. G. de Brevern, J. Rebehmed Amino Acids, 2013, 
45, 279-289. 
60 P. Dumy, M. Keller, D. E. Ryan, B. Rohwedder, T. Wohr, M. Mutter J. Am. Chem. Soc., 
1997, 119, 918-925. 
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cysteine residues at positions 1 and 6.
61
 Oxytocine is a 
mammalian neurohypophysial hormone which plays roles 
during child birth and is used clinically to stimulate uterine 
contractions during labour and to stimulate the secretion of 
breast milk. Specifically, it was studied the role of the proline 
residue at position 7 of oxytocine, linked to Cys
6
 through a 
trans peptide bond. 
Notably, the replacement of Pro
7
 in the oxytocine backbone
 
with cis-prolyl mimic 2,2-dimethyl-1,3-thiazolidine-4-
carboxylic acid yielded an analogue, characterized by a 92-





Pro, as demonstrated by 2D NMR studies. In addition, 
no antagonistic activities were observed for the analogue 52 
(figure 2.2), as an evidence of the importance of cis/trans 
conformational change in oxytocine receptor binding and 
activation. 
 In 2013 Albericio et al. reported the synthesis and the 
biological evaluation of a library of Cys(Ψ
Me,Me
Pro)-
containing analogues of phakellistatin 19 (53, figure 2.3).
62
 
Phakellistatin 19 is an octacyclopeptide and represents the last 
isolated member of the class of phakellistatins, biologically 
active cyclopeptides isolated from marine sponges. 
Interestingly, the natural phakellistatin 19 exhibits 
cytotoxicity whereas its synthetic counterpart is inactive. This 
phenomen could be ascribable to the presence of an impurity 
                                                 
61 A. Wittelsberger, L. Patiny J. Med. Chem., 2005, 48, 6553-6562. 
62 M. Pelay-Gimeno, A. Meli, J. Tulla-Puche, F. Albericio J. Med. Chem., 2013, 56, 9780-
9788. 
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in the natural peptide, which is responsible for the 
antiproliferative activity, or to conformational differences due 
to the presence of many proline residues in the peptide 
skeleton. On the basis of the second hypothesis, the effect of 
the replacement of one to three proline residues in 
phakellistatin 19 by Cys(Ψ
Me,Me
Pro) was studied by Albericio. 
Substantially, the incorporation of the pseudo-proline 
moieties increases the percentage of cis geometry in the prolyl 
peptide bonds determining enhanced biological activity in the 

























































Figure 2.2: Structure of oxytocine (51) and its analogue (52). 
 
 








































Figure 2.3: Structure of phakellistatin 19 (53) and one of its analogues 
(54). 
 
2.2 Aims of the work   
  In order to investigate the structural effects of proline 
and pseudo-proline residues and metal binding on 
cyclohexapeptoids with respect to the conformational 
equilibrium and the crystal structure, the synthesis of the 
cyclopeptoids 41, 42, 44 and of the proline free macrocycle 
43 (figure 2.4) was planned.  
  The proline and pseudo-proline residues would have 
imparted conformational rigidity to cyclopeptoid skeleton, 
forming a stable structure in absence of metal ions. In 
addition, N-methoxyethyl  glycine residue was chosen for its 
propensity to enhance the complexing attitudes of cyclic 
peptoids as a prerequisite to build coordination-driven metal-
organic framework structures.  
 









































































Figure 2.4: Proline-rich cyclopeptoids (41, 42, 44) and proline-free 
macrocycle (43). 
 
2.3 N-methoxyethyl cyclopeptoids containing 
proline63 
2.3.1 Synthesis 
The synthesis of the linear precursors of compounds 41, 42 
was accomplished through solid-phase mixed approach 
(submonomer
34
 and monomer approach) (scheme 2.1). N-
methoxyethyl glycine monomer, prepared on 2-chlorotrithyl 
resin in standard conditions, was coupled with N-Fmoc-L-
proline using HATU as condensing agent. Successive 
couplings DIC or HATU-induced yielded the required 
                                                 
63 I. Izzo, G. Ianniello, C. De Cola, B. Nardone, L. Erra, G. Vaughan, C. Tedesco, F. De 
Riccardis Org. Lett., 2013, 15, 598-601. 
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oligomers 55-57 (scheme 2.1 and figure 2.5). 
The linear precursor 58 (figure 2.5) of compound 43 was 
synthesized through a classic solid-phase submonomer 
approach. 
All linear compounds were successfully synthesized as 
established by HPLC analysis and mass spectrometry, with 











































Scheme 2.1: Synthesis of 55, linear precursor of 42. Reagents and 
conditions: (a) bromoacetic acid, DIPEA, DCM; (b) methoxyethylamine, 
DMF; (c) N-Fmoc-L-Proline, HATU, DIPEA, DMF; (d) Piperidine-DMF 
































Figure 2.5: Linear precursors 56, 57 of the diprolinate hexapeptoid 41 and 
linear precursor 58 of the proline-free hexapeptoid 44. 
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  Head-to-tail macrocyclizations in high dilution 
conditions of the linear N-substituted glycines were realized 
in the presence of HATU in DMF. 
Macrocyclization of the linear precursor 56 afforded 41 in a 
disappointing 3% yield. In order to improve the yield of the 
cyclization step, we exchanged the N-terminal proline residue 
with the less sterically demanding N-methoxyethyl glycine 
residue (peptomer 57, figure 2.5). The choice was propitious 
and the cyclization reaction proceeded smoothly affording, 
after silica gel chromatography, the pure eighteen-membered 
ring 41 in 20% yield.   




C NMR spectra recorded 
for the cycle 41 corroborated the contemporary presence of 
more than one conformer in slow exchange on the NMR time 
scale, already observed for structurally related compounds.
50
 
The stepwise addition of lithium picrate to a 9:1 
CD3CN/CDCl3 solution of 41 determined a  simplification of  
1
H NMR spectrum, reflecting the formation of a 
conformationally rigid C1-symmetric
64
 lithiated species and 
confirming the ability of cyclohexapeptoids to complex alkali 
metals (see section 1.2.5).
50
 Observation of the C
γ
 signals of 
proline residues in
13
C NMR spectrum  (δ = 25.8 and 25.4 in 
41 as lithium salt) indicates a trans N-methoxyethyl glycine-
proline peptoid junction. Resonances at δ = 21.7 and δ = 24.0 
correspond, infact, to the amide cis and trans X-Pro peptide 
                                                 
64 The absence of symmetry in 41 as a lithium salt (despite the C2 symmetry of its chemical 
structure) is ascribable to a nonsymmetric disposition of the carbonyls around the lithium 
cation. 






Overall, the presence of the two proline monomers did not 
seem to give any conformational restriction to the 
macrocycle.  
Cyclization of oligomer 53 afforded in 28% yield 





). It has been the first time that a cyclopeptoid 
exhibited a so high affinity with sodium to result in 
complexation during the cyclization step in glass vessels. 
Metal complexation was demonstrated by the presence of a 3-
fold symmetric species in the rt 
1
H-NMR spectrum and 
further by crystallization. The geometry of the N-
methoxyethyl glycine-Pro bond of the complex was trans as 
inferred by the 
13
C NMR resonance of the C
γ
 proline residue 
signal (δ = 25.0).
65 
Metal-free 42 was obtained through a demetallation procedure 
starting from the sodium complex (see section 2.3.2). 
  In order to better understand the influence of the 
proline residue on the structural properties, the proline-free N-
methoxyethyl cyclo hexapeptoid 43 was synthesized.
 
Particularly, purification of the crude after macrocyclyzation 







 On the other hand, 
purification by HPLC after cyclization step allowed to obtain 
                                                 
65 S. K. Sarkar, P. E. Sullivan, C. E. Torchia Proc. Natl. Acad. Sci. U.S.A., 1984, 81, 4800-
4803. 
66 The affinity of 43 for alkali metals induces complexation during the silica-gel column 
chromatography. 
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43 in uncomplexed form (29% yield).  
2.3.2 Decomplexation procedure of  the  
triprolinate cyclopeptoid 
  In order to isolate the uncomplexed species of 42 (the 
triprolinate cyclopeptoid) some attempts were made. The 
cyclization reaction and the subsequent work-up were made 
using polypropylene vessels and ultrapure deionized water 
(HPLC grade). In this conditions the macrocyclization proved 
to be less efficient (15% by HPLC analysis), suggesting a 
metal-templated effect.
 
In any case the crude, containing the 
desired uncomplexed product, showed in 
1
H-NMR spectrum 
the contemporary presence of more than one conformer in 
slow exchange on the NMR time scale. In order to obtain the 
uncomplexed hexapeptoid 42 in pure form a decomplexation 
procedure was realized. 





CDCl3 (figure 2.6 a), AgNO3 in water  (0.1 M) was added (in 
order to exchange the metal present in the complex with 
silver) . The two phase blend was stirred for 30 min and 
formation of the silver complex was hypotized (figure 2.6 b). 
Me4NI, insoluble in CDCl3, was added to the organic phase 
containing the silver complex, and formation of a yellow 
precipitate (AgI) was observed. Filtration afforded 42 in 
uncomplexed form (figure 2.6 c). 
1
H NMR spectrum of the 
desired product was characterized by a complex signal pattern 
(illustrating the presence of multiple conformers in slow 
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exchange on the NMR time scale), which highlighted the lack 
of metal complexation. 
    
Figure 2.6: a) 
1
H-NMR spectrum of sodium complex of cyclohexapeptoid 
42. b) 
1
H-NMR spectrum of silver complex of cyclohexapeptoid 42. c) 
1
H-
NMR spectrum of uncomplexed cyclohexapeptoid 42.      
 









, 43 were 
crystallized and analyzed by X-ray diffraction.  
Different crystallization techniques were used: 
1. slow evaporation; 
2. liquid-phase diffusion; 
3. vapour-phase diffusion. 
Slow evaporation of a solvent from a saturated solution of the 
examined compound is a very simple crystallization 
technique. Typically, two or more solvents are used in order 
to form single crystals. Solvents should not be too volatile to 
avoid the formation of microcrystals onto the walls of 
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crystallization camera, as a consequence of the rapid 
decreasing of the solvent level.  
In the case of liquid-phase diffusion, the solid compound is 
dissolved into a proper liquid solvent and another liquid 
solvent (which results to be immiscible) is layered over the 
solution. The layered liquid slowly diffuses in the solution of 
the compound determining the precipitation and the following 
formation of crystals at the interface. 
Similarly, in the third crystallization technique mentioned, a 
non-solvent diffuses from the outer camera to an inner 
crystallization camera containing the solution of the 
compound. In this way, a precipitation is induced and crystals 
are formed. 
Tables 2.1, 2.2 and 2.3 show the obtained results with the 
crystallization trials. 
 










SOLVENT          
          3                
Technique Results 
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1 CHCl3  Slow evaporation Crystals 
2 CHCl3 CH3CN Slow evaporation Precipitate 
3 AcOEt CH3CN Slow evaporation Precipitate 




6 CH3CN CH(CH3) 2OH Slow evaporation Little crystals 
7 CH3CN MeOH      Slow evaporation Crystalline 
precipitate 
8 Hexane CH3CN Diffusion between two 
liquids 
Precipitate 
9 CH3CN       Slow evaporation Crystalline 
precipitate 
 
Table 2.3: Results of crystallization of cyclopeptoid 43. 
 
# SOLVENT 1 SOLVENT 2 Technique Results 
1 AcOEt  Slow evaporation Crystals 
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shown at the entry 8 (table 2.1) produced hexagonal white 





, conditions shown at the entry 5 (table 
2.2) afforded prismatic colorless crystals (see section 2.3.5). 
Finally, compound 43 was crystallized making use of 
conditions shown at the entry 1 (table 2.3) (see section 2.3.5).  
2.3.4  Structural analysis of the triprolinate 
cyclopeptoid  





 (the triprolinate cyclopeptoid), 
suitable for synchrotron radiation diffraction studies, were 
harvested using the diffusion in vapour phase of hexane in 
an acetonitrile solution. Specifically, X-ray diffraction 
measurements were performed at beam line ID11 of 
European Synchrotron Radiation Facility (ESRF) located in 
Grenoble (FRANCE).  
The obtained structure demonstrated the complexation of 
42 with Na
+
 and the presence of PF6
-
, as counter ion 
derived from macrocyclization coupling agent HATU.  
The crystals showed a trigonal lattice (a = 16.382(5)° Å, c = 
39.89(2)° Å; space group = R3). X-ray diffraction data 
indicated that crystals correspond to a complexed species, 
made of three molecules of cyclopeptoid 42, four sodium 
cations and one molecule of acetonitrile (Na4cPP3L
4+
, 
cPP=cyclopeptoid 42, L=CH3CN) which form a triple-decker 
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salt sandwich (figures 2.7). Such complexed species proved to 
have C3 symmetry because a ternary cristallographic axis 
crosses the four sodium atoms, centers of gravity of the three 
cyclopeptoid rings and molecular axis of acetonitrile.  
In all the three cyclopeptoid rings the conformation of the 
cyclopeptoid backbone is all-trans, the carbonyl groups 
alternately point toward the sodium cations and force the N-
linked side chains to assume an alternate pseudo-equatorial 
arrangement (figure 2.8), as previously observed by De 










It is interesting to notice that the edge sodium ions complete 
the coordination sphere in two different ways: on one side by 
coordinating three alternate carbonyl groups and an 
acetonitrile molecule (bottom face of the complex: Na1 ion, 
fig. 2.7); on the opposite side by linking all six carbonyl 
groups (top side of the complex: Na4 ion, fig. 2.7). The 
distances between the Na ions and the mean planes 
constituted by C and N atoms of the rings are the following: 
Na1 1.93Å, Na2 2.17 and 1.84Å, Na3 2.76 and 2.45Å, Na4 
0.79Å. The last distance strongly suggests a cation-π 
interaction between Na4 and the π-bond of the carbonyl 




The unit cell presents three triple-decker metal complexes 
Na4cPP3L
4+
 and twelve anions PF
6
-
 (to allow for 
electroneutrality) together with other nine molecules of 
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acetonitrile, which occupy interstitial positions. The N-
methoxyethyl side chains are excluded by metal 
coordination, hampering crystal network extension. 














CN). The counter ion nature 
was justified considering that complex formation occurred 





The crystal packing is illustrated in figure 2.9. 
 















, constituted from three molecules of cyclopeptoid 












Figure 2.8: X-ray molecular structure of a single cyclopeptoid 




























2.3.5  Structural analysis of  N-
methoxyethy  cyclohexapeptoid 





for X-ray diffraction analysis, were obtained by slow 
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diffusion of ethyl acetate in an acetonitrile solution. 
Even in this case X-ray analysis confirmed the presence of the 
complexed form. In particular, the complexation took place 
during silica gel column purification of the crude. 
The crystals showed a triclinic lattice (a = 8.805(3) Å,  b = 
11.014(2) Å,  c = 12.477(2) Å, = 70.97(2)°, β = 
77.347(16)
°
, = 89.75(2)°; space group = P-1).   





 (figure 2.10). 
The metal adduct of 43 is characterized by unique properties, 
in  the following described. 
Each sodium ion results to be coordinated to three carbonyl 
groups and two side chains methoxy groups, one belonging to 
the same cyclopeptoide molecule and the other from an 
adiacent one (figure 2.11). Examples of pentacoordinated 
sodium atom have been observed in G-quadruplex DNA.
67
 
Side chain methoxy groups allow the formation of a 1D 
polymeric chain made of cyclopeptoid molecules and sodium 
ions extending along b axis (figure 2.11). 
Two side chains are folded toward the center of the 
cyclopeptoid ring to bind two sodium ions, two side chains 
extend outside to bind two other sodium ions and extend the 
polymeric structure, the remaining two other side chains point 
outward and are involved in crystal packing interactions. 
PF6

 ions (from HATU) are located in the interstitial space 
                                                 
67 (a) A. Wrong, G. J. Wu Phys. Chem. A, 2003, 107, 579-586; (b) J. T. Davis Angew. Chem. 
Int. Ed., 2004, 43, 668-698. 
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amongst the chains. 
The aggregative forces generate the first metal-organic 
frameworks (MOF) structure based on peptoids as linkers. 
 
















                     a                                                                                 b 
 
 
                                                                                                     
                                                                                                                    





as view along b 
axis. b) Crystal packing as view along a axis. 
 
Purification by HPLC after cyclization step proved to be 
successful and 43 was isolated in uncomplexed form and 
crystallized from ethyl acetate by slow evaporation. 
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 The crystals of 43 in uncomplexed form showed a triclinic 
lattice (a = 8.358(4) Å,  b = 9.176(4) Å, c = 11.623(4) Å,  
= 99.636(6)°, β = 101.488(12)°, = 104.239(13)°; space 
group = P-1).    





, the X-ray structure of 43 
possesses a crystallographic inversion center (figure 2.12). 
Instead, the backbone conformation results to be tcctcc (figure 
2.12), a typical conformation for a decomplexed 
cyclohexapeptoid (24, section 1.2.4).
49
 
Indeed, in the case of compound 43 the template effect of 
metal complexation can be confirmed due to the fact that the 
presence of  Na
+
 induces a conformational change in the 
peptoid bond configuration from the tcctcc geometry to the 
all-trans geometry. 
From the comparison between the crystal structures of 
cyclopeptoid 43 in free and complexed form, it is remarkable 
to notice that in both forms cyclopeptoid molecules are 
stacked  along the a axis to form columns (figure 2.13). 
Therefore, in spite of different ring conformation 
cyclopeptoid molecules in the free form are pre-organized to 
stack in columns and to host the metal ion. Substantially, the 
presence of the cation does not seem to modify the crystal 
packing.  












Figure 2.13: Crystal packing of 43 in complexed (left) and free form 
(right) as view along a axis. 
2.4 N-methoxyethyl cyclopeptoid containing 
pseudo-proline residues 
 In order to perform the solid phase synthesis of the 
linear precursor of 44, a dipeptide building block 65 (scheme 
2.2) containing the pseudoproline residue 49 was previously 
prepared. This kind of approach is required because of the 
low nucleophilicity of the secondary amine in addition to the 
steric hindrance imposed by the two methyl groups of the 2,2-
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The synthesis of the peptoid monomer 62 was realized as 
shown in scheme 2.2. The 2,2-dimethyl-1,3-thiazolidine-4-




The dipeptide building block 65 was obtained in 58% overall 
yield forming the Fmoc protected N–methoxyethylglycine 
fluoride of peptoid monomer with (diethylamino)sulfur 






                                                 
68 A. Wittelsberger, L. Patiny, J. Slaninova, C. Barberis, M. Mutter J. Med. Chem. 2005, 48, 
6553-6562. 
69 N.J. Lewis, R. L. Inloes, J. Hes, J. Med. Chem., 1978, 21, 1070-1072. 


















































 Synthesis of the peptoid monomer

























Scheme 2.2: Synthesis of the peptoid-peptide unit 63 (dipeptide building 
block). 
A classic monomer approach on solid phase produced the 
linear precursor of compound 44 in 40% yield (scheme 2.3). 
 
 




































Scheme 2.3: Synthesis of linear precursor for 44. Reagents and 
conditions: (a) 65, DIPEA, DCM; (b) Piperidine-DMF (1:5); (c) 65, 
HATU, DIPEA, DMF; (e) (CF3)2CHOH-DCM (1:5). 
 The linear compound 66 was subjected to three 
attempts of cyclization respectively with coupling agents 
HATU,  PyBOP,  FDPP (scheme 2.4). HATU and PyBOP are 
the most used coupling agents, while FDPP is considered to 
be an efficient coupling agent for the cyclization of 
cyclopeptides containing pseudo prolines.
71
 Unfortunately, in 
all cases it was obtained a complex mixture which did not 
contain the target molecule 44 (ES-MS analysis). We realized 
that, evidently, the impurities contained in the crude could 
influence the progress of the cyclization reaction.  
Futhermore, in order to remove most of the impurities a RP-
HPLC purification of the linear precursor 66 was achieved. 
Afterwards, to our delight, the cyclization of the purified 
linear peptoid with HATU in DMF was successfully 
                                                 
71 K. A. Fairweather, N. Sayyadi, I. J. Luck, J. K. Clegg, K. A. Joliffe Org. Lett., 2010, 12, 
3136-3139.  
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performed.  Finally, a RP-HPLC purification on a C18 
reversed-phase semi-preparative column of the crude cycle 





























Scheme 2.4: Cyclization of compound 66 in high dilution condition. 
 The cycle 44 was conformationally flexible in solution 
as indicated by its 
1
H NMR spectrum. Therefore, pseudo-
proline residues are not able to costrain the peptoid 
macrocycle as in the case of proline residues.  
In order to simplify the 
1
H NMR spectrum of the compound 
was tried at first the stepwise addition of lithium picrate, 
which this time did not induce a simplification of the 
spectrum through the formation of a rigid complex. 
We also registered high temperature 
1
H NMR spectra of the 
compound (up to 100 
°
C) in order to produce a conversion 
between rotamers more rapid in the NMR time scale, but a 
simplification was not obtained. 
With respect to the X-ray characterization, the following 
crystallization trials were unsuccessfully conducted on 
compound 44: a) Slow evaporation from a solution of AcOEt: 
CHCl3 1:1 (v/v); b) slow evaporation from a solution of 
 2  P R O L I N E - R I C H  C Y C L O P E P T O I D S 
 
 74 
CHCl3; c) slow evaporation from a solution of CH3CN; d) 
slow evaporation from a solution of CF3CH2OH. In table 2.4 
the solubility scale of 44 is reported. In definitive, it was not 
possible to evaluate the effect of pseudo-proline residues on 
the crystal structure. 
Table 2.4: Solubility scale of 44. 
 
Solvent Solubility order 
CHCl3 1 




In this chapter, the synthesis and structural characterization of 
the proline-rich cyclopeptoids 41, 42 and N-methoxyethyl 
cyclopeptoid 43 (proline-free) were reported. In addition, the 
synthesis of the pseudo-proline rich cyclopeptoid 44 was 
successfully obtained. 
First of all, NMR analysis of the proline-rich and 
pseudo-proline rich cyclopeptoids demonstrated that prolines 
and pseudo-prolines residues are not able to stabilize the 
conformation of cyclopeptoids in solution with respect to our 
expectations, on the other hand metal ions such as Na+ induce 
conformational rigidity in the macrocycle backbone.  
Notably, structural analysis via X-ray diffraction 
emphasized that rigid L-proline and chelating N-methoxyethyl 
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glycine residues determine the formation of fascinating 
metalated supramolecular frameworks.  
In particular, compound 42 was crystallized in the 




-. The crystal structure 
was characterized by the formation of a triple-decker salt 
sandwich metal complex Na4cPP3L
4+
 (cPP=cyclopeptoid 42, 
L=CH3CN) with a crystallographic 3-fold rotation symmetry. 
In addition, the geometry of the amide linkages in all three 
cyclopeptoid macrocycles present in metal complex of 42 is 
trans as in the case of a cyclopeptoid strontium complex 








 Compound 43 was crystallized both in the sodium 
complex and free form. In the sodium complex two sodium 
ions and one cyclopeptoid  molecule are linked to form a 1D-
coordination polymer extending along the a axis. In addition, 
the configuration of the amide bonds in the macrocycle is all-
trans. 
With respect to the free form, the crystal packing is 
practically the same of the complexed form, as an evidence of 
a pre-organization of the structure. Instead, the amide bond 
pattern is the typical tcctcc. As a consequence, Na
+
 is 
responsible for a template effect determining a 
conformational change in the peptoid bond pattern from the 
tcctcc to the all-trans geometry. 
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2.6 Experimental section 
2.6.1 General procedures 
Reagents purchased from commercial sources were used 
without further purification. All reactions involving air or 
moisture sensitive reagents were carried out under a dry argon 
atmosphere. CH2Cl2 was distilled from CaH2. Glassware was 
flame-dried (0.05 Torr) prior to use. When necessary, 
compounds were dried in vacuo over P2O5 or by azeotropic 
removal of water with toluene under reduced pressure. 
Starting materials and reagents purchased from commercial 
suppliers were generally used without purification. Reactions 
were monitored by TLC on silica gel plates (0.25 mm) and 
visualized by UV light or by spraying with  ninhydrin 
solutions or drying with iodine. Flash chromatography was 
performed on Silica Gel 60 (particle size: 0.040–0.063 mm) 
and the solvents employed were of analytical grade. HPLC 
analysis was performed on C18 reversed-phase analytical and 
semipreparative columns (Waters, Bondapak, 10 μm, 125 Å, 
3.9 mm × 300 mm and 7.8 × 300 mm, respectively) using a 
Modular HPLC System JASCO LC-NET II/ADC, equipped 
with a JASCO Model PU-2089 Plus Pump and a JASCO MD-
2010 Plus UV-vis multiple wavelength detector set at 220 nm. 





C NMR) pure materials. The NMR spectra were 
recorded on Bruker DRX 400, (
1
H at 400.13 MHz, 
13
C at 
100.03 MHz), Bruker DRX 250 (
1
H at 250.13 MHz, 
13
C at 
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62.89 MHz), and Bruker DRX 300 (
1
H at 300.1 MHz, 
13
C at 
75.5 MHz) spectrometers. Chemical shifts (δ) are reported in 
ppm relatively to the residual solvent peak (CHCl3, δ = 7.26, 
13
CDCl3, δ = 77.0; CD2HCN, δ = 1.98; 
13
CD3CN, δ = 1.80; 
CD2HOD, δ = 4.78, 
13
CD3OD, δ = 49.2, in the case of solvent 
mixtures, the considered residual peak was that of the most 
abundant deuterated solvent). The multiplicity of each signal 
is designated by the following abbreviations: s, singlet; d, 
doublet; t, triplet; q, quartet; m, multiplet; b, broad. Coupling 
costants (J) are quoted in Hz. Homonuclear decoupling, 
COSY-45 and DEPT experiments completed the full 
assignment of each signal. High resolution ESI-MS spectra 
were performed on a Q-Star Applied Biosystem mass 
spectrometer. ESI-MS analysis in positive ion mode was 
performed using a Finnigan LCQ Deca ion trap mass 
spectrometer (ThermoFinnigan, San Josè, CA, USA) and the 
mass spectra were acquired and processed using the Xcalibur 
software provided by Thermo Finnigan. Samples were 
dissolved in 1:1 CH3OH/H2O, 0.1 % formic acid, and infused 
in the ESI source by using a syringe pump; the flow rate was 
5 μl/min. The capillary voltage was set at 4.0 V, the spray 
voltage at 5 kV, and the tube lens offset at 4.0 V. The 
capillary temperature was 220 °C. Data were acquired in 
MS1and MSn scanning modes. Zoom scan was used in these 
experiments.  
X-ray analysis was performed with a Rigaku AFC11K 
diffractometer equipped with a Saturn944 CCD detector using 
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CuKα radiation and with a Rigaku AFC7S diffractometer 
equipped with a Mercury
72
 CCD detector using MoKα 
radiation. 
2.6.2  Solid-phase synthesis  
Mixed monomer/submonomer solid-phase 
synthesis  of linear precursors 55-57 
Linear peptoids 55-57 were synthesized by alternating 
submonomer and monomer solid-phase methods using 
standard manual Fmoc solid-phase peptide synthesis 
protocols. Typically 0.40 g of 2-chlorotrityl chloride resin 
(2,α-dichlorobenzhydryl-polystyrene crosslinked with 1% 
DVB; 100-200 mesh; 1.20 mmol/g) was swelled in dry DCM 
(4 mL) for 45 min and washed twice in dry DCM (3 mL). To 
the resin bromoacetic acid (107 mg, 0.77 mmol) and DIPEA 
(418 μL, 2.4 mmol) in dry DCM (4 mL) were added on a 
shaker platform for 40 min at room temperature, washes with 
dry DCM (3 × 4 mL) and then with DMF (3 × 4 mL) 
followed. To the bromoacetylated resin metoxyethylamine 
(413 μl, 4.80 mmol) in dry DMF (4 mL), was added. The 
mixture was left on a shaker platform for 40 min at room 
temperature, then the resin was washed with DMF (3 × 4 
mL). The resin was incubated with a solution of N-Fmoc-L-
proline (4.85 mg, 1.44 mmol), HATU (529 mmol, 1.39 
mmol), DIPEA (333 μl ) in dry DMF (4 mL) on a shaker 
platform for 1 h, followed by extensive washes with DMF (3 
                                                 
72 CrystalClear, Crystal Structure Analysis Package, Rigaku-Molecular Structure Corp. 
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× 4 mL), DCM (3 × 4 mL) and DMF (3 × 4 mL). Chloranil 
test was performed and once the coupling was complete the 
Fmoc group was deprotected with 20% piperidine/DMF (v/v, 
3 mL) on a shaker platform for 3 min and 7 min respectively, 
followed by extensive washes with DMF (3 × 3 mL), DCM (3 
× 3 mL) and DMF (3 × 3 mL). The yields of loading step and 
of the following coupling steps were evaluated interpolating 
the absorptions of dibenzofulvene-piperidine adduct (λmax = 





), obtained in Fmoc deprotection step (the average 
coupling yield was 63-70 %). Subsequent bromoacetylation 
reactions were accomplished by reacting the oligomer with a 
solution of bromoacetic acid (690 mg, 4.8 mmol) and DIC 
(817 μL, 5.28 mmol) in DMF (4 mL) on a shaker platform 40 
min at room temperature. Subsequent N-Fmoc-L-proline 
addition and Fmoc deprotection steps were performed as 
described above, addition of the proline at the fourth and sixth 
position required longer reaction time (2.5 h) and two 
treatments. The synthesis proceeded until the desired 
hexaoligomer was obtained. The oligomer-resin was cleaved 
in 4 mL of 20% HFIP in DCM (v/v). The cleavage was 
performed on a shaker platform for 30 min at room 
temperature the resin was then filtered away. The resin was 
treated again with 4 mL of 20% HFIP in DCM (v/v) for 5 
min, washed twice with DCM (3 mL), filtered away and the 
combined filtrates were concentrated in vacuo. The final 
products were dissolved in 50% ACN in HPLC grade water 
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and analysed by RP-HPLC and ESI mass spectrometry. The 
linear compounds were subjected to the cyclization without 
further purification. 
 Compound 55 
Purity: >95%. 
Yield: 62% (crude residue). 
ES-MS: 655.6 m/z [M + H
+
]. 
HPLC: tR: 10.5 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 Compound 56 
Purity: >95%. 
Yield: 70% (crude residue). 
ES-MS: 673.9 m/z [M + H
+
]. 
HPLC: tR: 10.3 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 Compound 57 
Purity: >95%. 
Yield: 40% (crude residue). 
ES-MS: 655.6 m/z [M + H
+
]. 
HPLC: tR: 10.2 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
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Submonomer solid-phase synthesis of linear 
precursor 58 
Linear peptoid  58 was synthesized using a submonomer 
solid-phase approach. 
Typically 0.40 g of 2-chlorotrityl chloride resin (2,α-
dichlorobenzhydryl-polystyrene crosslinked with 1% DVB; 
100-200 mesh; 1.20 mmol/g) was swelled in dry DCM (4 mL) 
for 45 min and washed twice in dry DCM (4 mL). The first 
sub-monomer was attached onto the resin by adding 
bromoacetic acid (107 mg, 0.77 mmol) and DIPEA (418 μL, 
2.4 mmol) in dry DCM (4 mL) on a shaker platform for 40 
min at room temperature, followed by washing with dry DCM 
(3 × 4 mL) and then with DMF (3 × 4 mL). To the 
bromoacetylated resin metoxyethylammine (413 μl, 4.80 
mmol) in dry DMF (4 mL), was added. The mixture was left 
on a shaker platform for 40 min at room temperature, then the 
resin was washed with DMF (3 × 4 mL). Subsequent 
bromoacetylation reactions were accomplished by reacting the 
oligomer with a solution of bromoacetic acid (690 mg, 4.8 
mmol) and DIC (817 μL, 5.28 mmol) in DMF (4 mL) on a 
shaker platform 40 min at room temperature. The filtered 
resin was washed with DMF (3 × 4 mL) and treated again 
with methoxyethylamine under the same conditions reported 
above. This cycle of reactions was iterated until the target 
oligomer was obtained. The oligomer-resin was cleaved in 4 
mL of 20% HFIP in DCM (v/v). The cleavage was performed 
on a shaker platform for 30 min at room temperature the resin 
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was then filtered away. The resin was treated again with 4 mL 
of 20% HFIP in DCM (v/v) for 5 min, washed twice with 
DCM (3 mL), filtered away and the combined filtrates were 
concentrated in vacuo. The final products were dissolved in 
50% ACN in HPLC grade water and analysed by RP-HPLC 
and ESI mass spectrometry. The linear compound was 
subjected to the cyclization without further purification. 
 Compound 58 
Purity: >95%. 
Yield: 65% (crude residue). 
ES-MS: 709.0 m/z [M + H
+
]. 
HPLC: tR: 10.4 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
Monomer solid-phase synthesis of linear 
precursor 66 
Linear peptoid 66 was synthesized using a monomer solid-
phase approach. 
Typically 0.30 g of 2-chlorotrityl chloride resin (2,α-
dichlorobenzhydryl-polystyrene crosslinked with 1% DVB; 
100-200 mesh; 1.20 mmol/g) was swelled in dry DCM (3 mL) 
for 45 min and washed twice in dry DCM (3 mL). To the 
resin monomer 65 (99 mg, 0.2 mmol) and DIPEA (139 μL , 
0.8 mmol) in dry DCM (3 mL) were added on a shaker 
platform for 1 h at room temperature, washes with dry DCM 
(3 × 3 mL) and then with DMF (3 × 3 mL) followed. The 
resin was capped with a solution of DCM/CH3OH/DIPEA 
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17:2:1 (3 mL) on a shaker platform for 30 min at room 
temperature, followed by extensive washes with DMF (3 × 3 
mL), DCM (3 × 3 mL) and DMF (3 × 3 mL). Fmoc group was 
deprotected with 20% piperidine/DMF (v/v, 3 mL) on a 
shaker platform for 3 min and 7 min respectively, followed by 
extensive washes with DMF (3 × 3 mL), DCM (3 × 3 mL) 
and DMF (3 × 3 mL). The yields of loading step and of the 
following coupling steps were evaluated interpolating the 
absorptions of dibenzofulvene-piperidine adduct (λmax = 301 




), obtained in Fmoc deprotection step 
(the average coupling yield was 63-70 %). Subsequently, the 
resin was incubated with a solution of monomer 65 (199 mg, 
0.4 mmol), HATU (145 mg, 0.38 mmol), DIPEA (139 μl, 0.8 
mmol) in dry DMF (3 mL) on a shaker platform for 2 h at 
room temperature. Chloranil test was performed and once the 
coupling was complete the Fmoc group was deprotected in 
the conditions described above. The last addition of monomer 
65 was carried out in the aforementioned conditions. The 
oligomer-resin was cleaved in 3 mL of 20% HFIP in DCM 
(v/v). The cleavage was performed on a shaker platform for 
30 min at room temperature and the resin was then filtered 
away. The resin was treated again with 3 mL of 20% HFIP in 
DCM (v/v) for 5 min, washed twice with DCM (3 mL), 
filtered away and the combined filtrates were concentrated in 
vacuo. The final product was dissolved in 50% ACN in HPLC 
grade water and analysed by RP-HPLC and ESI mass 
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spectrometry. Linear compound was purified by 
semipreparative RP-HPLC. 
 Compound 66 
Yield: 10% (purified by RP-HPLC). 
ES-MS: 793.3 m/z [M + H
+
]. 
HPLC: tR: 11.3 min; conditions: 25 →100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 2 mL 
min
−1
, 220 nm. 
2.6.3  General procedure for high dilution 
cyclization 
Synthesis of 41-44 
To a stirred solution of HATU (116 mg, 0.31 mmol), DIPEA 
(0.082 mL, 0.47 mmol) in dry DMF (20 mL) at room 
temperature, a solution of the linear compounds (crude 55-58, 
HPLC purified 66) (0.08 mmol) in dry DMF (20 mL) was 
added by syringe pump in 6 h. After 48 h (41, 42) or 12 h (43, 
44) the resulting mixture was concentrated in vacuo, diluted 
with DCM (20 mL) and washed with 1 M HCl (7 mL × 3). 
The mixture was extracted with DCM (10 mL × 2) and the 
combined organic phases were washed three times with water 
(10 mL), dried (MgSO4) and concentrated in vacuo. The 
crude residues from the HATU-induced cyclizations were 
purified by flash chromatography
73
 or by RP-HPLC. 
                                                 
73
 The high affinity of cyclohexapeptoids for alkali metals induces complexation during the 
silica-gel column chromatography or, in case of strongly coordinating compounds, even 
during their synthesis (and work-up procedures). A useful way to obtain metal-free 
compounds is to avoid glassware during their synthesis and manipulation (including glass 
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 Compound 41 
Yield: 20%. The crude residue from the HATU-induced 
cyclization was purified by flash chromatography 
(DCM/MeOH, from: 100/0 to 70/30). 
ES-MS: 677.0 m/z [M+Na
+
]. 
HPLC: tR: 13.2 min; conditions: 5 → 100% B in 30 min 
(A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile), flow: 
1.0 mL min
−1
, 220 nm. 
1
H NMR (400 MHz, CD3CN:CDCl3 9:1, mixture of 
rotamers) δ: 5.38 (0.3H, m, COCHN), 5.09-3.37 (29.7H, m, 
COCHN, COCH2N, NCH2CH2O, NCH2CH2O, 
CHCH2CH2CH2N), 3.36-3.20 (12H, bs, OCH3) 2.45-
1.82(8H, m, CH2CH2CH2N, CHCH2CH2CH2N). 
13
C NMR (100 MHz, CDCl3, mixture of rotamers) δ: 
172.7, 172.3, 170.6, 169.8, 169.1, 166.8, 166.3, 165.9, 71.8, 
71.1, 70.9, 70.5, 70.2, 69.6, 66.8, 59.1, 58.9, 58.7, 58.6, 
57.9, 57.8, 57.1, 55.1, 52.2, 51.5, 50.6, 50.3, 50.1, 49.9 
49.7, 49.4, 48.2, 47.8, 47.5, 47.1, 46.7, 46.3, 46.2, 43.2, 
39.6, 38.8, 32.0, 31.4, 30.1, 29.7, 29.2, 28.7, 25.5, 25.1, 
24.4, 23.2, 22.7, 22.1.  
 Compound 41 with lithium picrate 
To a 4.0 mM solution of 41 in CD3CN:CDCl3 9:1 (0.5 mL), 
were added 3 mg of lithium picrate. After the addition the 
                                                                                                     
pipettes or vials), use ultrapure water in the work up procedures and avoid silica-gel  column 
chromatography. Sometimes HPLC purification is able to break the complexes and liberate 
the cyclohexapeptoids from the metals. Cyclohexapeptoids should always be collected in 
polypropylene tubes and stored in eppendorf vials or falcon tubes. In the case of the highly 
coordinating cyclopeptoids, the NMR spectra should always be performed in teflon tubes.  
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suspension was stirred vigorously for 15 minutes and the 
1
H NMR and 
13
C NMR spectra was recorded. 
1
H NMR (400 MHz, CD3CN/CDCl3 = 9/1) δ: 8.75 (7H, s, 
protons of picrate present in excess), 4.82 (1H, m, COCHN, 
pro-1), 4.76 (1H, d, J = 15.0 Hz, NCHHCO), 4.65 (1H, d, J 
= 12.0 Hz, NCHHCO), 4.41 (2H d, J = 12.0 Hz, 
NCHHCO), 4.34 (1H, d, J = 15.0 Hz, NCHHCO), 4.34 (m, 
1H, COCHN, pro-2), 3.89-3.12 (23H, m, NCHHCO, 
NCH2CH2O, NCH2CH2O, CHCH2CH2CH2N), 3.38 (3H, s, 
OCH3), 3.35 (3H, s, OCH3), 3.30 (3H, s, OCH3), 3.29 (3H, 
s, OCH3), 2.45 (1H, m, CHCHHCH2CH2N, pro-1), 2.30 
(1H, m, CHCHHCH2CH2N, pro-2) 2.26-1.95 (4H, m, 
CHCH2CH2CH2N, pro-1 and pro-2 overlapped with 
CD2HCN), 1.93 (1H, m, CHCHHCH2CH2N, pro-1), 1.88 
(1H, m, CHCHHCH2CH2N, pro-2).  
13
C NMR (62.89 MHz, CD3CN/CDCl3 = 9/1) δ: 173.9, 
172.8, 172.2, 171.5, 168.3, 166.6, 71.7, 71.4, 71.2, 70.9, 
70.3, 59.9, 59.8, 59.7, 59.3, 59.1, 58.7, 52.2, 51.7, 51.1, 
50.3, 50.6, 50.0, 49.6, 49.4, 49.2, 48.0, 30.7, 30.3, 26.3, 
25.7.  
 Compound 42 with Na+PF
6
-  
Yield: 28%. The crude residue from the HATU-induced 
cyclization was purified by flash chromatography 
(DCM/MeOH, from: 98/2 to 70/30).
73
 
ES-MS: 659.5 m/z [M + Na
+
]; 341.4 m/2z [M + 2Na
+
]. 
 2  P R O L I N E - R I C H  C Y C L O P E P T O I D S 
 
 87 
HPLC: tR: 13.5 min.; conditions: 5 → 100% B in 30 min 
(A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile), flow: 
1.0 mL min
−1
, 220 nm. 
[α]
D
: -6.2 (c =1.0, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ: 4.81 (3H, m, COCHN), 
4.51 (3H, d, J = 16.6 Hz, NCHHCO), 3.74 (3H, m, 
NCHHCH2O), 3.72 (3H, d, J = 16.6 Hz, NCHHCO), 3.61-
3.50 (15H, m, CHCH2CH2CH2N, NCH2CH2O and 
NCH2CH2O), 3.33 (9H, s, OCH3), 2.30 (3H, m, 
CHCHHCH2CH2N), 2.04 (6H, m, CHCH2CH2CH2N), 1.92 
(3H, m, CHCHHCH2CH2N).  
13
C NMR (100 MHz, CDCl3) δ: 174.2 (× 3, q), 168.0 (× 3, 
q), 70.3 (× 3, CH2), 58.9 (× 3, CH3), 58.0 (× 3, CH), 50.3 (× 
3, CH2), 49.4 (× 3, CH2), 46.5 (× 3, CH2), 29.2 (× 3, CH2), 
25.0 (× 3, CH2).  
 Compound 43 
Yield: 29%. The crude residue from the HATU-induced 
cyclization was purified by RP-HPLC on a C18 reversed-
phase semi-preparative column (tR: 18.0 min.; conditions: 5 
→ 100% B in 30 minutes (A: 0.1% TFA in water, B: 0.1% 
TFA in acetonitrile), flow: 2.0 mL min
−1
, 220 nm). 
ES-MS: 691.8 m/z [M + H
+
]; 713.7 m/z [M + Na
+
]. 
HPLC: tR: 11.8 min.; conditions: 5 → 100% B in 30 min 
(A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile), flow: 
1.0 mL min
−1
, 220 nm. 




H-NMR (400 MHz, CDCl3, mixture of rotamers) δ: 10.1 
(CF3COOH), 4.92–3.86 (m, 12 H, COCH2N), 3.86–2.80 (m, 
42 H, NCH2CH2O, NCH2CH2O, OCH3). 
13
C-NMR (100 MHz, CDCl3, mixture of rotamers) δ: 171. 5, 
171.0, 170.6, 170.1, 170.0, 169.8, 169.7, 169.5, 169.3, 169.1, 
168.9, 168.7, 168.2, 168.1, 158.7 (q, J = 40 Hz, CF3COOH), 
115.0 (q, J = 285 Hz, CF3COOH), 71.7, 71.5 , 71.4 , 71.3, 
71.0, 70.8, 70.6, 70.2, 70.0, 69.8, 69.6, 69.3, 69.1, 68.8, 68.7 , 
59.1 , 58.9, 58.6, 58.2, 53.4, 52.5, 52.3, 50.9, 50.7, 50.4, 50.3, 
50.2, 49.9, 49.1, 48.7, 48.4 , 48.3, 48.0, 47.6 , 47.4, 47.0, 46.8, 
46.6, 45.9, 45.5, 43.3. 
 Compound 44 
Yield: 41%. The crude residue from the HATU-induced 
cyclization was purified by RP-HPLC on a C18 reversed-
phase semi-preparative column (tR: 13.2 min.; conditions: 
25 → 100% B in 30 min (A: 0.1% TFA in water, B: 0.1% 
TFA in acetonitrile), flow: 2.0 mL min
−1
, 220 nm). 





: - 6.7 (c =1.0, CHCl3). 
1
H-NMR (400 MHz, CDCl3, mixture of rotamers) δ: 5.64-
4.03 (18H, m, COCH2N), 3.91-2.89 (27H, m, NCH2CH2O, 
NCH2CH2O, SCH2, OCH3), 1.97-1.84 (18H, m, CH3). 
13
C-NMR (100 MHz, CDCl3, mixture of rotamers) δ: 172.6, 
172.4, 171.9, 171.8, 170.5, 170.4, 170.0, 168.3, 167.4, 167.0, 
166.6, 166.4, 166.3, 166.0, 165.3, 75.1, 75.0, 74.5, 74.1, 71.9, 
71.7, 71.5, 71.0, 70.6, 70.5, 70.3, 70.1, 69.9, 69.4, 68.0, 66.1, 
66.0, 65.9, 64.6, 64.3, 63.6, 63.0, 62.8, 62.4, 59.0, 58.8, 58.7, 
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54.1, 53.8, 53.3, 53.0, 52.6, 51.8, 51.7, 51.3, 50.9, 50.7, 50.6, 
50.3, 50.0, 49.7, 49.4, 49.2, 49.1, 49.0, 48.7, 48.4, 37.2, 31.6, 
31.5, 31.1, 31.0, 30.6, 30.5, 30.4, 30.0, 29.8, 29.7, 29.6, 27.3, 
26.6, 26.5, 26.3. 




To a solution of the compound 42, complexed with Na
+
 (22.0 
mg, 0.027 mmol) in CDCl3 (4.4 mL), a 0.1 M solution of 
AgNO3 in water (4.4 mL) was added. The two phase mixture 
was stirred for 30 min. The organic phase was washed with 
deuterated water and, after recording an 
1
H NMR, an excess 
of Me4NI (50 mg, 0.25 mmol) was added. The suspension 
was sonicated for 3 h in a sonicator bath and once filtered the 
excess of Me4NI and the AgI formed, the organic phase was 
again subjected to a 
1
H NMR, demonstrating the liberation of 
the cyclic peptoid from the metal complexation. 
 Compound 42 
ES-MS: 659.7 m/z [M + Na
+




H NMR (400 MHz, CDCl3, mixture of rotamers) δ: 5.53 
(0.75H, d, J = 17.6 Hz, NCHHCO), 5.40 (0.34H d, J = 18.8 
Hz, NCHHCO), 5.31 (0.34H, d, J = 14.0 Hz, NCHHCO), 
4.93 (0.34H, d, J = 14.0 Hz, NCHHCO), 4.79 (0.34H, m, 
COCHN), 4.74-4.61 (1.84H, m, COCHN), 4.60 (0.34H, d, 
J = 14.4 Hz NCHHCO), 4.48 (0.34H, d, J = 16.3 Hz 
NCHHCO), 4.34 (0.85H, m, COCHN), 4.25 (0.85H, d, J = 
18.0 Hz, NCHHCO), 4.14 (0.85H, d, J = 18.0 Hz, 
NCHHCO), 4.09-3-96 (1.6H, m, NCHHCO, NCH2CH2O), 
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3.91 (0.75H, d, J = 18.8 Hz, NCHHCO), 3.81-3.36 
(17.95H, m, NCH2CH2O, NCH2CH2O, CHCH2CH2CH2N), 
3.35 (0.44H, bs, OCH3), 3.34 (0.34H, bs, OCH3), 3.32 
(1.5H, bs, OCH3), 3.31 (0.44H, bs, OCH3), 3.30 (1.5H, bs, 
OCH3), 3.27 (2H, bs, OCH3), 3.15 (2.3H, bs, OCH3), 2.60-
1.73 (12H, m, CHCH2CH2CH2N, CHCHHCH2CH2N).  
13
C NMR (100 MHz, CDCl3, mixture of rotamers) δ: 
172.9, 172.5, 172.0, 171.6, 171.3, 170.45, 168.6, 168.4, 
167.6, 167.2, 166.9, 165.8, 71.9, 71.7, 70.6, 70.3, 70.2, 
68.8, 59.2, 59.0, 58.7, 58.4, 58.1, 56.3, 56.0, 53.4, 51.7, 
51.2, 50.9, 50.7, 50.2, 49.7, 49.4, 49.11, 48.9, 48.5, 47.9, 
47.6, 46.9, 47.3, 46.7, 46.3, 32.7, 31.9, 31.5, 31.2, 29.9, 
29.2, 28.6, 26.4, 25.7, 25.0. 
2.6.4  Synthesis of monomer 65 
 Synthesis of 61  
To a solution of  methoxyethylamine (4.1 mL, 47.8 mmol) in 
acetonitrile (80 mL), DIPEA (8.3 mL, 47.8 mmol) and ethyl 
bromoacetate (4.0 g, 23.9 mmol) were added. The reaction 
mixture was stirred overnight, concentrated in vacuo, 
dissolved in DCM (20 mL) and washed with brine solution. 
The aqueous layer was extracted with DCM (× 3). The 
combined organic phases were dried over NaSO4, filtered and 
the solvent evaporated in vacuo to give a crude material 61 
(3.8 g, 98%) which was used in the next step without further 
purification. 
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  Compound 61
 
1
H-NMR (400 MHz, CDCl3) δ: 4.18(2H, q, J = 7.1 Hz, 
OCH2CH3), 3.50 (2H, t, J = 4.7 Hz, CH2OCH3), 3.44(2H, s, 
COCH2), 3.35(3H, s, OCH3), 2.81(2H, t, J = 4.7 Hz, 
CH2NHCH2), 2.29 (1H, bs, CH2NHCH2), 1.26 (3H, t, J = 7.1 
Hz, OCH2CH3).            
13
C-NMR (75 MHz, CDCl3) δ: 171.8, 71.6, 60.6, 58.6, 50.6, 
48.5, 14.0. 
Synthesis of 62 
To a solution of  61 (0.48 g, 2.99 mmol) in 1,4-dioxane-water 
1:1 (30 mL) at 0°C, LiOH.H2O (0.21 g, 5.08 mmol) was 
added. After two hours, NaHCO3 (0.30 g, 3.59 mmol) and  
Fmoc-Cl (0.93 g, 3.59 mmol) were added. The reaction 
mixture was stirred overnight. Subsequently, KHSO4 (until 
pH= 3) was added and the mixture was concentrated in vacuo, 
dissolved in DCM (20 mL) and washed with brine solution. 
The aqueous layer was extracted with DCM (× 3). The 
combined organic phases were dried over NaSO4, filtered and 
the solvent evaporated in vacuo to give a crude material (1.4 
g, yellow oil), which was purified by flash chromatography 
(DCM/MeOH, from: 100/0 to 80/20, 0.1% ACOH) to give 62 
(0.86 g, 81%). 
  Compound 62
 
1
H-NMR (400 MHz, CDCl3, mixture of rotamers) δ: 7.55-
7.25 (8H, m, ArFmoc), 4.54 (2H, d, J = 6.4 Hz, CH2Fmoc), 
4.43 (2H, d, J = 6.4 Hz, CH2Fmoc), 4.26 (1H, t, J = 6.4 Hz, 
CHFmoc), 4.20 (1H, t, J = 6.4 Hz, CHFmoc), 4.10 (2H, s, 
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NCH2COOH), 4.04 (2H, s, NCH2COOH), 3.54 (4H, s, 
CH2OCH3), 3.34 (2H, s, NCH2CH2O), 3.31(3H, s, OCH3), 
3.24 (2H, s, NCH2CH2O), 3.22 (3H, s, OCH3).         
13
C-NMR (100 MHz, CDCl3, mixture of rotamers) δ: 174.2 
(× 2), 156.3, 155.9, 143.8 (× 2), 141.4, 141.3, 127.7 (× 4), 
127.1 (× 2), 127.0 (× 2), 124.9 (× 2), 124.8 (× 2), 119.9 (× 4), 
71.5, 71.3, 67.9, 67.5, 58.6 (× 2), 50.4 (× 2), 48.9, 48.3, 47.2, 
47.1. 
Synthesis of  49 
L-Cysteine hydrochloride monohydrate (63) (4.8 g, 22.8 
mmol) and 57 mL of 2,2-dimethoxypropane were refluxed for 
1 h at 60
°
C in 286 mL of acetone. Then, the reaction mixture 
was allowed to cool down to 25
°
C, filtered and the white solid 
washed with cold acetone to yield 49 (3.04 g, 68%). 
  Compound 49
 
1
H-NMR (400 MHz, D2O) δ: 4.80 (1H, m, CH, overlapped 
with water signal), 3.67 (1H, dd, J = 12.1, 7.4 Hz, SCHH), 
3.52 (1H, dd, J = 12.1, 7.4 Hz, SCHH), 1.86 (3H, s, CH3), 
1.84 (3H, s, CH3).  
13
C-NMR (100 MHz, D2O, 1,4-dioxane as internal standard) 
δ: 170.9, 73.5, 63.1, 32.3, 28.2, 27.2. 
Synthesis of 64 
To a solution of 62 (0.95 g, 2.67 mmol) in dry DCM (27 mL) 
at 0 
°
C, DAST (0.211 mL, 1.602 mmol) was added and the 
mixture was stirred for 1h. Then, after monitoring the reaction 
by TLC, more DAST was added (0.211 mL, 1.602 mmol) and 
the resulting mixture was allowed to react for 1h more. The 
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reaction was quenched by adding H2O, and the organic layer 
was washed with brine (× 1), dried over MgSO4, filtrated and 
concentrated under vacuum to give a crude material 64 which 
was used in the next step without further purification. 
Coupling of 62 and 49 
To a solution of 49 (0.788 g, 3.99 mmol) in dry DCM (80 
mL), 62 (0.95 g, 2.66 mmol) and DIPEA (1.02 mL, 5.85 
mmol) were added and the resulting mixture was stirred 
overnight under a N2 atmosphere. After, the organic layer was 
washed with a 5% aqueous solution of citric acid (× 1) and 
with brine (× 1), dried over MgSO4, filtrated and concentrated 
under vacuum. The residue was purified by silica flash 
(DCM/MeOH, from: 98/2 to 85/15) to give 65 (0.73 g, 55%). 
  Compound 65
 





: -22.0 (c = 1.0, CHCl3). 
1
H-NMR (300 MHz, C2D2Cl4, 100°C) δ: 7.62-7.15 (8H, m, 
ArFmoc), 4.74 (1H, bs, CHCOOH), 4.35 (2H, m, CH2Fmoc), 
4.10 (1H, m, CHFmoc), 3.94 (1H, d, J = 7.9 Hz, NCHHCO), 
3.82 (1H, d, J = 7.9 Hz, NCHHCO), 3.34-3.25 (4H, m, 
NCH2CH2OCH3), 3.16 (2H, m, SCH2), 3.13 (3H, s, OCH3), 
1.74 (3H, s, CH3), 1.70 (3H, s, CH3).             
13
C-NMR (75 MHz, C2D2Cl4, 100°C) δ: 172.9, 165.1, 154.7, 
142.3, 139.5, 127.2, 126.4, 123.0, 118.0, 69.3, 65.9, 65.8, 
62.6, 56.7, 49.8, 46.1, 45.8, 29.5, 28.2, 26.0.  
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2.6.5  X-ray analysis 





















CCDC 897772 897773 897774 
Formula C98H156F24N22Na4O27P4  
 












0.30060 CuKα MoKα 
Cristal system  trigonal triclinic triclinic 

























V (Å3 ) 97271(6) 1131(5) 824.5(6) 
Z 3 2 1 
DX (g cm
-3 
) 1.476 1.532 1.391 
μ (mm
-1 
) 0.016 2.105 0.107 
F(000) 4302 532 372 





11518 2648 3734 
Param. / 
restraints 
519 / 1 290 / 0 217 / 0 
R1[F0>4σ(F0)], 
wR2(all refl) 
0.1436, 0.485 0.116, 0.396 0.046, 0.1295 
GooF 2.29 1.396 1.075 
Δρ min (e Å
-3
), 
Δρ max (e Å
-3
) 







 was crystallized by slow diffusion of 
hexane in an acetonitrile solution. Rather small needle-like 
crystals resulted to be suitable for synchrotron radiation 





 was mounted on 
a cryo-loop and measured at 100 K at the European 
Synchrotron Radiation Facility beam line ID11.  
Data reduction was performed with the Bruker package 
(SMART, Saint, SADABS)
74
. Data have been corrected for 






was crystallized by slow diffusion of 






were analyzed using a rotating anode as X-ray 
source available at IBB-CNR (Naples, Italy). A suitable 
crystal was selected and glued on a glass fiber and measured 
at room temperature with a Rigaku AFC11K diffractometer 
equipped with a Saturn944 CCD detector using CuKα 
                                                 
74 Bruker AXS Inc., Madison, Wisconsin, USA. 
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X-ray diffraction quality single crystals of 43 were obtained 
by slow evaporation of a solution of ethyl acetate.  
A suitable crystals of 43 was selected and glued on a glass 
fiber and measured at room temperature with a Rigaku 
AFC7S diffractometer equipped with a Mercury
75
 CCD 
detector using MoKα radiation. Data reduction was performed 
with the crystallographic package CrystalClear.  
In all case collected data have been properly corrected for 
Lorentz, polarization and absorption.  
The structures of all three compounds were solved by direct 
methods using the program SIR2002
76
 and refined by means 




All non-hydrogen atoms were refined anisotropically, 
hydrogen atoms were positioned geometrically and included 
in structure factors calculations but not refined.  
Refinement details are summarized in Table 2.5.  




are rather high due to 
the presence of disordered PF6
- 
ions, whose associated 
electron density resulted to be rather difficult to model. This 






                                                 
75 CrystalClear, Crystal Structure Analysis Package, Rigaku-Molecular Structure Corp. 
76 M. C. Burla, M. Camalli, B. Carrozzini, G. Cascarano, C. Giacovazzo, G. Polidori, R. 
Spagna, J. Appl. Cryst. 2001, 34, 523-526. 
77 G. M. Sheldrick, Acta Cryst. 2008, A64, 112-122. 
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3 AMPHIPHILIC CYCLOPEPTOIDS 
3.1 Introduction 
Amphiphilic peptides and peptoids represent a 
fascinating class of molecules with broad-spectrum 
applications in many fields such as material science and 
biomedicine.
78,79
   
For example, a very interesting application of 
amphiphilic peptides consists in the design of supramolecular 
micelles of different size and shape, called “peptide 
amphiphile micelles” (PAs).
79
 A typical PA molecule contains 
a biologically active hydrophilic peptide “headgroup” which 
is linked through an amide bond to a hydrophobic “tail”. The 
tails can be double-chain lipids, single-chain fatty acids, 
hydrophobic peptides, polymers.  In some cases a linker of 
different length and flexibility (e.g. PEG, polyproline linker, 
polyalanine linker) is introduced between the headgroup and 
the tail.  
 In aqueous solution the self assembly of PA molecules 
determines the formation of nanofibers, whose core is made 
of packed tails while the surface contains the hydrophilic 
portion. The main driving force for the self assembly process 
is the hydrophobic aggregation of the hydrocarbon tails, 
dictated by their shielding from the aqueous solvent.  
                                                 
78 R. Kudirka, H. Tran, K. T. Nam, B. Sanii, P. H. Choi, N. Venkateswaran, R. Chen, S. 
Whitelam, R. N. Zuckermann Peptide Science, 2011, 96, 586-595. 
79 A. Trent, R. Marullo, B. Lin, M. Black, M. Tirrel Soft Matter, 2011, 7, 9572-9582. 
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The hydrophilic peptide regions can interact generating α-
helix or β-sheet secondary structures. Notably, the peptide 
secondary structure was demonstrated to influence PA micelle 
morphology. 
An intriguing family of PAs, whose self assembly is 
reversibly induced through pH changes or addition of Ca
++
, 
was reported by Stupp and co-workers.
80
  
They prepared a set of PA molecules containing cysteine-rich 
hydrophilic peptide sequences with biologically active RGD 
motif linked to a fatty acid of various length. One of the PA 
molecules synthesized (67) is reported in figure 3.1. 
These molecules were solubilized in water at pH 8 exploiting 
the negative charges located on aspartate and the C-terminal 
carboxylate. Upon full reduction of the PA molecules with 
dithiothreitol (DTT), on pain of the formation of 
intramolecular disulfide bridges unfavouring the self 
assembly, and acidification at pH below 4.5 it was found the 
formation of a gel phase containing micelles, as shown in 
figures 3.2 and 3.3. The gel is disassembled at neutral and 
basic pH, so the gelification process is reversible. The effect 
of pH can be explained as follows. 
In essence, the self assembly process is favourite at low pH 
due to the fact that in these conditions the peptides do not 
posses negative charges, which inhibit in basic media the 
micelle formation as a result of electrostatic repulsion 
phenomena.  
                                                 
80 J. D. Hartgerink, E. Beniash, S. I. Stupp Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 5133-
5138. 
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It was also possible to form micelles adding Ca
++
 to an 
aqueous solution at pH 8 of the PA molecule. In this case the 
divalent cation acts as gelator agent shielding the negative 
charges of the peptide chains. 
Very interestingly, it was realized a reversible linkage of the 
nanofibers oxidating the cysteine residues with I2 (figure 3.3). 
In this way intermolecular disulfide bridges were produced, 
generating  a very stable supramolecular structure which is 










































Figure 3.1: Chemical structure of an amphiphilic peptide synthesized by 




Figure 3.2: Time sequence of pH-controlled PA self assembly and 
disassembly. (Upper) From left to right PA molecule dissolved in water at 
pH 8 is exposed to HCl vapour. The diffusion of the acid causes the 
formation of a gel phase (far left). (Lower) The same gel is treated with 
NH4OH vapour, which disassembles the gel. 
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Figure 3.3: Schematic representation of the self-assembly and covalent 
linkage of the PAs based on pH and oxidation state. 
3.2 Aims of the work 
The great interest engendered by amphiphathic peptide 
and peptoid structures suggested us to prepare some 
amphiphilic cyclopeptoids.     
In particular, with the aim to evaluate the effect of side chain 
polarity and orientation on the organization in the crystal 
structure, the synthesis of amphiphilic cyclopeptoids 
containing at the same time an hydrophobic molecular portion 
and a polar one was planned. The choice fell to 
cyclohexapeptoids decorated with three side chains of 
benzylamine and ethanolamine in alternate and continuous 
positions (45 and 46, figure 3.4). 



































Figure 3.4: Amphiphilic cyclopeptoids synthesized. 
3.3 Synthesis  
 In order to carry out the classic submonomer solid 
phase synthesis it was necessary to prepare a protected 
ethanolamine (figure 3.5). The nucleophilic alcoholic function 
could indeed lead to secondary reactions during the coupling 
reaction. 
The protecting group which in our experience proved to be 
the most suitable was the t-butylchlorodiphenylsilane 
(TBDPS). It assures a good resistance both to basic and acidic 
conditions, which will be used during elongation and cleavage 
of the resin respectively. 










                                                 
81 M. Rayesh, J. Sen, M. Srujan, K. Mukherjee, B. Sreedhar, A.Chaudhuri  J. Am. Chem. 
Soc., 2007, 129, 11408-11420. 
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Synthesis of linear precursor, followed by the cyclization step 
in high dilution, gave protected compounds 71 and 73 

























































Scheme 3.1: Synthesis of 71 (alternate protected hexacyclopeptoid). 
Cleavage of the resin is conducted with 20% (CF3)2CHOH in DCM. 









































Figure 3.6: Compound 73 (continuous protected hexacyclopeptoid) and 
its linear precursor (72). The synthesis of 73 is performed in the same way 
as compound 71 (scheme 3.1). Purification was conducted through silica 
flash chromatography.  
The deprotection of compounds 71, 73 revealed to be quite 
difficult. 
Classic deprotection conditions of silylether protecting groups 
(HF/Piridine, NaOH/MeOH, TBAF (tetra-n-butylammonium 
fluoride) unexpectedly failed. Finally, deprotection of the 
compounds 71 and 73 was successful achieved with a 3% 
solution of HCl/MeOH (scheme 3.2).
82
 
                                                 
82 E. M. Nashed, C. P. J. Glaudemans  J. Org. Chem., 1987, 52, 5255-5260. 







































































Scheme 3.2: Deprotection reaction of compounds 71 and 73. Target 
molecules 45 and 46 were purified via RP- HPLC. 
 
3.4 Structural analysis of the alternate 
protected cyclopeptoid 
  
Table 3.1: Solubility scale for the compound 71. 
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The solubility scale of 71 (table 3.1) indicates that 
ethylacetate is a good crystallization solvent and, at the same 
time, MeOH can play the role of non solvent. Indeed, 
sparkling crystals of compound 71 (the alternate protected 
cyclopeptoid), suitable for X-ray structure analysis, were 
obtained by vapour phase diffusion of methanol in a solution 
of ethylacetate.  
The crystals showed a triclinic lattice (a = 14.707(4) 
Å, b = 16.200(5) Å, c = 18.353(5) Å,  α = 99.654(9)
°
, β = 
90.154(5)
°
, γ = 100.828(10)
°
; space group = P-1; cavities 
volume = 40 Å
3 
(probe radius 1.2 Å)). X-ray diffraction data 
indicated that the crystals correspond to an uncomplexed 
species devoid of a co-crystallization solvent. The 
conformation of the peptoid backbone is tcctcc (figure 3.7), 
similarly to cyclopeptoid 43 in uncomplexed form (see 
section 2.3.5). Moreover, it is interesting to notice that in the 
X-ray structure are present T shaped interactions between aryl 
rings (figure 3.7). In addition, there is some positional 
disorder around a specific aryl ring. The discussed disorder 
arises from one of the aryl moieties which can adopt two 
different positions in the crystal structure. The movement is 
allowed by the void space present in the crystal (figure 3.8). 
Interestingly, t-butyl groups lead to some complications in 
crystal packing and as a consequence the crystal structure 
exhibits empty cavities of 40 Å
3
 volume (probe radius = 1.2 
Å). The porosity of the structure under investigation is a so-
called closed porosity because only closed pores (non-
connected cavities) are present. 
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The dimension of the cavities permits to accommodate tiny 
molecules like water.   
 
Figure 3.7: X-ray molecular structure of 71. Distances between centroids 
of aryl rings are reported in Å. It is reported the positional disorder around 




Figure 3.8: Crystal packing of 71 with the void space (40 Å
3
) represented 
by Van Der Waals spheres. It is reported the positional disorder around a 
specific aryl ring.  
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3.5 Crystallization trials for 73 
The compound 73 (the continuous protected 
cyclopeptoid) contained some impurities derived from 
HATU. In CH3CN the impurities are soluble whereas the 
product 73 precipitates as a white powder. Later, the 
solubility scale (table 3.2) for 73 was determined and some 
crystallization trials were unsuccessfully carried out: 
a) Slow evaporation from a solution CH3CN/CHCl3 1:1; b) 
slow evaporation from a solution of CHCl3; c) slow 
evaporation from a solution of toluene.  
Table 3.2: Solubility scale for the compound 73. 
Solvent Solubility order 
CHCl3 1 






3.6 Crystallization trials for 45 
The solubility scale for the compound 45 (the alternate 
amphiphilic cyclopeptoid) is illustrated in table 3.3. Some 
crystallization trials were unsuccessfully performed: a) Slow 
evaporation from a solution of EtOH/hexane 1:1 (v/v); b) 
diffusion in vapour phase of hexane in a solution 
MeOH/CHCl3 2:1 (v/v); c) diffusion in vapour phase of 
hexane in a solution AcOEt/CHCl3 1:1 (v/v).  
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Table 3.3: Solubility scale for the compound 45. 
Solvent Solubility order 
EtOH, MeOH 1 
CHCl3, H2O 2 
CH3CN 3 
AcOEt 4 
3.7 Crystallization trials for 46 
The solubility scale for the compound 46 (the 
continuous amphiphilic cyclopeptoid) is illustrated in table 
3.4. Some crystallization trials were unsuccessfully 
performed: a) Slow evaporation from a solution of 
EtOH/hexane 1:1 (v/v); b) slow evaporation from a solution 
of EtOH/acetone 1:1 (v/v); c) slow evaporation from a 
solution of EtOH/H2O 1:1 (v/v).   
 
Table 3.4: Solubility scale for the compound 46. 
Solvent Solubility order 
EtOH, MeOH 1 
CHCl3, H2O 2 
CH3CN 3 
AcOEt 4 
   
3.8 Conclusions 
 The synthesis of the continuous and alternate 
amphiphilic cyclopeptoids (45, 46) was successfully 
performed. The final aim was to crystallize amphiphatic 
peptoid structures, and at the same time to compare the 
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crystal structure of a specific amphiphilic isomer with that of 
its protected precursor.  Unfortunately, only the alternated 
protected compound 71 was crystallized whereas all the 
crystallization attempts carried out on the other three cyclic 
molecules failed. 
Notably, the crystal structure of 71 is characterized by a 
tcctcc conformation, typical of a decomplexed 




3.9 Experimental section83 
3.9.1 Submonomer solid-phase synthesis of 
linear precursors 70 and 72 
Linear peptoid precursors of 70, 72 were synthesized using a 
submonomer solid-phase approach. Typically 0.40 g of 2-
chlorotrityl chloride resin (2,α-dichlorobenzhydryl-
polystyrene crosslinked with 1% DVB; 100-200 mesh; 1.30 
mmol/g) was swelled in dry DCM (4 mL) for 45 min and 
washed twice in dry DCM (4 mL). The first sub-monomer 
was attached onto the resin by adding bromoacetic acid (107 
mg, 0.77 mmol) and DIPEA (418 μL, 2.4 mmol) in dry DCM 
(4 mL) on a shaker platform for 40 min at room temperature, 
followed by washing with dry DCM (3 × 4 mL) and then with 
DMF (3 × 4 mL). To the bromoacetylated resin benzylamine 
(524 μl, 4.80 mmol) in dry DMF (4 mL), was added. The 
mixture was left on a shaker platform for 40 min at room 
                                                 
83 See section 2.6.1 for general procedures. 
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temperature, then the resin was washed with DMF (3 × 4 
mL). Subsequent bromoacetylation reactions were 
accomplished by reacting the oligomer with a solution of 
bromoacetic acid (690 mg, 4.8 mmol) and DIC (817 μL, 5.28 
mmol) in DMF (4 mL) on a shaker platform 40 min at room 
temperature. The filtered resin was washed with DMF (3 × 4 
mL) and treated again with benzylamine under the same 
conditions reported above in the case of linear precursor of 
70, or with amine 67 (864 mg, 2.88 mmol) in the case of 
linear precursor of 69. This cycle of reactions was iterated 
until the target oligomer was obtained. The oligomer-resin 
was cleaved in 4 mL of 20% HFIP in DCM (v/v). The 
cleavage was performed on a shaker platform for 30 min at 
room temperature the resin was then filtered away. The resin 
was treated again with 4 mL of 20% HFIP in DCM (v/v) for 5 
min, washed twice with DCM (4 mL), filtered away and the 
combined filtrates were concentrated in vacuo. The final 
product was dissolved in 50% ACN in HPLC grade water and 
analysed by RP-HPLC and ESI mass spectrometry. The linear 
compounds were subjected to the cyclization without further 
purification. 
 Compound 70 
Purity: >95%. 
Yield: 76% (crude residue). 
ES-MS: 1477.7 m/z [M + H
+
]. 
HPLC: tR: 26.4 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
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 Compound 72 
Purity: 76%. 
Yield: 74% (crude residue). 
ES-MS: 1477.7 m/z [M + H
+
]. 
HPLC: tR: 23.6 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
3.9.2  General procedure for high dilution 
cyclization. Synthesis of  71 and 73  
To a stirred solution of HATU (116 mg, 0.31 mmol), DIPEA 
(0.082 mL, 0.47 mmol) in dry DMF (20 mL) at room 
temperature, a solution of the linear compounds (crude 70, 
72) (0.08 mmol) in dry DMF (20 mL) was added by syringe 
pump in 6 h. After 12 h the resulting mixture was 
concentrated in vacuo, diluted with DCM (20 mL) and 
washed with 1 M HCl (7 mL × 3) was added. The mixture 
was extracted with DCM (10 mL × 2) and the combined 
organic phases were washed three times with water (10 mL), 
dried (MgSO4) and concentrated in vacuo. The crude residues 
of 71, 73 from the HATU-induced cyclizations were 
respectively purified by precipitation in CH3CN/H2O 3:1 (v/v) 
and flash chromatography (DCM/MeOH, from: 100/0 to 
96/4). 
 Compound 71 
Yield: 51%. The crude residue from the HATU-induced 
cyclization was purified by precipitation in CH3CN/H2O 
3:1 (v/v). 
3 A M P H I P H I L I C  C Y C L O P E P T O I D S 
 113 
ES-MS: 1481.7 m/z [M + Na
+
]. 
HPLC: tR: 28.2 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
1
H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 7.68–
6.89 ( 45 H, m, Ar), 5.36–5.24, 4.75–2.71 (30 H, m, 
COCH2N, NCH2CH2O, NCH2CH2O, CH2Ph), 1.25–0.82 (27 
H, m, SiC(CH3)3). 
13
C-NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 171.8, 
171.3, 170.4, 170.2, 170.1, 169.7, 169.5, 169.1, 168.9, 168.6, 
168.1, 167.8 , 167.7, 167.6, 167.2, 167.0, 137.1, 136.7, 135.4, 
134.7, 133.5, 133.0, 132.8 , 129.9, 129.8, 129.6 , 129.0, 128.6, 
128.3, 127.9, 127.7 , 127.2 , 126.9 , 126.8, 125.3, 82.8–79.7, 
63.3, 62.9, 62.6, 62.3, 62.0, 61.7, 61.3, 61.0, 60.6, 53.2, 52.6, 
51.8, 51.5, 51.1, 50.8, 50.5, 50.0, 49.7, 49.1, 48.3, 48.1, 47.7, 
47.4, 47.0, 46.6, 46.2, 32.0, 31.6 , 31.4, 31.2, 30.9, 30.6, 29.7, 
26.9. 
 Compound 71 with sodium picrate 
To a 4.0 mM solution of 71 in CD3CN:CDCl3 9:1 (0.5 mL), 
were added 3 mg of sodium picrate. After the addition the 





C NMR spectra was recorded. 
1
H-NMR: (400 MHz, CD3CN/CDCl3 = 9/1) δ: 8.73 (s, 
protons of picrate present in excess), 7.75–7.16 (45H, m, Ar), 
4.74 (3H, d, J = 17.4 Hz, CHHPh or NCHHCO), 4.69 (3H, d, 
J = 16.9 Hz, CHHPh or NCHHCO), 4.68 (3H, d, J = 16.6 Hz, 
CHHPh or NCHHCO), 4.17 (3H, d, J = 17.4 Hz, CHHPh or 
NCHHCO), 3.67 (9H, m, NCHHCH2O and NCH2CH2O, 
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overlapped), 3.61 (3H, d, J = 16.6 Hz, CHHPh or NCHHCO), 
3.53 (3H, d, J = 16.9 Hz, CHHPh or NCHHCO), 3.17 (3H, d, 
J = 12.2 Hz, NCHHCH2O), 0.91 (27H, s, SiC(CH3)3). 
13
C-NMR: (62.89 MHz, CD3CN/CDCl3 = 9/1) δ: 171.1 (× 3), 
170.6 (× 3), 163.3 (picrate), 143.3 (picrate), 137.0 (× 3), 136.7 
(× 12), 134.1 (× 6), 131.3 (× 6), 130.2 (× 9), 129.2 (× 15), 
129.1 (× 3), 128.3 (picrate), 127.2 (picrate), 63.1 (× 3), 53.7 
(× 3), 51.8 (× 3), 50.6 (× 3), 50.4 (× 3), 30.7 (× 3), 27.6 (× 9).  
 Compound 73 
Yield: 54%. The crude residue from the HATU-induced 
cyclization was purified by flash chromatography 
(DCM/MeOH, from: 100/0 to 96/4).
84
 
ES-MS: 1481.7 m/z [M + Na
+
]. 
HPLC: tR: 26.5 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
1
H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 7.62–
6.91 (45 H, m, Ar), 5.30–5.28, 4.71–2.79 (30 H, m, COCH2N, 
NCH2CH2O, NCH2CH2O), 1.12–0.83 (27 H, m, SiC(CH3)3).  
13
C-NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 169.9, 
169.8, 169.6, 169.5, 135.4, 135.3, 135.0, 134.6, 134.5, 132.6, 
132.4, 130.0, 129.5, 129.0, 127.9, 127.4, 127.3, 126.5, 120.7, 
62.1, 61.8, 61.6, 61.3, 61.2, 52.6, 52.5, 50.9, 50.1, 49.6, 49.3, 
48.9, 48.8, 48.7, 38.0, 36.5, 32.7, 31.9, 30.2, 29.6, 29.3, 29.0, 
26.9. 
                                                 
84 With flash chromatography it was not possible to separate well the product 73 from HATU 
byproducts. 
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3.9.3  Deprotection reaction of 71 and 73 
To a flask containing  the compound 71 or 73 (45 mg, 0.031 
mmol), 9 mL of 3% HCl solution in MeOH was added and 
the resulting mixture was stirred at room temperature for 48h. 
The reaction was monitored via RP-HPLC. Later, the reaction 
mixture was neutralized with Amberlite IR-45 (OH
-
), 
concentrated, and purified by RP-HPLC on a C18 semi-
preparative reversed-phase column. Thus, compounds 45 and 
46 were obtained.  
 Compound 45 
Yield: 68%. The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 8.6 
min.; conditions: 25 → 100% B in 30 min (A: 0.1% TFA in 








H-NMR: (400 MHz, CD3OD, mixture of rotamers) δ: 7.72–
7.21 ( 45 H, m, Ar), 4.55–2.60 (30 H, m, COCH2N, 
NCH2CH2O, NCH2CH2O). 
 Compound 46 
Yield: 18%.
85
 The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 10.8 
min.; conditions: 25 → 100% B in 30 min (A: 0.1% TFA in 




                                                 
85 The low yield is due to the fact that the purified protected-precursor 73 contained HATU 
byproducts. 
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H-NMR: (400 MHz, CD3CN, mixture of rotamers) δ: 7.38–
7.06 ( 45 H, m, Ar), 4.16–2.45 (30 H, m, COCH2N, 
NCH2CH2O, NCH2CH2O). 
3.9.4  Synthesis of  69 
A solution of 2-aminoethanol (68) (0.5 g, 8.2 mmol) dissolved 
in 9 mL of dry DCM was transferred to a flask, and the 
solution was cooled to 0 °C. DBU (3.7 g, 24.6 mmol) was 
addedto this cold solution at 0 °C. t-butylchlorodiphenylsilane 
(6.8 g, 24.6 mmol) was added to the cold reaction mixture and 
stirred for 15 min 
at 0 °C. The temperature was gradually raised to room 
temperature, and stirring was continued for additional 12 h. 
The reaction mixture was then diluted with DCM (100 mL) 
and washed with water (2 × 50 mL). The organic layer was 
separated, dried over anhydrous Na2SO4, and concentrated on 
a rotary evaporator. The residue, upon chromatographic 
purification by flash silica (DCM/MeOH, from: 100/0 to 
91/9), afforded the amine 69 as a light brown liquid (2.3 g, 
94%). 
 Compound 69 
1
H-NMR: (250 MHz, CDCl3) δ: 7.68-7.66 (4H, m, ArH), 
7.43-7.38 (6H, m, ArH), 3.69 (2H, t, J = 4.3 Hz, CH2OSi), 
2.83 (2H, t, J = 4.3 Hz, t, CH2NH2), 1.83 (2H, bs, NH2), 1.06 
(9H, s, SiC(CH3)3).     
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3.9.5  X-ray analysis 
Table 3.5: Crystal data and structure refinement details for compound 71. 
Compound 71 













Space group P-1 




























Indep. refl. measured 17970 
Param. / restraints 9 / 1 
R1[F0>4σ(F0)], wR2(all refl) 0.1104, 0.3830 
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GooF 1.046 
Δρ min (e Å
-3
) , Δρ max (e Å
-3
) -0.03, 0.032 
 
X-ray diffraction quality single crystals of 71 were obtained 
by slow diffusion of methanol in an ethyl acetate solution.  
A suitable crystals of 71 was selected and glued on a glass 
fiber and measured at room temperature with a Rigaku 
AFC7S diffractometer equipped with a Mercury
74
 CCD 
detector using MoKα radiation. Data reduction was performed 
with the crystallographic package CrystalClear.
75
  
Collected data have been properly corrected for Lorentz, 
polarization and absorption. The structures was solved by 
direct methods using the program SIR2002
76
 and refined by 




All non-hydrogen atoms were refined anisotropically, 
hydrogen atoms were positioned geometrically and included 
in structure factors calculations but not refined. Refinement 


































4 CYCLOPEPTOIDS AS PHASE 
TRANSFER CATALYSTS 
4.1 Introduction 
Phase-transfer catalysis (PTC) is a laboratory scale 
synthetic method and industrial process which is employed in 
a variety of organic reactions (e.g. alkylation, Michael 
addition, aldol condensation, oxidation, etc.).
86
 Some areas of 
application are the production of polymers, pharmaceuticals, 
dyes, perfumes, agrochemicals. The advantages of PTC in 
industial context are operational simplicity, mild conditions, 
high reaction rates, waste reduction and catalyst reuse.
87
 Most 
commercially available phase-transfer catalysts are quaternary 
ammonium and phosphonium salts, crown ethers and open 
chain polyethers. 
Phase-transfer catalysis was first introduced in the 
1960’s as an efficient strategy to carry out organic reactions 
between water soluble inorganic reagents and organic 
substrates in a biphasic liquid-liquid system.
 87,88
 In a typical 
PT reaction, such as the SN2 reaction of 1-chlorooctane (RY) 
with NaCN (MX) in an aqueous-organic system, the 









                                                 
86 M. Halpern "Phase-Transfer Catalysis" in Ullmann's Encyclopedia of Industrial Chemistry 
2002, Wiley-VCH, Weinheim. 
87 G. Pozzi, S. Quici, R.H. Fish  J. of Fluorine Chem. 2008, 129, 920–929. 
88 T. Ooi, K. Maruoka Angew. Chem. Int. Ed., 2007, 46, 4222-4266; S. Shikarawa, K. 
Maruoka Angew. Chem. Int. Ed., 2013, 52, 4312-4348. 




induces a many thousand fold increase of the reaction rate. 
According to the first general PTC mechanism proposed by 
Starks (scheme 4.1)
87
, the PT catalyst, partitioned between the 









), in which the anion interacts 
very weakly with the bulky cation and as a consequence its 
reactivity is enhanced. In this way, the reacting anion (CN
-
) is 
transferred from the aqueous to the organic phase where the 
reaction happens and the catalyst is regenerated. 
Altough the exact mechanism of PTC is elusive, many 
different mechanisms can be hypothesized depending on the 
catalyst and the organic reaction analyzed.  Indeed, it was 
proposed a revision of the Starks mechanism, in which the 




) and the inorganic 





 and RY takes place in the bulk organic 
phase.
87
 This interphase mechanism is valid also in the case of 
a neutral PT catalyst, such as lipophilic cyclic and acyclic 
polyethers (scheme 4.2). 
Another possible mechanism for liquid-liquid PTC reactions 
was proposed by Mazoska and it can be applied when 




) are employed 
to form the reactive organic species from weakly acidic 
substates (SH), as illustrated in scheme 4.3.
87
 In essence, OH
-
 
anion can not migrate in the organic phase by the action of 
lipophilic onium salts due to its high hydrophilicity. So, the 
deprotonation of SH occurs at the aqueous-organic interphase 








, which is 
unable to leave the phase boundary because M
+
 can not be 
extracted in non-polar organic solvents and S
-
 is unsoluble in 
the MOH solution. The ion exchange with a PT catalyst 





migrates from the interface to the bulk organic phase, where 










Q+X-   +    Y-  +    2M+   +     Y-    +   Q+Y-
Aqueous phase  











X-           +        2M+          +          Y-
Aqueous phase  
Scheme 4.2: Revision of the Starks mechanism of PTC. 
 
















Scheme 4.3: Mazoska mechanism of PTC. 
  
 In addition to liquid-liquid phase-transfer catalysis, it 
is also possible to perform reactions under solid-liquid PTC 
conditions.
87
 Particularly, this reaction is conducted 
suspending a solid salt in an anhydrous organic solution 
containing the substrate and the PT catalyst. Substantially, the 
PT catalyst extracts the reacting anion from the solid salt 
causing the collapse of the crystal lattice. 
 In the PTC context, asymmetric phase-transfer 
catalysis represents a very active research field and in the past 
few decades several chiral PT catalysts have been designed 
and used in different asymmetric reactions.
88
 
A very important PT asymmetric reaction is the 
enantioselective alkylation of active methylene compounds, 
and its development was aroused from a pioneering study of a 






 Specifically, Dolling and co-workers 
performed the methylation of the phenylindanone derivative 
74 under phase-transfer conditions making use of the 
chinconine-derived quaternary ammonium salt 75 as 
asymmetric PT catalyst, obtaining the corresponding 
alkylated product 76 in high yield and enantiomeric excess 
(scheme 4.4). The first step of the alkylation is the interfacial 
deprotonation of the α-proton of 74 with NaOH to generate 
the corresponding metal enolate, which is localized at the 
interface between the two liquid phases. Further cation-
exchange forms the lipophilic ionic complex 77 between the 
enolate and the catalyst (scheme 4.4), which goes in the 
organic phase where the reaction occurs. This complex is 
stabilized via hydrogen bonding, electrostatic and Π-Π 
stacking interactions. The enantioselective pathway of the 
reaction occurs through a selective attack of the electrophile 
(RCl) to the least sterically hindered face of the enolate (si-
face) belonging to the complex 77, so that a chiral product is 
afforded. The re-face of the enolate is blocked by the 
quinoline ring. 
                                                 
89
 S. Jew, H. Park Chem. Commun., 2009, 46, 7090-7103. 
 










catalyst 75 (10%mol), RCl
toluene/50% aq NaOH



























Scheme 4.4: Asymmetric PT alkylation of an indanone derivative. 
 Another example of enantioselective alkylation of 
active methylene compounds is the alkylation of N-
(diphenylmethylene)glycine t-buthyl ester, which allows to 
obtain the iminic precursor of an α-aminoacid. This reaction is 
usually performed in presence of a chiral catalyst making use 
of the alkylating agent benzyl bromide and employing an 
organic solvent and an aqueous solution  of an alkaline 
hydroxide (scheme 4.5). During the years different catalysts 
were tested in this reaction and in scheme 4.5 are reported 
some examples of catalysts: N-antracenylmethylammonium 
salt 80 developed by Lygo
88
, the binaphtyl N-spiro catalyst 81 
developed by Maruoka
88
 and the more recent catalyst 82 
developed by Grover
90
, which contains two chiral elements 
(tartaric acid and 2,5-dimethylpyrroline rings). 80 and 81 are 
                                                 
90 W. E. Kowtoniuk, D. K. MacFarland, G. N. Grover Tetrahedron Lett., 2005, 46, 5703-
5705. 




classic asymmetric PT catalyst whereas 82 represents a novel 
catalytic system. Specifically, as illustrated in table 4.1, high 
enantioselectivity was obtained with 80 and 81 while the 






























Scheme 4.5: Asymmetric PT alkylation of N-(diphenylmethylene)glycine 
t-buthyl ester. 
 
Table 4.1: Catalytic activities of 80-82 in the alkylation of N-
(diphenylmethylene)glycine t-buthyl ester. 
   Catalyst  Base    Solvent Temperature 
       (
°
C) 
   Time 





80 (10 mol %)  KOH 
50% 
    toluene     20    18   63    89 




    toluene         0    3   90    98 
82 (5 mol %)  CsOH     DCM    0    1   55    32 
 
 Another reaction of great interest in asymmetric PTC 
is the asymmetric Michael addition. In particular, the first 




successful Michael addition in phase-transfer conditions was 
carried out making use of a chiral crown ether (85) in the role 
of asymmetric catalyst. So, in the presence of 85, the Michael 
addition of the β-keto ester 83 to metyl vinyl ketone goes in 
moderate yield but with excellent enantioselectivity (scheme 
4.6).
88



















Scheme 4.6: Asymmetric phase-transfer Michael addition catalyzed by a 
chiral crown ether. 
 
 Recently, Makò et al. reported the PT epoxidation of 
trans-chalcone analogues making use of a α-D-glucose-based 
crown ether catalyst (87) and a α-D-mannose-based crown 
ether catalyst (89).
91
 87 and 89 are lariat ether catalyst derived 
from the corresponding monosaccaride. The reaction was 
performed at  
                                                 
91 A. Makò, Z. Rapi, G. Keglevich, A. Szöȍllosky, L. Drahos, L. Hegedus Tetrahedron, 
2010, 21, 919-925. 






C using t-BuOOH as oxidant and employing toluene and 
20% aq NaOH solution. Specifically, in presence of the 
catalyst 87 and with the chalcone 86 it was obtained the 
enantiomer αR-βS with an excellent enantioselectivity and a 
moderate yield (scheme 4.7). On the other hand, the catalyst 
89 leaded to the opposite enantiomer αS-βR with worse 
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    0°C, 4h
20% NaOH, t-BuOOH







Scheme 4.7: Asymmetric phase-transfer epoxidation of a trans-chalcone 
derivative catalyzed by chiral crown ethers derived from monosaccharides.  
4.2 Aims of the work 
Cyclopeptoids appear as an ideal platform for the 
design of new phase-transfer catalysts because of their 




versatility of decoration, the high-yield solid phase synthesis,  
and their attitude to chelate alkali metal ions. In section 1.2.5 
the complexation properties towards metal ions and 
ionophoric activities in the HPTS assay of the N-
benzyloxyetyl cyclohexapeptoid (25, figure 4.1) synthesized 
by De Riccardis et al. has been described.
50
 Specifically, the 
cyclohexapeptoid 25 is characterized by a good affinity to Na
+
 
and a transmembrane transport selectivity for the same ion.  
 In spite of the large use of peptides in catalysis, 
peptoids oligomers of N-substituted glycines have been 
narrowly covered with respect to the catalytic applications 




Therefore, we decided to find out the use of 
cyclopeptoids as novel PT catalysts. In particular, in section 
4.3 the binding affinities and catalytic activities of 
cyclohexapeptoids 43, 47, 71, 91, 92 (figure 4.1) in a liquid-
liquid two phase benchmark SN2 reaction in comparison with 
classic phase-transfer catalysts have been reported. 
 




















25, R,R' = (CH2)2OBn
43, R,R' = (CH2)2OMe
47, R,R' = (CH2)2O(CH2)2OMe
71, R = Bn; R' = (CH2)2OTBDPS
91, R,R' = Bn
92, R,R' = (CH2)5CH3
R'
 
Figure 4.1: Cyclopeptoids (43, 47, 71, 91, 92) tested as PT catalysts in a 
benchmark SN2 reaction. Cyclopeptoid 25, synthesized by De Riccardis et 
al., exhibits a good affinity to sodium ion. 
 
In section 4.4 the catalytic activities of some proline-
rich cyclopeptoids (42, 93-95, figure 4.2) and of a 
cyclopeptoid containing valine (96, figure 4.2), employed as 
chiral catalysts in two common asymmetric phase-transfer 
reactions, have been discussed. Moreover, these results 
prompted us to investigate the catalytic activities in 
asymmetric PTC of some structural analogues of N-benzyl 
proline-rich cyclopeptoid 85 (48 and 97-100, figure 4.2), 
affording a promising candidate compound (48). 


















42, R = (CH2)2OMe
93, R = (CH2)2O(CH2)2OMe
94, R = Bn









































Figure 4.2: Cyclopeptoids examined in the role of asymmetric PT 
catalysts. 




4.3 Cyclopeptoids as PT catalysts in a 
benchmark SN2 reaction92  
4.3.1 Design and synthesis of the new 
catalysts 
The purpose was to evaluate the potential of 
cyclopeptoids as PT catalysts, and, for this reason, we 
prepared a series of structurally different cyclohexapeptoids 
(43, 47, 71, 91, 92), decorated with various N-alkyl side 
chains, making use of the submonomer approach
34
 (figure 
4.3) and finally purifying the cycle via RP-HPLC. All the 
amines are commercially available except for the 2-(2-
methoxyethoxy)ethanamine (106), which was prepared 
through a rapid two step sequence (scheme 4.4), as well 
described in the literature.
93 
The choice of the side chains was 
dictated from the intention of providing a good degree of 
lipophilicity (benzyl and n-hexyl appendages) or cation 
affinity (methoxyethyl and methoxyethoxyethyl pendant 
groups).  
In order to assess the catalytic activity of complexed 
cyclopeptoids in the phase-transfer reactions in comparison 
with metal free cyclopeptoids, it was decided to synthesize the 
sodium hexafluorophosphate adducts 107 and 108 shown in 
figure 4.4 (from neutral 43 and 91, respectively). 
                                                 
92 G. Della Sala, B. Nardone, F. De Riccardis, I. Izzo Org. Biomol. Chem. 2013, 11(5), 726-
731. 
93 J. R. Harjani, C. Liang, P. G. Jessop J. Org. Chem., 2011, 76, 1683–1691. 




In figure 4.4 the commercial phase-transfer catalysts, 

















58, R,R' = (CH2)2OMe
70, R = Bn; R' = (CH2)2OTBDPS
101, R,R' = (CH2)2O(CH2)2OMe
102, R,R' = Bn






43, R,R' = (CH2)2OMe
47, R,R' = (CH2)2O(CH2)2OMe
71, R = Bn; R' = (CH2)2OTBDPS
91, R,R' = Bn


























Scheme 4.8: Two step synthesis of 2-(2-methoxyethoxy)ethanamine. 
 




















107, R = (CH2)2OMe






































Figure 4.5: Commercial PT catalysts discussed. 
4.3.2  Determination of association 
constants by Cram’s method 
 It is noteworthy to underline that a PT catalyst can not 
prescind from an efficient metal complexation. Table 4.2 
reports the association constants (Ka) together with -ΔG
0
 and 
RCHCl3 values, which were determined for the complexation of 






 in H2O/CHCl3 biphasic 
system according to Cram’s method
51
, and in comparison 
with the well-known complexing agents
51
 such as 
dicyclohexyl-18-crown-6 and 15-crown-5 (109 and 111, 




figure 4.5). Particularly, in Cram’s method it is evaluated the 
ability of a macrocycle to extract picrate salts of a specific 
cation from bulk water to a chloroformic phase. The results 
indicate a good degree of selectivity towards  Na
+
 for 15-
crown-5 (111) and all the synthesized cyclopeptoids apart 






] = 3.3, see section 1.2.5). Specifically, the macrocycle 47 
resulted to be the best complexing agent, showing a Ka value 
for Na
+
 higher than that determined for 15-crown-5 (111) and 
more than six times greater than that calculated for 
dicyclohexyl-18-crown-6 (109). Differently from 
cyclopeptoids 43, 47, 92 dicyclohexyl-18-crown-6 
macrocycle 100 and the other structurally related 
compounds
51
 possess a far more higher association constant 
with K
+















Table 4.2: Parametres for association between hosts and picrate salts in 
CHCl3 at 25 
°
C. 
Entry  Host  M
+ 
 
















+ 0.07 0.27 7.4 
1 43 Na
+ 0.31 2.5 8.7 
  K
+ 0.03 0.51 6.4 
  Li
+ 0.38 4.9 9.1 
2 47 Na
+ 0.55 15 9.8 
  K
+ 0.48 5.9 9.2 
  Li
+ 0.13 0.63 7.9 
  3b) 91 Na
+ 0.22 1.2 8.3 
  K
+ - - - 
  Li
+ 0.24 1.7 8.5 
4 92 Na
+ 0.32 2.6 8.8 
  K
+ 0.12 0.31 7.5 
  Li
+ 0.0530 0.192 7.20 
5c) 109 Na
+ 0.308 2.34 8.68 
  K
+ 0.809 200 11.3 
  Li
+ <0.01 <0.03 - 
6d)   111 Na
+ 0.49 8.8 9.5 
  K
+ 0.10 0.23 7.3 
a)
[Guest]/[Host] in CHCl3 layer at equilibrium obtained by direct 
measurement, or calculated by difference from measurement made on 
aqueous phase. 
b) 
For compound 91  it was not possible to determine the 
association constant with the potassium picrate for the formation of  a 
precipitate (probably an insoluble complex with the salt). 
c)
 See reference 
51. 
d)
 For compound 111 it was not possible to determine the association  
with the lithium picrate because the amount of  it extracted in organic 
phase was too low. 
4.3.3  Evaluation of ionophoric activities 
with the HPTS assay 
 The general correlation between the complexing 
properties of macrocycles towards metal ions and their 




ionophoric activities suggested us to evaluate the transport 
properties through a phospholipid membrane for 
cyclopeptoids 43, 47, 91, 92. Experimentally, the ionophoric 
properties were investigated using the pH-sensitive 
fluorescent dye HPTS (HPTS = 8-hydroxypyrene-1,3,6-
trisulfonic acid, pKa = 7.2).
94
 This experiment was performed 
at the University of Trieste, precisely in the laboratory of 
Prof. Paolo Tecilla. 
In this assay the dye is entrapped inside phospholipid vesicles 
buffered at pH = 7 and, after addition of the ionophore, a pH 
shock of 0.6 pH units is applied by external addition of 
NaOH. The suppression of this transmembrane pH-gradient 
determines basification of the liposome inner water pool 
which is indicated by an increase of the HPTS fluorescence 





 influx and this transmembrane charge translocation 





















The ionophoric activity of the cyclic peptoids under study 
with respect to sodium ion is reported in figure 4.5. In the 
presence of NaCl as added salt (figure 4.6), the cyclopeptoids 
examined are poorly active differently from compound 25
50
 
(see section 1.2.5), which in a previous investigation 
exhibited a good ionophoric activity in the case of sodium 
                                                 
94 N. Sakai , S. Matile, J. Phys. Org. Chem., 2006, 19, 452-460. 




ion. Anyway, the scale of ionophoric activity of the 
cyclopeptoids tested for the sodium ion is: 47>92>91>43. 
This scale partially agrees with the Cram data, infact the 
compound 47 exhibits at the same time the highest Ka and the 
best ionophoric activity among the cyclopeptoids examined.  
 
Figure 4.6: Normalized fluorescence change in HPTS emission (FI, λex = 
460 nm, λem  = 510 nm) as a function of time. The time course of 
fluorescence was recorded for 200s and then 50 μL of 0.5 M NaOH were 
rapidly added to 95:5 EYPC/EYPG LUVs (100 nm diameter) loaded with 
HPTS (0.1 mM HPTS, 0.17 mM total lipid concentration, 25 mM HEPES, 
100 mM NaCl, pH 7.0, total volume 3 mL), in the presence of cyclic 
peptoids 43, 47, 91, 92. The concentration of the ionophore was 2% with 
respect to the total concentration of lipids. Maximal changes in dye 
emission were obtained by final lysis of the liposomes with detergent (40 
μL of 5% aqueous Triton® X-100). (HEPES: 4-(2-hydroxyethyl)-1-
piperazine ethanesulfonic acid; EYPC: egg yolk phosphatidyl choline; 




























4.3.4  Catalytic activities and comparison 
with commercial  phase transfer 
catalysts 
 With the aim of testing the ability of the cyclopeptoids 
in the role of PT catalysts we chose the substitution reaction 
of p-nitrobenzyl bromide, in a liquid-liquid two phase system, 
using sodium or potassium thiocyanate as nucleophilic 
species (table 4.3). These phase-transfer reactions follow 
pseudo-first order kinetics. In addition, the observed rates of 
the reaction are proportional to the amount of the catalyst and 
the process occurs in the organic layer.
95 
 
All reactions were performed in a CHCl3/H2O two-
phase system, with 5 mol% of catalyst. The reactions were 
monitored via TLC to evaluate the time necessary for total 
conversion. All the reactions were stopped within 24h and the 
conversion % was measured by 
1
H-NMR. Table 4.3 illustrates 
the activities of the synthesized cyclohexapeptoids compared 
to some commercially available PT catalysts, such as 
dicyclohexyl-18-crown-6 (109), 18-crown-6 (110), 15-crown-
5 (111), crypt-222 (112), tetrabutylammonium bromide (113), 
poly(ethyleneglycol) (average Mn 300, 114) (figure 4.4).  
 All compounds (43, 47, 71, 91, 92, 107 and 108, 
entries 2-8) catalyzed the substitution reaction, as it is 
possible to infer from the comparison with the uncatalyzed 
reaction (entry 1). 
                                                 
95 C. M. Starks, R. M. Oweres, J. Am. Chem. Soc. 1973,  5, 3613-3617. 




 It is remarkable to point out that whereas all the 
commercially available PT catalysts (109-114) demonstrated 
to be more efficient in the presence of potassium thiocyanate, 
with almost all the new cyclohexapeptoids the reaction is 
quicker with sodium thiocyanate. Cyclopeptoid 91 represents 
an exception, both in the free or complexed form (entries 5 
and 8, respectively). Interestingly, the catalysts in the 
complexed form (107 and 108, entries 7 and 8) revealed to be 
less efficient than those in the free form (43 and 91, entries 2 
and 5). All the uncomplexed cyclopeptoids proved to be more 
effective catalysts than the known poly(ethylene glycol) 
(114). 
 The most active cyclopeptoids (43, 47, 92) exhibited 
activities close to the crown ethers. And, icing on the cake, 
macrocycle 47, containing N-[2-(2-methoxyethoxy)ethyl] side 
chains, showed, in the reaction with NaSCN, higher 
efficiency than crown ethers, and an activity comparable to 
that observed for cryptand 112, one of the best amongst the 
PTC catalysts. A high activity, although lower, was also 












Table 4.3: SN2 reaction with NaSCN or KSCN catalyzed by cyclopeptoids 












                                                 
Entry Catalyst 
NaSCN                                       
time(h)        Conversion(%) 
 KSCN                                     
  time(h)   Conversion(%) 
1 - 24 10 24 5 





3 47 2.5 
 
>99 7.5 > 99 



















55 24 79 
 8 108 
 
24 78 24 30 











7.5 > 99 




1 > 99 




3 > 99 




1 > 99 
 14 114 24 81 24 85 
 
a)
 All the reactions were carried out using a 0.25 M solution of p-
nitrobenzyl bromide (106) in CHCl3 (0.4 mL, 0.10 mmol), a 0.75 M 
aqueous solution of NaSCN or KSCN (0.2 mL, 0.15 mmol) and catalyst 
(0.005 mmol). 
 




The observed experimental data can be interpreted 
making the following considerations. 
The weak performance of the complexed catalysts 107 
and 108 could be ascribed to the low solubility of such 
compounds in the reaction medium. This observation also 
stems from the comparison of reactions carried out with the 
macrocycles 43, 47, 71, 91, 92. The better solubility for the 
compounds 43, 47, 71, 83 relative to the products 91, 107 and 
108, obtained with the introduction of a more lipophilic N-
alkyl chain, determined reduced reaction times. 
Nevertheless, the solubility in chloroform is not the only 
parameter to be taken into account. The very soluble 
compound 71, indeed, proved to be less active than 43, 47, 92 
likely because of the presence of the sterically hindered silyl 
group. It is more difficult to rationalize the data collected for 
the N-benzyl glycine hexacyclopeptoid both in free and 
complexed form (91 and 108), which showed an opposite 
trend to that of the other macrocycles. In fact, shorter reaction 
times and a higher conversion, were observed using 
potassium thiocyanate. Unfortunately, for the macrocycle 91 
was not possible to determine the Ka for K
+
, in order to 
compare it with those estimated for the other ions. Anyhow, 
Ka values for Na
+
 was lower than that of the other 
macrocycles, and that might explain the poorer activity of the 
discussed catalyst. Ultimately, the data determined by Cram’s 
method agree with the results observed in catalysis since the 




compound 47, which shows the greatest Ka values, resulted to 
be the best catalyst. 
4.4 Cyclopeptoids in the role of asymmetric PT 
catalyst 
4.4.1 Design and synthesis of the first 
generation catalysts 
 We decided to evaluate the catalytic activity in phase-
transfer conditions of some chiral cyclopeptoids: the 
prolinated cyclohexapeptoids 42, 93-95 and a 
cyclohexapeptoid containing residues of L-valine (96). The 
choice of incorporating L-proline in the peptoid backbone was 
mainly dictated by the ability to complex sodium exhibited by 
the proline-rich cyclopeptoid 42, as illustrated in section 
2.3.4. On the other hand, L-valine was introduced in order to 
establish the effect of an hydrogen-bond donor secondary 
nitrogen on the asymmetric induction. Futhermore, the side 
chains of cyclopeptoids 42, 93-96 are exactly the same of  
cyclopeptoids earlier tested in a benchmark SN2 reaction (43, 
47, 91, 92).     
 Two well-known PT asymmetric reactions were 
considered: i) the enantioselective epoxidation of trans-
chalcone (scheme 4.9), which represents an useful synthetic 
route to prepare chiral epoxides; ii) the alkylation of N-
(diphenylmethylene)glycine t-buthyl ester  (scheme 4.5), 
which allows to obtain the iminic precursor of an α-
aminoacid. These reactions are often reported in literature in 































Scheme 4.9: Asymmetric PT reactions examined.   
 The synthesis of the cyclopeptoids tested was 
performed making use of a solid-phase mixed approach 
(submonomer
34
 and monomer approach) (scheme 4.10) with 
the only exception of 96. Specifically, compound 96 
containing L-valine was prepared with a modified mixed 
approach
96
 (scheme 4.11) due to side reactions of alklylation 
undergone by the primary nitrogen of  L-valine, which were 
observed in previous attempts of synthesis carried out with 
the general mixed approach. Usually, during submonomer 
synthesis, the alkylation side reaction is not observed because 
acylation of an N-terminal secondary amine by means of 
bromoacetic acid is not reversible and is 1000 times faster 
than alkylation. On the other hand, acylation of an N-terminal 
                                                 
96 T. S. Burkoth, A. T. Fafarman, D. H. Charych, M. D. Connolly, R. N. Zuckermann J. Am. 
Chem. Soc., 2003, 125, 8841-8845. 




primary amine (L-valine) is reversible and, as a consequence, 
the alkylation reaction can occur leading to the accumulation 
of alkylation side products during the acylation step. So, in 
order to avoid the formation of alkylation byproducts, 
according to the Zuckermann protocol
96
, chloroacetic acid 
was used in place of bromoacetic acid. In this way, the 
alkylation is less favoured because chloride is a worse leaving 
group than bromide. In addition, the displacement step must 
be conducted in presence of KI to convert the less reactive 
chloride species in iodide. Zuckermann made use of this 
protocol
96
 for the submonomer synthesis of peptoid oligomers 
containing aromatic amine submonomers such as aniline and 
5-amino-2-methoxypyridine.      
With respect to the synthesis of 96 (scheme 4.11), the 
general mixed approach was used until the dipeptide unit and 
further the submonomer method was accomplished using 
chloroacetic acid at 45
°
C for the acetylation step and a 
solution of KI and the required amine in DMF at 35
°
C for the 
following displacement step.   













































55, R = (CH2)2OMe
119, R = (CH2)2O(CH2)2OMe
120, R = Bn
121, R = (CH2)5CH3
42, R = (CH2)2OMe
93, R = (CH2)2O(CH2)2OMe
94, R = Bn
95, R = (CH2)5CH3
Scheme 4.10: Solid-phase mixed approach for the synthesis of 42, 93-95. 
Reagents and conditions: (a) bromoacetic acid, DIPEA, DCM; (b) RNH2, DMF; 
(c) N-Fmoc-L-proline, HATU, DIPEA, DMF; (d) Piperidine-DMF (1:5); (e) 















































Scheme 4.11: Solid-phase mixed approach for the synthesis of 96. Reagents and 
conditions: (a) bromoacetic acid, DIPEA, DCM; (b) hexilamine, DMF; (c) N-
Fmoc-L-valine, HATU, DIPEA, DMF; (d) Piperidine-DMF (1:5); (e) chloroacetic 
acid, DIC, DMF, 45°C; (f) hexanamine, KI, DMF, 35°C; (g) HFIP-DCM (1:5), (h) 
HATU, DIPEA, DMF. 




4.4.2  Catalytic activities in the 
enantioselective epoxidation  
Cyclopeptoids 42, 93-95 were initially tested as chiral 
PT catalyst in the enantioselective  epoxidation of trans-
chalcone (table 4.4). The reactions were monitored via TLC 
in order to evaluate the time required for total conversion. The 
slow reactions (entry 2, 4, 8, 9 ) were stopped within 24h 
(with the only exception of entry 8) and the percentage of 
conversion was measured by 
1
H-NMR. The crude was 
purified by flash cromatography. It was employed as reaction 
mixture both a liquid-liquid system with a 50% water solution 
of NaOH and a solid-liquid system with NaOH(s). The 
reactions were conducted at 0
°
C with the only exception of a 
test performed at room temperature with worse results. The 
first solvent used was DCM in order to properly solubilize the 
catalyst and, as a result of the very low enantioselectivity 
obtained with this solvent (entry 2), toluene was employed. It 
was also tried Bu2O to evaluate the effect of the solvent on the 
asymmetric induction, but with this solvent a racemic mixture 
was obtained (entry 7). t-BuOOH was employed as oxidant 
agent and only a test was performed with NaOCl, which 
demonstrated to be less efficient.  
In general, the only noteworthy enantioselectivity, 
although low, was the 14%  ee obtained with the catalyst 94 
(entry 6). Nevertheless, the ee % measured are clearly worse 
than those reported in literature for other PT asymmetric 
catalysts. So, the cyclopeptoids examined revealed to be poor 




active chiral catalyst in the asymmetric PT reaction 
considered. In the epoxidation reaction it is observed the 
formation of the enantiomer αSβR, as it is possible to infer 
















Entry                                      
 
Catalyst  Base    Solvent Time (h) Yield (%) ee (%) 
1 42  NaOH aq.     toluene   3    78  10 
2 93  NaOH aq.     toluene        23    81  4 
3 94  NaOH (s)    DCM  4    83    rac.    
4 94  NaOH aq.    DCM    26    54  5 
5 94  NaOH (s)      toluene  2    81    rac. 
6 94  NaOH aq.     toluene     3.5    83   14 
7 94  NaOH aq.    Bu2O 
  
 3    80     rac. 
  8b) 94         -     toluene      100    78   10 
9 95  NaOH aq.     toluene    25    79  8 
 
a) 
The reactions were carried out at 0
°
C using a 0.1 M solution of trans-
chalcone (117) in the organic solvent (0.8 mL), 1.2 eq of t-BuOOH (5.5 M 
in decane), a 50% aqueous solution of NaOH or 3eq of NaOH(s) and 
catalyst (0.005 mmol). 
b)
 The reaction was carried out at room temperature 
with a 11% aqueous solution of NaOCl as oxidant. 
                                                 
97 M. Yoo, D. Kim, M. W. Ha, S. Jew, H. Park Tetrahedron Letters, 2010, 51, 5601-5603. 
 




4.4.3  Catalytic activities in the 
enantioselective alkylation  
Cyclopeptoids 42, 93-95 were further employed in a 
second asymmetric reaction, namely the enantioselective 
alkylation of N-(diphenylmethylene)glycine t-buthyl ester 
(table 4.5). In this case also the compound 96 containing L-
valine was tested. The reactions were monitored via TLC and 
stopped after 24h, with the only exception of entry 1. The 
percentage of conversion was measured by 
1
H-NMR. The 
crude was purified by flash cromatography. It was employed 
as reaction mixture both a liquid-liquid system with a 50% 
water solution of NaOH and a solid-liquid system with 
NaOH(s). The reactions were conducted at 0
°
C and at room 
temperature in order to evaluate the effect of temperature on 
the asymmetric induction. The unique solvent used was 
toluene, which resulted to be the best solvent in the previous 
study. Compound 94 was first tested as catalyst in this 
reaction. 
As illustrated in table 4.5, in presence of oxygen it was 
observed a low ee  (14%) and a low yield due to the 
decomposition of the substrate 78. Specifically, 78 in aerobic 
atmosphere converts into benzophenone, as demonstrated by 
1
H NMR.  From the comparison with the retention times 
reported in literature, it is deduced the formation of the 
enantiomer R.
98
 Analogous decompositions of glycine imines 
                                                 
98 T. Ooi, M. Kameda, K. Maruoka J.Am. Chem. Soc. , 1999, 121, 6519-6520. 




in presence of oxygen were reported and Maruoka solved the 
problem operating in inert atmosphere.
99
 As  a consequence, 
the reaction was firstly performed under nitrogen registering a 
better ee equal to 36% for 94 (entry 6) and a significative 
reduction of the benzophenone formation. Afterwards, to 
prevent the decomposition, the deoxygenation of reagents and 
solvents was carried out. In this way the enantioselectivity 
was increased up to 38% (entry 7) and the side reaction of 
decomposition was effectively inhibited.  
From the results illustrated in table 4.5 it is possible to infer 
that the compounds 42, 93, 95, 96 are characterized by a 
worse catalytic activity with respect to 94, both in terms of 
yield and ee. On the other hand, cyclopeptoid 93 leads to a 
higher yield in relation to 94, but the ee  is clearly lower. So, 
the methoxyethoxyethyl side chains of 93 determine a 
positive effect on the reaction rate in a similar manner to what 
happened in the benchmark SN2 reaction studied before 
(section 4.3.4). 
In conclusion, cyclopeptoid 94 with L-proline and 
benzyl chains in alternate positions resulted to be the best 





                                                 
99 T. Ohshima, T. Shibuguchi, Y. Fukuta, M. Shibasaki Tetrahedron, 2004, 60, 7743-7754. 
 




Table 4.5: Enantioselective alkylation of N-(diphenylmethylene)glycine t-


























ee( %)  
   1d) 42    44  7     rac. 
2d) 93    21    66  10 
3b) 94    23    29  14     
4c) 94    25    28    rac. 
   5 94    20    36   29 
6d) 94    23    39   36 
7e) 94    19    54   38 
8e) 95    21    36   10 
9e) 96    18    11  8 
 
a)
 The reactions were carried out at 0
°
C using a 0.1 M solution of N-
(diphenylmethylene)glycine t-buthyl ester (78) in toluene (0.8 mL), 1.2 eq 
of BnBr, a 50% aqueous solution of NaOH or 3eq of NaOH(s) and catalyst 
(0.005 mmol).  
b)
 The reaction was carried out at room temperature. 
c)
 The reaction was carried out at room temperature with NaOH(s). 
d)
 The reaction was conducted under nitrogen atmosphere. 
e)
 Reagents and solvents have been deoxygenated.
 
4.4.4  Catalytic activities in the 
enantioselective alkylation: second 
generation catalysts 
On the wake of the promising result obtained with the 
catalyst 94, we prepared some structural analogues of 94 (48 




and 97-100), containing variously functionalized aromatic 
side chains. Particularly, the substituents on the aromatic rings 
present different stereoelectronic features so that it was 
possible to evaluate the effect on the asymmetric induction. 
The synthesis of the cyclopeptoids 48, 97-100 was performed 
making use of a solid-phase mixed approach (submonomer
34
 



























































100, R =  
Scheme 4.12: Solid-phase mixed approach for the synthesis of 48, 97-100. 
Reagents and conditions: (a) bromoacetic acid, DIPEA, DCM; (b) RNH2, 
DMF; (c) N-Fmoc-L-Proline, HATU, DIPEA, DMF; (d) Piperidine-DMF 
(1:5); (e) bromoacetic acid, DIC, DMF;  (f) HFIP-DCM (1:5); (g) HATU, 
DIPEA, DMF. 
 
The novel catalysts were tested in the same asymmetric 
alkylation reaction in which the first generation catalysts were 




employed (table 4.6). The reactions were carried out 
identically to the best conditions (entry 7, table 4.5). 
Observing the results in table 4.6, it is possible to 
make the following considerations. With the compound 97 
it was achieved an higher ee and a lower yield with respect 
to the reaction catalyzed by 94, reasonably due to the 
increased steric hindrance of the naphthyl group and to the 
presence of a more large aromatic system. The electron-
withdrawing group –CF3 of 98 exercises a negative effect 
both on the reaction rate and the ee. With two electron-
withdrawing groups –CF3 (compound 99) the reaction rate 
is higher, but the enantioselectivity is scarce. 
The electron-donating group –OMe of 100 leads to low 
reaction rates and the ee is comparable with that obtained 
with 97. The two electron-donating groups –Me of 48 play 
a favourable effect in the asymmetric induction, resulting in 













Table 4.6: Enantioselective alkylation of N-
(diphenylmethylene)glycine t-buthyl ester catalyzed  by cyclopeptoids 
48 and 97-100, in comparison with 94.
a) 
 
Entry                                                  
 








1 94    19    54   38 
2 48    20    38   66 
3 97    18    12   50     
4 98    18   7   30 
  5b) 98    20    30   10 
6 99    19    65   28 
7 100    18   8   46 
 
a)
 The reactions were carried out at 0
°
C using a 0.1 M solution of N-
(diphenylmethylene)glycine t-buthyl ester (78) in toluene (0.8 mL), 1.2 eq 
of BnBr, a 50% aqueous solution of NaOH or 3eq of NaOH(s) and catalyst 
(0.005 mmol). Reagents and solvents were deoxygenated. 
b) 
The reaction was performed at room temperature.
 
Finally, a screening of the reaction conditions was 
conducted making use of the best catalyst (48) in order to 
improve the enantioselectivity. It is a brief study in which a 
few experimental parameters were modified. Specifically, 
in table 4.7 are reported the reactions conducted with 
different solvents (DCM, CHCl3, mesitylene, o-xylene, m-
xylene) and employing an aqueous solution of NaOH with 
concentration of 50% and 33%. 
It is possible to deduce from the results the following 
information. First of all, both the yield and the ee get worse 
employing a 33% aqueous solution of  NaOH. Futhermore, 
the enantioselectivity in all the solvents used is by far lower 




than that obtained in toluene. Specifically, DCM and CHCl3 
determine a strong decrease of the ee. In addition, the yield 
with DCM is the same of that in toluene and with CHCl3 is 
lower. With respect to the aromatic solvents proved, in 
mesitylene the reaction resulted to be very rapid (yield = 
68%) but a racemic mixture is formed. Futhermore, with o-
xylene the yield is moderate (51%) but the ee is scarce. In 
the case of m-xylene both the yield and the ee are low.    
Table 4.7: Enantioselective alkylation of N-(diphenylmethylene)glycine t-




  Entry                                                
 
Solvent







1 toluene    20    38  66 
  2b) toluene    20    4  22    
  3b) toluene    44    10  14 
4        DCM 
 
   20    38  8 
5       CHCl3 
 
   18    14  8 
6 mesitylene    20    68   rac. 
7     o-xylene    22    51  16 
8 m-xylene    22    12  2 
 
a)
 The reactions were carried out at 0
°
C using a 0.1 M solution of N-
(diphenylmethylene)glycine t-buthyl ester (78) in the organic solvent (0.8 
mL), 1.2 eq of BnBr, a 50% aqueous solution of NaOH or 3eq of NaOH(s) 
and catalyst (0.005 mmol).  Reagents and solvents were deoxygenated. 
b) 
30% aqueous solution of NaOH was employed. 





In the first part of this chapter, the binding affinities 
and the catalytic activities of some cyclopeptoids with 
different side chains (43, 47, 71, 91, 92) in the liquid-liquid 
two phase nucleophilic substitution reaction of p-nitrobenzyl 
bromide with thiocyanate salts and in comparison with classic 
phase-transfer catalysts were reported. Later, the catalytic 
activities of some proline-rich cyclopeptoids (42, 48, 93-95, 
97-100) and of a cyclopeptoid containing valine (96), 
employed as chiral catalysts in two common asymmetric 
phase-transfer reactions, were described.  
With respect to the first subject, compound 47 with N-
[2-(2-methoxyethoxy)ethyl] side chains showed Ka values for 
Na
+
 greater than that reported for the efficient complexing 
agents dicyclohexyl-18-crown-6 (109) and 15-crown-5 (111), 
and, in agreement with Cram data, the best ionophoric activity 
towards Na
+
 among the cyclopeptoids tested in the HPTS 
assay. More interestingly, 47 exhibited high catalytic activity 
in the reaction with NaSCN, comparable to that evaluated for 
cryptand 112  and higher than those displayed by commonly 
used crown ethers and the tetrabutylammonium bromide. A 
good activity was also achieved in the reaction with the 
KSCN. This is the first example of the use of cyclopeptoids in 
PTC. 
Regarding the challenging studies in PT asymmetric 
catalysis, the proline-rich cyclopeptoid 94 containing benzyl 




side chains resulted to be the best catalyst in terms of 
enantioselectivity (38% ee) among the first generation chiral 
catalysts (42, 93-96) tested in the enantioselective alkylation 
of N- diphenylmethylene)glycine t-buthyl ester. On the wake 
of the promising result, some structural analogues of 94 (48, 
97-100) were prepared and used as second-generation chiral 
PT catalyst in the aforementioned reaction. To our delight, the 
proline-rich cyclopeptoid 48, containing a 3,5-dimethyl 
benzylamine side chain, revealed to be the most active 
asymmetric PT catalyst proved with a 66% ee at 0
°
C in 
toluene and employing a 50% NaOH solution. The moderate 
enantioselectivity obtained with 48 represents an interesting 
result in the vast aerea of asymmetric PT catalysis considering 
that cyclopeptoids constitute a totally new class of chiral 
phase-transfer catalysts with respect to the well-known 
cinchona alkaloids, whose great potential mainly derives from 
modulability of their backbone. Finally, this work opens the 
doors for a future employment of more efficient cyclopeptoids 
in various asymmetric PT reactions. 
4.6 Experimental section83 
4.6.1 Solid-phase synthesis  
Submonomer solid-phase synthesis of linear 
precursors 101-103 
Linear precursors 101-103 were synthesized using a 
submonomer solid-phase approach. In a typical synthesis 0.60 




g of 2-chlorotrityl chloride resin (2,α-dichlorobenzhydryl-
polystyrene crosslinked with 1% DVB; 100–200 mesh; 1.3 
mmol/g) was swelled in dry DCM (6 mL) for 45 min and 
washed twice with dry DMF (6 mL). The first submonomer 
was attached onto the resin by adding bromoacetic acid (173 
mg, 1.25 mmol) in dry DCM (6 mL) and DIPEA (680 μL, 
3.9 mmol) on a shaker platform for 60 min at room 
temperature, followed by washing with dry DCM (6 mL) and 
then with DMF (3 × 6 mL). To the bromoacetylated resin was 
added a DMF solution of the desired amine (1 M, 6 mL). All 
the amines are commercially available except for the 
methoxyethoxyethyl 
amine, which was prepared through a rapid two step 
sequence, as described in section 4.6.5. The mixture was left 
on a shaker platform for 30 min at room temperature, then the 
resin was washed with DMF (3 × 3 mL). Subsequent 
bromoacetylation reactions were accomplished by reacting the 
aminated oligomer with a solution of bromoacetic acid (1.08 
g, 7.80 mmol) in DMF (6 mL) and of DIC (1.3 mL, 8.40 
mmol) for 40 min at room temperature. The filtered resin was 
washed with DMF (3 × 6 mL) and treated again with the 
amine under the same conditions reported above. This cycle 
of reactions was iterated until the target oligomer was 
obtained. The cleavage was performed by treating twice the 
resin, previously washed with DCM (3 × 6 mL), with a 
solution of HFIP in DCM (20% v/v, 8 mL) on a shaker 
platform at room temperature for 30 min and 5 min, 




respectively. The resin was then filtered away and the 
combined filtrates were concentrated in vacuo. The final 
products were dissolved in 50% acetonitrile in 
HPLC grade water and analysed by RP-HPLC. The linear 
oligomers were subjected to the cyclization reaction without 
further purification with the exception of  97 which was 
purified by semipreparative RP-HPLC. 
 Compound 101 
Yield: 69% (purified by RP-HPLC). 
ES-MS: 973.5 m/z [M + H
+
]. 
HPLC: tR: 7.8 min; conditions: 25 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 2 mL 
min
−1
, 220 nm. 
 Compound 102 
Purity: >95%. 
Yield: 71% (crude residue). 
ES-MS: 902.1 m/z [M + H
+
]. 
HPLC: tR: 16.0 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 Compound 103 
Purity: >95%. 
Yield: 61% (crude residue). 
ES-MS: 865.9 m/z [M + H
+
]. 




HPLC: tR: 20.3 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
Mixed monomer/submonomer solid-phase 
synthesis  of linear precursors 55 and 119-127 
Linear precursors 55, 119-127 were synthesized by alternating 
submonomer solid-phase method using standard manual 
Fmoc solid-phase peptide synthesis protocols. Typically 0.40 
g of 2-chlorotrityl chloride resin (2,α-dichlorobenzhydryl-
polystyrene crosslinked with 1% DVB; 100-200 mesh; 1.20 
mmol/g) was swelled in dry DCM (4 mL) for 45 min and 
washed twice in dry DCM (3 mL). To the resin bromoacetic 
acid (107 mg, 0.77 mmol) and DIPEA (418 μL, 2.4 mmol) in 
dry DCM (4 mL) were added on a shaker platform for 40 min 
at room temperature, washes with dry DCM (3 × 4 mL) and 
then with DMF (3 × 4 mL) followed. To the bromoacetylated 
resin metoxyethylamine (413 μl, 4.80 mmol) in dry DMF (4 
mL), was added. The mixture was left on a shaker platform 
for 40 min at room temperature, then the resin was washed 
with DMF (3 × 4 mL). The resin was incubated with a 
solution of N-Fmoc-L-proline (4.85 mg, 1.44 mmol), HATU 
(529 mmol, 1.39 mmol), DIPEA (333 μl ) in dry DMF (4 mL) 
on a shaker platform for 1 h, followed by extensive washes 
with DMF (3 × 4 mL), DCM (3 × 4 mL) and DMF (3 × 4 
mL). Chloranil test was performed and once the coupling was 
complete the Fmoc group was deprotected with 20% 




piperidine/DMF (v/v, 3 mL) on a shaker platform for 3 min 
and 7 min respectively, followed by extensive washes with 
DMF (3 × 3 mL), DCM (3 × 3 mL) and DMF (3 × 3 mL). The 
yields of loading step and of the following coupling steps 
were evaluated interpolating the absorptions of 





), obtained in Fmoc deprotection step (the average 
coupling yield was 63-70 %). Subsequent bromoacetylation 
reactions were accomplished by reacting the oligomer with a 
solution of bromoacetic acid (690 mg, 4.8 mmol) and DIC 
(817 μL, 5.28 mmol) in DMF (4 mL) on a shaker platform 40 
min at room temperature. Subsequent N-Fmoc-L-proline 
addition and Fmoc deprotection steps were performed as 
described above, addition of the proline at the fourth and sixth 
position required longer reaction time (3 h) for all the linear 
peptoids and two treatments only in the case of 55. The 
synthesis proceeded until the desired hexaoligomer was 
obtained. The oligomer-resin was cleaved in 4 mL of 20% 
HFIP in DCM (v/v). The cleavage was performed on a shaker 
platform for 30 min at room temperature the resin was then 
filtered away. The resin was treated again with 4 mL of 20% 
HFIP in DCM (v/v) for 5 min, washed twice with DCM (3 
mL), filtered away and the combined filtrates were 
concentrated in vacuo. The final products were dissolved in 
50% ACN in HPLC grade water and analysed by RP-HPLC 
and ESI mass spectrometry. The linear compounds were 
subjected to the cyclization without further purification. 




 Compound 55100 
 Compound 119 
Purity: >60%. 
Yield: 60% (crude residue). 





HPLC: tR: 11.7 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 Compound 120 
Purity: >80%. 
Yield: 34% (crude residue). 
ES-MS: 751.8 m/z [M + H
+
]. 
HPLC: tR: 13.1 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 Compound 121 
Purity: >88%. 
Yield: 63% (crude residue). 
ES-MS: 733.4 m/z [M + H
+
]. 
HPLC: tR: 15.9 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 Compound 122 
Purity: >83%. 
Yield: 52% (crude residue). 
                                                 
100 See section 2.6.2. 




ES-MS: 739.3 m/z [M + H
+
]. 
HPLC: tR: 15.9 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 Compound 123 
Purity: >70%. 
Yield: 39% (crude residue). 
ES-MS: 835.0 m/z [M + H
+
]. 
HPLC: tR: 15.3 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 Compound 124 
Purity: >70%. 
Yield: 42% (crude residue). 
ES-MS: 901.0 m/z [M + H
+
]. 
HPLC: tR: 15.6 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 Compound 125 
Purity: >82%. 
Yield: 48% (crude residue). 
ES-MS: 955.0 m/z [M + H
+
]. 
HPLC: tR: 15.4 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 




 Compound 126 
Purity: 78%. 
Yield: 55% (crude residue). 
ES-MS: 1159.0 m/z [M + H
+
]. 
HPLC: tR: 17.2 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 Compound 127 
Purity: >85%. 
Yield: 38% (crude residue). 
ES-MS: 841.0 m/z [M + H
+
]. 
HPLC: tR: 12.9 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
4.6.2  General procedure for high dilution 
cyclization 
Synthesis of  47, 48 and 91-100 
To a stirred solution of HATU (116 mg, 0.31 mmol), DIPEA 
(0.082 mL, 0.47 mmol) in dry DMF (20 mL) at room 
temperature, a solution of the linear compounds (crude 101-
103, 119-127) (0.08 mmol) in dry DMF (20 mL) was added 
by syringe pump in 6 h. After 12 h the resulting mixture was 
concentrated in vacuo, diluted with DCM (20 mL) and 
washed with 1 M HCl (7 mL × 3) was added. The mixture 
was extracted with DCM (10 mL × 2) and the combined 
organic phases were washed three times with water (10 mL), 




dried (MgSO4) and concentrated in vacuo. The crude residues 
from the HATU-induced cyclizations were purified by HPLC. 
Compounds 91, 92 were purified by precipitation in 
CH3CN/H2O 1:1 (v/v). 
 Compound 47 
Yield: 42%. The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 15.4 
min.; conditions: 25 → 100% B in 50 min (A: 0.1% TFA in 








H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 4.94–
3.32 (42 H, m, COCH2N, OCH2CH2O, OCH2CH2O, 
NCH2CH2O, NCH2CH2O, OCH3). 
13
C-NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 172.6, 
172.3, 171.3, 170.9, 170.7, 170.5, 170.1, 169.7, 169.4, 169.0, 
168.9, 168.4, 168.3, 168.0, 71.8, 71.8, 70.4, 70.3, 70.2, 70.1, 
69.8, 69.7, 69.4, 69.2, 69.0, 68.8, 68.7, 68.5, 68.0, 67.8, 67.4, 
58.9, 52.4, 51.0, 50.3, 49.5, 49.3, 48.8, 48.1, 47.3, 46.3. 
 Compound 48 
Yield: 43%. The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 17.2 
min.; conditions: 25 → 100% B in 30 min (A: 0.1% TFA in 




ES-MS: 817.6 m/z [M + H
+ 
]. 





H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 7.26-
6.72 (9H, m, ArH), 5.75-3.22 (27H, m, COCHN, NCHHCO, 
NCHHCO, NCH2Ar, CHCH2CH2CH2N), 2.66-0.94 (30H, m, 
CHCH2CH2CH2N, CHCH2CH2CH2N, ArCH3).  
13
C-NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 173.9, 
173.4, 172.6, 171.9, 171.6, 171.5, 168.5, 168.3, 167.6, 167.4, 
166.1, 165.8, 138.8, 138.7, 138.6, 138.3, 138.1, 137.8, 136.9, 
136.8, 135.9, 129.5, 129.3, 129.1, 128.6, 126.3, 125.9, 125.5, 
125.0, 124.5, 124.4, 124.2, 58.4, 58.1, 57.5, 56.8, 56.1, 53.6, 
53.0, 52.8, 52.0, 51.3, 50.5, 50.1, 48.8, 48.1, 47.9, 47.6, 47.1, 
46.7, 46.4, 46.2, 37.4, 37.1, 32.8, 32.2, 31.9, 31.4, 30.0, 29.7, 
29.4, 29.2, 28.3, 27.4, 25.0, 24.9, 24.8, 23.0, 22.7, 22.0, 21.7, 
20.9, 19.7, 18.3. 
 Compound 91 
Yield: 39%. The crude residue was purified by precipitation 
in CH3CN/H2O 1:1 (v/v).  




H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ:  3.25-




C-NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 171.9, 
171.3, 169.6, 168.9, 168.6, 167.9, 137.2–135.4 ,129.3, 125.4, 
53.0, 51.6, 50.2, 48.9, 48.6, 48.4, 47.7, 47.5. 
HPLC: tR: 19.9 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 




 Compound 92 
Yield: 37%. The crude residue was purified by precipitation 
in CH3CN/H2O 1:1 (v/v).  




H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ:  4.73–
3.76 (m, 12 H, COCH2N), 3.58–2.70 (m, 12 H, 
NCH2(CH2)4CH3), 2.05–1.20 (m, 48 H, NCH2(CH2)4CH3), 
0.89–0.83 (bs, 18 H, NCH2(CH2)4CH3).
 
13
C-NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 171. 8, 
171.5, 171.0, 170.5, 170.3, 170.2, 169.9, 169.5, 169.2, 169.1, 
168.8, 168.6, 168.4, 168.3, 168.2, 168.0, 167.6, 167.4, 167.3, 
166.8, 166.7, 166.4, 166.3, 51.5, 51.1, 50.9, 50.4, 50.0, 49.7, 
49.5, 49.3, 49.0, 48.8, 48.7, 48.6, 48.3,48.2, 47.9, 47.7, 47.5, 
47.3, 47.1, 46.8, 46.6, 46.3, 46.0, 43.3, 32.7, 31.6, 31.5, 30.1, 
30.0, 29.9, 29.7, 29.4, 29.1, 29.0 , 28.9, 28.7, 28.5, 28.1 , 28.0 
, 27.7, 27.6, 27.5, 27.3, 27.2, 27.0 , 26.9, 26.5 , 22.60, 14.0. 
HPLC: tR: 23.2 min; conditions: 5 → 100% B in 30 min (A, 
0.1% TFA in water, B, 0.1% TFA in acetonitrile); flow: 1 mL 
min
−1
, 220 nm. 
 Compound 93 
Yield: 28%. The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 9.0 
min.; conditions: 40 → 100% B in 30 min (A: 0.1% TFA in 















: -0.72 (c =1.1, CHCl3).
 
1
H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 4.82 
(3H, bs, COCHN), 4.17 (6H, bd, J = 16.0 Hz, NCHHCO), 
4.00-2.76 (36H, m, NCH2CH2O, NCH2CH2O, OCH2CH2O, 
OCH2CH2O, NCHHCO, CHCH2CH2CH2N,), 3.57 (9H, bs, 




C-NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 173.5, 
167.9, 71.9, 70.7, 69.5, 59.0, 57.8, 57.5, 50.4, 49.6, 49.0, 46.8, 
31.9, 29.7, 29.3, 27.3, 25.1, 22.6, 19.1. 
 Compound 94 
Yield: 49%. The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 14.8 
min.; conditions: 25 → 100% B in 30 min (A: 0.1% TFA in 









: +25.5 (c =1.0, CHCl3).
 
1
H-NMR: (300 MHz, CDCl3, mixture of rotamers) δ: 7.85-
6.96  (15H, m, ArH), 5.88-3.24 (27H, m, COCHN, 
NCHHCO, NCHHCO, NCH2Ar, CHCH2CH2CH2N), 2.55-
1.30 (12H, m, CHCH2CH2CH2N, CHCH2CH2CH2N).
 
13
C-NMR: (75 MHz, CDCl3, mixture of rotamers) δ: 174.2, 
173.8, 173.2, 172.7, 172.6, 172.2, 171.9, 170.9, 169.9, 168.9, 
168.4, 168.1, 167.9, 167.7, 167.3, 167.1, 166.8, 166.7, 165.4, 
137.0, 136.7, 136.6, 136.5, 136.4, 136.2, 136.1, 135.7, 129.3, 




129.0, 128.7, 128.5, 128.4, 128.3, 128.2, 128.0, 127.8, 127.7, 
127.6, 127.5, 127.3, 127.1, 126.9, 126.7, 126.6, 126.4, 126.2, 
116.7, 113.8, 58.9, 58.8, 57.9, 57.8, 57.3, 56.7, 56.5, 56.1, 
53.6, 53.3, 53.1, 53.0, 52.3, 51.7, 51.4, 50.8, 50.1, 50.0, 49.9, 
49.8, 49.4, 49.1, 48.8, 48.4, 48.1, 47.8, 47.7, 47.6, 47.4, 47.1, 
46.9, 46.8, 46.4, 46.3, 46.2, 32.2, 32.0, 31.9, 31.4, 31.3, 29.9, 
29.6, 29.4, 29.2, 28.9, 28.6, 28.2, 25.9, 25.4, 25.2, 25.0, 24.8, 
24.6, 22.9, 22.7, 22.6, 22.0, 21.6. 
 Compound 95 
Yield: 64%. The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 17.6 
min.; conditions: 40 → 100% B in 30 min (A: 0.1% TFA in 









: -2.3 (c =1.0, CHCl3).
 
1
H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 5.66-
4.50 (15H, m, NCHHCO, NCHHCO, COCHN), 4.36-3.08 
(15H, m, CH3(CH2)4CH2N, CHCH2CH2CH2N), 2.51-1.47 
(12H, m, CHCH2CH2CH2N, CHCH2CH2CH2N), 1.28 (24H, 
m, CH3(CH2)4CH2N), 0.86 (9H, m, CH3(CH2)5N).
 
13
C-NMR: (75 MHz, CDCl3, mixture of rotamers) δ: 173.3, 
172.8, 172.1, 171.6, 168.3, 167.8, 167.5, 167.0, 166.7, 58.9, 
58.3, 57.7, 56.5, 50.5, 50.2, 49.8, 49.4, 49.0, 48.8, 48.5, 48.2, 
47.8, 47.6, 47.3, 47.1, 46.8, 32.1, 31.9, 31.6, 31.4, 30.2, 29.8, 




29.7, 29.5, 29.3, 29.2, 29.0, 28.7, 28.4, 27.8, 27.5, 27.2, 27.0, 
26.9, 26.5, 26.4, 26.2, 25.5, 25.1, 24.9, 22.9, 22.6, 22.1, 13.9. 
 Compound 96 
Yield: 18%. The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 18.6 
min.; conditions: 25 → 100% B in 30 min (A: 0.1% TFA in 









: +5.7 (c =0.8, CHCl3).
 
1
H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 7.68-
6.88 (3H, m, CONH), 4.76-3.39 (21H, m, NCHHCO, 
NCHHCO, COCHN, CH3(CH2)4CH2N),  2.05-1.25  (m, 
CH3(CH2)4CH2N, (CH3)2CH, (CH3)2CH) , 1.00-0.88 (m, 
(CH3)2CH), 0.86 (9H, m, CH3(CH2)5N).
 
13
C-NMR: (75 MHz, CDCl3, mixture of rotamers) δ: 173.4, 
172.4, 171.9, 171.4, 170.0, 169.9, 169.5, 168.8, 168.2, 167.7, 
54.6, 54.5, 54.0, 52.1, 51.7, 51.4, 50.8, 50.5, 50.4, 50.1, 49.8, 
48.2, 47.9, 47.4, 32.1, 31.9, 31.4, 31.1, 30.5, 29.9, 28.9, 28.7, 
28.2, 27.0, 26.3, 22.5, 19.8, 19.7, 19.6, 18.3, 17.8, 17.7, 17.5, 
13.9. 
 Compound 97 
Yield: 22%. The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 17.4 
min.; conditions: 40 → 100% B in 30 min (A: 0.1% TFA in 













: +8.3 (c =0.9, CHCl3).
 
1
H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 8.30-
6.96  (21H, m, ArH), 6.10-3.13(27H, m, COCHN, NCHHCO, 




C-NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 175.5, 
174.4, 173.7, 173.4, 173.2, 173.0, 172.2, 172.1, 171.8, 171.4, 
169.9, 169.8, 169.1, 168.9, 168.5, 168.3, 168.0, 167.6, 166.9, 
166.1, 166.0, 165.8, 133.8, 133.7, 133.0, 132.6, 132.5, 132.3, 
132.1, 131.9, 131.7, 131.5, 131.3, 131.2, 131.0, 130.9, 130.8, 
130.6, 130.3, 129.2, 129.0, 128.7, 128.4, 128.3, 128.2, 127.8, 
127.6, 127.0, 126.8, 126.6, 126.3, 125.9, 125.6, 125.4, 125.3, 
125.2, 124.4, 123.6, 123.5, 123.1, 122.9, 122.6, 122.5, 122.3, 
121.7, 59.0, 58.9, 58.6, 57.9, 57.8, 57.4, 57.3, 56.9, 56.7, 56.6, 
56.1, 55.8, 51.6, 51.5, 51.1, 50.7, 50.5, 50.1, 50.0, 49.3, 48.9, 
48.7, 48.5, 47.9, 47.6, 47.5, 47.3, 47.2, 46.8, 46.6, 46.4, 46.2, 
45.6, 32.0, 31.9, 31.6, 31.3, 31.2, 31.1, 30.0, 29.7, 29.3, 29.1, 
28.7, 28.3, 27.5, 27.3, 27.1, 25.8, 25.4, 25.2, 25.1, 24.8, 23.2, 
23.0, 22.6, 22.1, 21.4, 20.6, 20.1, 19.7. 
 Compound 98 
Yield: 18%. The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 17.5 
min.; conditions: 25 → 100% B in 30 min (A: 0.1% TFA in 













: +28.6 (c =0.9, CHCl3).
 
1
H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 7.78-
7.26 (12H, m, ArH), 5.90-2.85(27H, m, COCHN, NCHHCO, 




C-NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 174.4, 
173.9, 173.8, 173.6, 173.5, 172.9, 172.4, 172.1, 171.9, 171.5, 
171.0, 169.9, 169.8, 169.7, 169.2, 168.8, 168.5, 168.2, 167.7, 
167.0, 166.8, 166.6, 166.3, 165.9, 165.6, 165.3, 141.5, 141.3, 
141.1, 140.9, 140.5, 140.1, 139.8, 139.6, 139.1, 130.8, 130.3, 
130.0, 129.7, 129.4, 129.2, 128.5, 128.3, 127.9, 127.7, 127.4, 
127.1, 126.9, 126.7, 126.5, 126.0, 125.6, 125.5, 125.3, 122.5, 
59.5, 58.9, 57.7, 57.5, 57.3, 56.6, 56.5, 56.2, 53.3, 53.2, 52.7, 
52.3, 51.8, 51.7, 51.5, 51.0, 50.7, 50.5, 50.6, 50.4, 49.8, 49.6, 
49.3, 49.0, 48.8, 48.4, 48.3, 48.1, 47.8, 47.6, 47.4, 47.2, 46.9, 
46.6, 46.5, 46.3, 37.4, 32.7, 32.1, 31.9, 31.6, 31.4, 30.3, 30.0, 
29.6, 29.3, 28.9, 28.7, 28.3, 27.8, 27.3, 27.1, 26.3, 25.9, 25.6, 
25.4, 25.2, 25.0, 24.8, 23.0, 22.9, 22.6, 22.1, 21.6, 21.1, 19.7.  
 Compound 99 
Yield: 23%. The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 19.0 
min.; conditions: 25 → 100% B in 30 min (A: 0.1% TFA in 













: +22.9 (c =1.0, CHCl3).
 
1
H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 8.17-
7.56 (9H, m, ArH), 5.73-2.79 (27H, m, COCHN, NCHHCO, 




C-NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 174.4, 
173.7, 172.8, 172.4, 169.9, 169.7, 168.4, 168.2, 167.4, 168.2, 
167.4, 166.3, 166.1, 159.6, 159.3, 139.6, 139.1, 138.3, 133.0, 
132.7, 132.4, 132.1, 131.8, 131.5, 128.5, 128.3, 127.5, 127.2, 
127.0, 126.5, 124.6, 124.5, 124.3, 122.2, 121.9, 121.6, 121.4, 
119.2, 118.9, 116.6, 113.7, 59.6, 58.0, 57.8, 57.8, 56.6, 56.3, 
53.4, 53.1, 52.4, 52.0, 51.9, 50.7, 50.4, 49.8, 49.2, 48.8, 48.5, 
47.6, 46.9, 46.8, 46.6, 37.4, 37.1, 32.7, 31.9, 31.6, 31.3, 30.0, 
29.7, 29.5, 29.3, 28.5, 27.8, 27.6, 27.3, 27.0, 25.5, 25.4, 25.1, 
24.4, 22.8, 22.7, 20.8, 19.7. 
 Compound 100 
Yield: 57%. The crude residue was purified by RP-HPLC 
on a C18 reversed-phase semi-preparative column (tR: 14.1 
min.; conditions: 25 → 100% B in 30 min (A: 0.1% TFA in 









: +30.8 (c =1.0, CHCl3).
 





H-NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 7.54-
6.59(12H, m, ArH), 5.87-3.16(36H, m, COCHN, NCHHCO, 
NCHHCO, NCH2Ar, CHCH2CH2CH2N, OCH3), 2.76-0.92 
(12H, m, CHCH2CH2CH2N, CHCH2CH2CH2N).
 
13
C-NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 173.3, 
173.2, 172.5, 171.9, 171.8, 171.6, 171.0, 169.8, 168.5, 168.3, 
168.0, 167.3, 167.1, 166.9, 166.8, 165.6, 159.4, 159.2, 159.0, 
158.7,  129.9, 129.5, 129.2, 129.0, 128.9, 128.7, 128.4, 128.3, 
128.1, 127.9, 127.7, 114.4, 114.3, 114.2, 114.1, 113.9, 113.7, 
58.7, 58.5, 58.2, 57.8, 57.6, 57.3, 57.0, 56.7, 56.2, 56.1, 55.7, 
55.3, 55.1, 53.0, 52.6, 52.5, 52.3, 51.2, 50.8, 50.4, 50.3, 49.5, 
49.2, 48.7, 48.4, 47.9, 47.7, 47.5, 47.4, 47.2, 46.7, 46.5, 46.4, 
46.2, 37.4, 37.0, 36.8, 32.7, 32.0, 31.9, 31.6, 31.5, 31.4, 31.2, 
30.2, 30.0, 29.6, 29.3, 29.2, 28.9, 28.2, 27.7, 27.5, 27.3, 27.0, 
25.7, 25.4, 24.9, 24.8, 24.4, 22.9, 22.6, 22.1, 21.7, 21.3, 21.1, 
20.5, 20.3, 19.7. 
4.6.3  General procedure for the synthesis 
of complexed cyclopeptoids 107 and 
108 
To a solution of cyclopeptoid 43 or 91 (0.034 mmol) in 
DCM:MeOH 9:1 (v/v) sodium hexafluorophosphate (5.6 mg, 
0.034 mmol) was added. The mixture was stirred overnight 
and then concentrated in vacuo. 
 Compound 107 
ES-MS: 713.7 m/z [M + Na
+ 
]. 





H-NMR: (400 MHz, CD3CN, mixture of rotamers) δ: 4.69 (6 
H, d, J = 16.7 Hz, 
NCHHCO), 3.84 (6H, d, J = 16.7 Hz, NCHHCO), 3.59–3.33 
(24H, m, NCH2CH2O, NCH2CH2O), 3.34 (18 H, s, OCH3). 
13
C-NMR: (100 MHz, CD3CN, mixture of rotamers) δ: 170.6, 
71.0, 59.1, 50.5, 49.6. 
 Compound 108 




H-NMR: (400 MHz, CD3CN, mixture of rotamers) δ: 7.37–
7.26 (30 H, m, ArH), 4.86 (6 H, d, J = 16.8 Hz, CHHAr), 4.72 
(6 H, d, J = 16.3 Hz, NCHHCO), 4.41 (6 H, d, J = 16.8 Hz, 
CHHAr), 3.72 (6 H, d, J = 16.3 Hz, NCHHCO). 
13
C-NMR: (100 MHz, CD3CN, mixture of rotamers) δ: 171.7, 
136.8, 129.8 (×3), 128.9, 128.7, 53.2, 50.8. 
4.6.4  Synthesis of 106 
Synthesis of  tosylate ester from 104 
Alcohol 104 (9.61 g, 80 mmol) was mixed with DCM (200 
mL) in a round-bottom flask, and p-toluenesulfonyl chloride 
(18.3 g, 96mmol) and 4-(N,N- dimethylamino)pyridine (80 
mg, 655 mmol) were added to this solution. A reflux 
condenser was attached to the round-bottom flask, and the 
mixture was stirred for 10 min. Anhydrous triethylamine 
(10.5 g, 104 mmol) was added to the reaction mixture 
dropwise over 15 min, and as the stirring was continued, a 
white solid (triethylammonium chloride) precipitated out of 
the reaction mixture. This was accompanied by the liberation 




of heat that caused visible evaporation and condensation of 
dichloromethane from the reaction mixture. The reaction 
mixture was stirred for 12 h, after which it was treated with 
1M HCl (160 mL). The dichloromethane layer was separated 
from the aqueous layer, washed with water, dried over 
anhydrous magnesium sulfate, and evaporated under reduced 
pressure to yield the tosylate ester (21.9 g). This product was  
used in the next step without purification.  
 Tosylate ester from 104 
1
H-NMR: (400 MHz, CDCl3) δ: 7.80–7.32 (30 H, m, ArH), 
4.17 (2 H, t, J = 4.8 Hz, TsOCH2), 3.69 (2 H, t, J = 4.8 Hz, 
TsOCH2CH2), 3.58-3.48 (4H, m, OCH2CH2O), 3.35 (3H, s, 
OCH3), 2.44 (3 H, s, ArCH3). 
Synthesis of  105 
A mixture of tosylate ester from 104, finely powdered 
potassium phthalimide (17.7g, 96 mmol), and DMF (68 mL) 
were combined in a round-bottom flask. The reaction mixture 
was stirred at 80 
°
C under an air condenser for 12 h. Diethyl 
ether was added to the reaction mixture, which was then 
filtered to remove precipitated potassium tosylate. The salt 
was washed with diethyl ether and the washings were 
combined with the filtrate. To remove the solvents, diethyl 
ether was first evaporated under reduced pressure on a rotary 
evaporator. This was followed by vacuum distillation of 
DMF. The residue was purified by column chromatography 




(petroleum ether/AcOEt, from: 85/25 to 45/55) to afford 105 
(15.4 g, 77%). 
 Compound 105 
1
H-NMR: (400 MHz, CDCl3) δ: 7.86-7.70(4H, m, ArH), 3.91 
(2H, t, J = 6.0 Hz,  NCH2), 3.75 (2H, t, J = 6.0 Hz,  
NCH2CH2), 3.66-3.48 (4H, m, OCH2CH2O), 3.31 (3H, s, 
OCH3). 
Formation of amine 106 
The phthalimide 105 (7.26 g, 29 mmol), hydrazine (1.81 mL, 
58 mmol), and ethanol (147 mL) were combined in a round-
bottom flask. The reaction mixture was stirred while being 
refluxed at 76 
°
C for 3 h, during which a white solid 
(phthalhydrazide) was formed in the reaction mixture. Ethanol 
was removed from the reaction mixture by rotary evaporation 
until the precipitate was nearly dry. Cold diethyl ether was 
added to the round-bottom flask, and the amine was extracted 
from the fluffy phthalhydrazide by stirring the mixture over a 
magnetic stir plate. The solution was filtered and the residual 
phthalhydrazide was washed using cold diethyl ether. The 
combined filtrate and washings were evaporated under 
reduced pressure to obtain 106. 
 Compound 106 
1
H-NMR: (400 MHz, CDCl3) δ: 3.61-3.50 (6H, m, 
CH2OCH2CH2O), 2.89 (2H, s, NCH2). 




4.6.5  General procedure for the 
substitution reaction  
To a solution of p-nitrobenzyl bromide (21.5 mg, 0.10 mmol) 
in CHCl3 (0.25 M, 0.200 mL), containing 5 mol% of the 
catalyst, a 0.75 M aqueous solution of thiocyanate salt (0.15 
mmol) was added and the resulting mixture was stirred for up 
to 24 h in total. The reaction was monitored by TLC at 
intervals of 30 min. The mixture was filtered through a 
shortpath silica gel column and removal of the solvent in 
vacuo afforded a residue that was analyzed by 
1
H-NMR to 
determine the % of conversion. 
 Compound 115 
1
H-NMR: (400 MHz, CDCl3) δ: 8.20 (2H, d, J = 8.0 Hz, 
ArH), 7.56 (2H, d, J = 8.0 Hz, ArH), 4.51 (2H, s, CH2). 
 Compound 116 
1
H-NMR: (400 MHz, CDCl3) δ: 8.27 (2H, d, J = 8.0 Hz, 
ArH), 7.56 (2H, d, J = 8.0 Hz, ArH), 4.20 (2H, s, CH2). 
4.6.6  General procedure for the 
enantioselective epoxidation  
To a mixture of trans-chalcone (117) (0.08 mmol) and 
catalyst (5% mol, 0.004 mmol) in toluene (0.8 mL) a 5.5 M 
solution of t-BuOOH in decane (0.096 mmol) and a 50% 
aqueous solution of NaOH (0.2 mL) were added 
subsequently. The mixture was stirred overnight at 0 
°
C. The 
reaction was stopped adding 3 mL of HCl 2 M. The aqueous 
phase was then extracted with DCM (2 x 4 mL). The 




combined organic extracts were dried over Na2SO4. The 
solvent was evaporated and the residue was purified by 
column chromatography (petroleum ether/AcOEt, from: 95/5 
to 90/10) to afford the epoxy ketone 118. The enantiomeric 
eccess was determined by chiral HPLC analysis. The absolute 
configuration was determined by comparison of the HPLC 




 Compound 118 
1
H-NMR: (400 MHz, CDCl3) δ: 8.01 (m, 2H, o-COC6H4H), 
7.63 (m, 1H, p- COC6H4H), 7.49 (m, 2H, m-COC6H4H), 7.45-
7.33 (m, 5H, ArH), 4.30 (d, 1H, J = 1.8 Hz, COCH), 4.08 (d, 
1H, J = 1.8 Hz, PhCH). 
HPLC: DAICEL CHIRALPAK AD-H, tR: 21.3 min (αRβS) 
(minor), tR: 27.8 min (αSβR) (major); conditions: 
hexane:ethanol = 9:1; flow: 1 mL min
−1
, 260 nm. 
4.6.7  General procedure for the 
enantioselective alkylation 
Benzyl bromide (0.096 mmol) was added under a nitrogen 
atmosphere to a mixture of (diphenylmethylene)glycine t-
buthyl ester (78) (23.0 mg, 0.08 mmol) and catalyst (5% mol, 
0.004 mmol) in toluene (0.8 mL). The organic mixture was 
deoxygenated. Then, 50% aqueous NaOH (0.5 mL), 
previously deoxygenated, was added dropwise at 0
°
C and the 
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resulting mixture was stirred overnight at the same 
temperature. The mixture was then poured into water (2.5 
mL) and extracted with DCM (2 x 4 mL). The organic 
extracts were dried over Na2SO4. The solvent was evaporated 
and the residue was purified by column chromatography 
(petroleum ether/AcOEt, from: 98/2 to 95/5) to give the 
benzylation product 79. The enantiomeric eccess was 
determined by chiral HPLC analysis. The absolute 
configuration was determined by comparison of the HPLC 




 Compound 79 
1
H-NMR: (400 MHz, CDCl3) δ: 7.59 (m, 2H, ArH), 7.43-
7.24 (m, 6H, ArH), 7.24-7.14 (m, 3H,  ArH), 7.12-7.02 (m, 
2H, ArH), 6.63 (bd, 2H,  J  = 6.8 Hz, ArH), 4.14 (dd, 1H,  J = 
9.0, 4.5 Hz, NCHCO), 3.26 (dd, 1H,  J = 13.3, 4.5 Hz, 
NCHCHH), 3.18 (dd, 1H, J = 13.3 Hz, 9.0 Hz, NCHCHH), 
1.46 (s, 9H, C(CH3)3). 
13
C-NMR: (75 MHz, CDCl3) δ: 170.8, 170.3, 139.5, 138.3, 
136.3, 130.0, 129.8 (x 2), 128.7 (x 2), 128.1 (x 3), 128.0 (x 2), 
127.9 (x 2), 127.6 (x 2), 126.1, 81.0, 67.9, 39.6,  28.0 (x 3). 
HPLC: DAICEL CHIRALCEL OD-H, tR: 15.3 min (R) 
(major), tR: 25.9 min (S) (minor); conditions: 
hexane:isopropanol = 9:1; flow: 0.5 mL min
−1
, 260 nm. 
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4.6.8  Determination of binding affinities 
for compounds 43, 47, 91, 92, 111 
Association constants Ka were calculated from the equation Ka 
= Ke/Kd, according to methodology reported by Cram and 
coworkers.
51
 Kd values, which represent the distribution 
constants of the picrate salts between water and CHCl3, were 
previously determined by Cram,
51
 while Ke values were 
calculated following the “ultraviolet method” reported by 
Cram and coworkers.
51
 All ultraviolet (UV) measurements 
were made on a Varian Cary 50 UV-Vis Spectrophotometer at 
380 nm at 24–26 °C, using spectrophotometric grade solvents. 
The picrate salts were prepared according to literature 
procedures,
103
 and dried under high vacuum before use. 













) were introduced in six Eppendorf vials, and to each 
of these, 250 μL of a 0.015 M solution of the host in CHCl3 
was added. The vials were capped (in order to prevent 
evaporation) and mixed thoroughly, using a Vortex “Maxi 
Mixer”, for 5 minutes and then centrifuged (1000 rpm). 
Aliquots of 50 μL of each aqueous phase were diluted with 
CH3CN up to 5.0 mL. Successively 200 μL of these solutions 
were diluted with CH3CN up to 1.0 mL. Aliquots of 100 μL 
of each organic phase were also diluted with CH3CN up to 5.0 
mL. Successively 200 μL of the latter solutions were diluted 
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with CH3CN up to 1.0 mL. The absorbance of each sample 
was then measured against the appropriate blank solution at 




4.6.9  Transport studies for compounds 43, 
47, 91, 92 
General procedures    
L-α-phosphatidyl-DL-glycerol sodium salt (EYPG, 20 mg/mL 
chloroform solution) and 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC, 20 mg/mL chloroform solution) were 
purchased from Avanti Polar Lipids; egg yolk 
phosphatidylcholine (EYPC, 100 mg/mL chloroform 
solution), and 8-hydroxypyrene-1,3,6-trisulfonic acid 
trisodium salt (HPTS) were from Sigma; Triton
® 
X-100 and 
HEPES buffer were purchased from Fluka; all salts were of 
the best grade available from Aldrich and were used without 
further purification. Size exclusion chromatography (SEC) 
was performed using pre-packed columns Sephadex
TM 
G-25 
M (PD-10) from Amersham Biosciences. Liposomes were 
prepared by extrusion using a 10 mL Lipex
TM 
Thermobarrel 
EXTRUDER (Northern Lipids Inc.) connected to a 
thermostatic bath (25°C). The 100 nm polycarbonate 
membranes are Nucleopore Track-Etch Membranes from 
Whatman. Fluorescence spectra were recorded on Perkin-
Elmer LS-50B fluorimeter. Fluorimetric experiments were 




conducted at 25°C. The ionophores concentration is given in 
percent with respect to the total concentration of lipids. 
Mother solutions of ionophores were prepared in methanol. 
Control experiments showed that the amount of methanol 
added to the vesicular suspension in the different experiments 
(maximum amount 1.0 % in volume) did not affect the 
permeability of the membrane. 
HPTS assay104 
A mixture of 225 μL of EYPC chloroform solution (100 
mg/mL, 30 μmol) and 60 μL of EYPG chloroform solution 
(20 mg/mL, 1.5 μmol) was first evaporated with Ar-flux to 
form a thin film and then dried under high vacuum for 3 h. 
The lipid cake was hydrated in 1.5 mL of 0.1 mM HPTS 
solution (HEPES 25 mM, 100 mM NaCl, pH 7) for 30 min at 
40°C. The lipid suspension was submitted to 5 freeze-thaw 
cycles (-196°C/40°C) using liquid nitrogen and a thermostatic 
bath, and then extruded under nitrogen pressure (15 bar) at 
room temperature (10 extrusions through a 0.1 μm 
polycarbonate membrane). The LUV suspension was 
separated from extravesicular dye by size exclusion 
chromatography (SEC) (stationary phase: pre-packed column 
Sephadex™ G-25, mobile phase: HEPES buffer) and diluted 
with HEPES buffer to give a stock solution with a lipid 
                                                 
104 S. S. Moore, T. L. Tarnowski, M. Newcomb, D. J. Cram. J. Am. Chem. Soc. 1977, 99, 
6398-6405.  
 




concentration of 5 mM (assuming 100% of lipids were 
incorporated into liposomes). 104 μL of the lipid suspension 
were placed in a fluorimetric cell, diluted to 3040 μL with the 
same buffer solution used for the liposome preparation and 
kept under gently stirring. The total lipid concentration in the 
fluorimetric cell was 0.17 mM. An aliquot of methanolic 
solution of the ionophore (5-30 μL of the appropriate mother 





was then added to the lipid suspension and the cell was 
incubated at 25°C for 30 min. After incubation the time 
course of fluorescence was recorded for 200 s (λ
ex 
= 460 nm, 
λ
em 
= 510 nm) and then 50 μL of 0.5 M NaOH were rapidly 
added through an injector port and the fluorescence emission 
was recorded for 1200 s. Maximal changes in dye emission 
were obtained by final lysis of the liposomes with detergent 
(40 μL of 5% aqueous solution Triton
®
 X-100). Fluorescence 
time courses were normalized using the following equation: 
   
       
       
      
where F
t 
is the fluorescence intensity measured at time t, F
0 
is 
the fluorescence intensity at ionophore addition, F
∞
 is the 
fluorescence intensity at saturation after lysis with Triton. The 
apparent first order rate constants for the transport process 
were obtained by non-linear regression analysis of the 




fluorescence data vs. time. The fit error on the rate constant 
was always less than 1%.   
Determination of sodium selectivity with the 
HPTS assay (Matile’s protocol)94 
The vesicle suspension (104 μL stock solution, prepared as 
described above) was placed in a fluorimetric cell and diluted 
to 3040 μL with the appropriate buffer solution (25 mM 
HEPES, 100 mM NaCl). The total lipid concentration in the 
fluorimetric cell was 0.17 mM. An aliquot of methanolic 
solution of the ionophore (5-30 μL of the appropriate mother 





was then added to the lipid suspension and the cell was 
incubated at 25°C for 30 min. After incubation the time 
course of fluorescence was recorded for 200 s (λ
ex 





510 nm) and then 50 μL of 0.5 M NaOH were rapidly 
added through an injector port and the fluorescence emission 
was recorded for 1200 s. Maximal changes in dye emission 
were obtained by final lysis of the liposomes with detergent 
(40 μL of 5% aqueous solution Triton
® 
X-100). Fluorescence 
time courses were normalized as previously described and 
corrected for the permeation of the sodium cation in the 
absence of ionophore by subtracting the relative fluorescence 
time course.    
 
 






















5 SYNTHETIC STRATEGIES FOR 
KALATA B1 CYCLOTIDE 105 
5.1 Introduction 
The last part of doctorate research project has been 
devoted to novel synthetic strategies for kalata B1 cyclotide 
based on Fmoc/t-Bu solid-phase synthesis, and has been 
realized in the laboratories of the IRB institute in Barcelona 
(SPAIN) under the supervision of Prof. Fernando Albericio 
and Dr. Juan Baptista Blanco-Canosa.  
Cyclotides are cysteine-rich cyclic peptides of vegetal 
origin, characterized by an enzymatic resistant secondary 
structure made up of a special arrangement of disulfide 
bridges, as illustrated in section 1.1.2.
13
 This class of 
molecules represents a promising scaffold in drug design, 
infact it is possible to perform the grafting of small terapeutic 
peptide epitopes into the sequence of the cyclotide in order to 
stabilize them preventing the enzymatic degradation.
15
 
Up to the date the cystine-knot peptides such as 
cyclotides are mainly synthesized with the Boc/Bn protection 
strategy on solid phase employing alkyl thioesther linkers 
located in the C-terminal position.
106
 This strategy is 
hazardous and impracticable in many research laboratories 
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because automated peptide synthesizers compatible with Boc 
chemistry are very expensive (corrosive HF is required for the 
cleavage). The thioester linkers are sensitive to the piperidine 
used in the Fmoc/t-Bu protection strategy and so are fully 
incompatible with this more convenient approach.  
As a consequence recently many efforts have been devoted to 
find out an alternative route for obtaining these kinds of 
compounds. For example, recombinant DNA expression 
techniques have been applied to the biosynthesis of 
cyclotides.
107
 Specifically, recombinant DNA which encodes 
for a certain cyclotide is transplantated in living bacterial 
cells. Indeed, recombinant DNA is expressed and a 
recombinant peptide is produced.  
Moreover, an interesting chemical method makes use of the 
Fmoc/t-Bu strategy.
108
 Particularly, the linear peptide is 
converted in the corresponding thioester with p-
acetamidothiophenol, and finally it is performed the 
cyclization via native chemical ligation and the oxidative 
folding. 
5.2 Fmoc/t-Bu solid-phase synthesis of kalata 
B1: General strategy 
The retrosynthetic analysis of  kalata B1 (figure 5.1) 
allows to identify as suitable initiation point for the synthesis 
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of the linear precursor 128 the valine, located in the very 
flexible loop 6, next to cysteine I.  
CGETCVGGTCNTPGCTCSWPVCTRNGLPV CGETCVGGTCNTPGCTCSWPVCTRNGLPV






Figure 5.1: Retrosynthetic analysis of kalata B1 (10). The initiation point 
for the synthesis is the valine depicted in blue. 
The choice of the specific initiation point is dictated by the 
possibility to perform the cyclization of the linear peptide 
precursor 128 containing a cysteine in the N-terminal position 
through a straightforward native chemical ligation reaction 
and afterwards to form the disulfide bonds. In addition, the 
flexibility of the loop 6 including the initiation point should 
reasonably favour the cyclization process. 
 At this point, in order to better understand the topic it 
is necessary to describe the general mechanism for a native 
chemical ligation (NCL) reaction  (scheme 5.1).
109
 The 
starting material for a native chemical ligation reaction is a 
peptide-thioester which can react with an other peptide 
containing an N-terminal cysteine in order to generate a 
longer peptide or a protein. Alternatively, as shown in scheme 
5.1, a linear peptide reacts intramolecularly with an N-
terminal cysteine forming a cyclopeptide according to a 
multistep proposed mechanism (scheme 5.1). Typically, NCL 
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is conducted in water at neutral pH and an exogenous 
aromatic thiol is added to promote the in situ formation of a 
more active thioesters (step 1 in scheme 5.1) and 
consequently to increase the kinetic of ligation. The added 
thiol also maintains the N-terminal cysteine in reduced form 
and reverses any nonproductive transthioesterification with 
the thiol moieties of side chains of internal cysteine residues. 
The most effective thiol catalysts used for NCL are (4-
carboxymethyl)thiophenol and 4-mercaptophenol (129 and 
130, figure 5.2). 
The second step (scheme 5.1) consists in a 
transthioesterification with the thiol side chain of N-terminal 
cysteine so that a thioester-linked intermediate ligation 
product is formed. Finally, the thioester-linked intermediate 
undergoes spontaneous and irreversible acylation to form a 
















Scheme 5.1: Proposed mechanism for NCL. 
 










                     Figure 5.2: NCL thiol catalysts. 
Returning to the synthesis of kalata B1, the key point 
is the generation of a peptide-thioester making use of the 
Fmoc/t-Bu solid-phase synthesis. In this regard, in 2008 
Blanco and Dawson found an innovative approach for the 
Fmoc/t-Bu synthesis of a peptide-thioester precursor using 3-
Fmoc-4-diaminobenzoic acid (Fmoc-Dbz) as special linker 
(131, figure 5.3), which is synthesized in a single step from 
3,4-diaminobenzoic acid (scheme 5.2).
110
  
This approach is described in scheme 5.3, in the case of a 
generic peptide containing a cysteine in the N-terminal 
position and cyclizable via NCL.  
In detail, Fmoc-Dbz is coupled to the resin and the Fmoc 
group is deprotected with 20% piperidine. Subsequent amino 
acids were coupled by standard Fmoc/t-Bu approach with the 
N-terminal cysteine being introduced as Boc-Cys(Trt)-OH to 
protect the N-terminus of the peptide during subsequent 
acylation and to allow simultaneous deprotection. After the 
chain elongation, the linker is activated through acylation 
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with p-nitrophenylchloroformate followed by the addition of 
DIPEA to promote intramolecular attack of the anilide to 
form the resin-bound benzimidazolinone. The N-acyl-
benzimidazolinone (Nbz) represents an aromatic N-acylurea 
moiety, precursor of a peptide-thioester. Indeed, following the 
cleavage of the peptide, in NCL reaction medium it is formed 
an aromatic thioester which converts in the cyclic molecule 

























Scheme 5.2: Synthesis of linker 131. 
 








































































Scheme 5.3: Fmoc/t-Bu solid-phase synthesis (SPS) of peptide-thioesters 
with Fmoc-Dbz linker. Following SPS, aminoanilide 134 undergoes 
specific acylation and cyclization to yield the resin-bound acylurea peptide 
135. Following cleavage, peptide-Nbz 136 forms an aromatic thioester 
(137) in the NCL reaction medium and it converts in the cyclic peptide 
138. 
The linker Fmoc-Dbz (131) was successfully used by 
Göransson et al. in the Fmoc/t-Bu synthesis of kalata B1.
111
 
Recently, Blanco developed the new linker Fmoc-
Dbz(Me) (132, figure 5.3)
112
, an improved version of the 
linker Fmoc-Dbz, to eliminate acylated or branched 
byproducts arising from the second, free, amine of Dbz, 
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during the synthesis of long glycine-rich peptides, as reported 
by Ottesen and co-workers.
113
  
The second generation linker Fmoc-Dbz(Me) has been 
tested in the Fmoc/t-Bu solid-phase synthesis of kalata B1-
Nbz(Me) (139). Through a NCL step and a following folding 
step (formation of the disulfide bonds) the linear peptide 139 
is converted in the final product kalata B1(10), as shown in 
scheme 5.4.  
The use of an interposed glycine between the resin and 
the linker to increase its loading with respect to the direct 


















Scheme 5.4: General strategy for Fmoc/t-Bu solid-phase synthesis of 
kalata B1-Nbz(Me) (139). Kalata B1(10) is formed through the two 
following step of NCL and folding. 
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5.3 Aims of the work 
Following the general Fmoc/t-Bu strategy, described 
in scheme 5.4, kalata B1 synthesis was investigated 
considering four different synthetic modifications: 
a) Solid-phase synthesis with ChemMatrix rink amide resin 
(0.52 mmol/g); 
b) Solid-phase synthesis making use of the O-acyl 
isodipeptide unit Boc-Thr(Fmoc-Gly)-OH (140, figure 5.4) in 
place of the TG dipeptide sequence, and with ChemMatrix 
rink amide resin (0.52 mmol/g); 
c)  Solid-phase synthesis with the commercial pseudo-proline 
dipeptide Fmoc-Gly-Thr(ψ(Me,Me)pro)-OH (141, figure 5.4) 
in place of the TG dipeptide sequence, and with a 
ChemMatrix rink amide resin (0.52 mmol/g); 
d) Solid-phase synthesis with Boc-Thr(Fmoc-Gly)-OH (141, 
figure 5.4) and making use of a Tentagel SH resin (0.29 
mmol/g).  
The four different methodologies a-d were compared 
taking into account the purity of kalata B1-Nbz(Me) obtained 
(139) (section 5.4). 
 



















Figure 5.4: Building-block dipeptides incorporated in the backbone of 
kalata B1-Nbz(Me) (139) instead of the TG dipeptide sequence, in the 




























Scheme 5.5: Three-step synthesis of the O-acyl isodipeptide 140. 
Specifically, we employed two different resins: a 
ChemMatrix resin, made up of crosslinked PEG and 
characterized by a high chemical and thermal stability along 
with an excellent degree of swelling in DCM, DMF compared 
to polystyrene based resins; a tentagel resin which is a PEG 
hybrid polystyrene resin containing a core of polystyrene on 




which are attached long chains of PEG. Both the resins are 
suitable for synthesizing long peptides such as kalata B1. 
The use of  the O-acyl isodipeptide unit 140, 
synthesized according to a three step sequence (scheme 5.5) 
as described in literature
114
, and of the pseudo-proline unit 
141 is explained as follows. 
The synthesis of long or difficult-sequence containing 
peptides is a challenging task because these kind of peptides 
are often obtained in a low synthetic yield and purity on solid-
phase. This is usually due to aggregation phenomena in 
solvent during synthesis caused by inter-/intramolecular 
hydrophobic interactions and the hydrogen bond network 
among resin-bound peptide chains, resulting in the formation 
of extended secondary structures such as β-sheets. To solve 
this problem, it is possible to make use of the Boc/Bn 
approach in which the deprotection step in acidic conditions 
generates repulsing protonate chains. Alternatively, in the 
Fmoc/t-Bu approach pseudo-proline building blocks can be 
used, which are dipeptide derivatives containing Ser/Thr-
derived oxazolidines or Cys-derived thiazolidines. These 
building blocks are able to disrupt the secondary structure of 
the peptide and are converted in the regular dipeptide 
sequence during the cleavage. 
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Another building block recently discovered is the O-acyl 
isodipeptide, which allows to synthesize peptides with very 
difficult sequences. Specifically, the presence of an O-acyl 
instead of N-acyl residue within the peptide backbone 
significantly changes the secondary structure of the native 
peptide. Moreover, the target peptide is subsequently 
generated by an O–N intramolecular acyl migration reaction 
at neutral pH (scheme 5.6).
114
  
 In the case of the methodologies b-d the dipeptide 
building blocks as TG dipeptides of pseudo-proline (141 in 
synthesis c) and O-acyl nature (140 in synthesis b, d) only in 
the terminal region of the linear peptide 139 were 
incorporated due to the fact that in the first 20 aminoacid 



















Scheme 5.6: O–N intramolecular acyl migration reaction of O-acyl 
isopeptides. 
5.4 Comparation of the methodologies a-d 
We compared  the methodologies a-d, used for the 
Fmoc/t-Bu synthesis of  kalata B1-Nbz(Me) (139) on the 
basis of its relative purity obtained. The relative purities were 




calculated from integration of the HPLC trace at 220 nm, 
considering only peptidic peaks. Hereafter analytic HPLC 
chromatograms are illustrated.  
 
Figure 5.5: Analytic chromatogram of kalata B1-Nbz(Me) crude (139) in 
the case of the synthesis a. The relative purity is 56.99%. tR = 15.39 min; 
conditions: 0 → 70% acetonitrile in 30 minutes (A: 0.1% TFA in water, B: 
0.1% TFA in acetonitrile), flow: 1.0 ml/min, 220 nm, column: C18 
XBridge, 4.6 x 150 mm, 5 µm. 
 
Figure 5.6: Analytic chromatogram of kalata B1-Nbz(Me) crude (139) in 
the case of the synthesis b. There are two peaks with the mass of 139 
(ESI-MS determination) corresponding to the native sequence and to the 
sequence containing 140. The relative purity calculated as sum of the two 
peaks is 62.87% (32.38% + 37.49%). tR = 15.06 min, 15.40 min; 
conditions: 0 → 70% acetonitrile in 30 minutes (A: 0.1% TFA in water, B: 
0.1% TFA in acetonitrile), flow: 1.0 ml/min, 220 nm, column: C18 
Xbridge, 4.6 x 150 mm, 5 µm. 





Figure 5.7: Analytic chromatogram of kalata B1-Nbz(Me) crude (139) in 
the case of the synthesis c. The relative purity is 55.56%. tR = 15.40 min; 
conditions: 0 → 70% acetonitrile in 30 minutes (A: 0.1% TFA in water, B: 
0.1% TFA in acetonitrile), flow: 1.0 ml/min, 220 nm, column: C18 
Xbridge, 4.6 x 150 mm, 5 µm. 
 
 
Figure 5.8: Analytic chromatogram of kalata B1-Nbz(Me) crude (139) in 
the case of the synthesis d. There are two peaks with the mass of 139 
(ESI-MS determination) corresponding to the native sequence and to the 
sequence containing 140. The relative purity calculated as sum of the two 
peaks is 56.40% (37.63% + 37.54%).   tR = 15.08 min, 15.41 min; 
conditions: 0 → 70% acetonitrile in 30 minutes (A: 0.1% TFA in water, B: 
0.1% TFA in acetonitrile), flow: 1.0 ml/min, 220 nm, column: C18 
Xbridge, 4.6 x 150 mm, 5 µm. 
 
The above HPLC chromatograms are discussed as 
follows. 




First of all, in addition to the peak of kalata B1-Nbz(Me) 
(139) are observed some secondary peaks corresponding in 
ESI-MS analysis to M+57 uma, M+44 uma, M-18 uma (M is 
the mass of 139). The peak at mass M+57 uma derives from 
the addition of a t-Bu aminoacid protecting group on a 
cysteine or a tryptophan of the peptide backbone. Moreover, 
the peak at mass M+44 uma is attributed to the peptide 
containing an N-carboxylated indole originated from 
(Boc)Trp during the cleavage.
115
 The conversion of the N-
carboxylated indole in the free indole is slow so it is detected 
also the N-carboxylated compound (scheme 5.7).
115
 The last 
peak at M-18 uma is ascribable to the aspartimide formation 
from an asparagine close to a glycine of the sequence (scheme 
5.8). Aspartimide formation is a very common side reaction in 
peptide synthesis, and it is caused in Fmoc/t-Bu solid-phase 
synthesis by the repetitive piperidine treatments.
116
 In 
addition, the deamidation reaction to aspartimide is more 
rapid if the susceptible amino acid (Asp, Asn) is followed by 
a small, flexible residue such as glycine. 
Interestingly, in the case of the synthesis b and d, in 
the HPLC chromatogram are present two peaks with the mass 
of 139 (ESI-MS determination) corresponding respectively to 
the native sequence and to the sequence containing the O-acyl 
isopeptide 140. This happens because the O–N intramolecular 
                                                 
115 A. Isidro-Llobet, M. Alvarez, F. Albericio Chem. Rev., 2009, 109, 2455-2504. 
116 M. Mergler, F. Dick, B. Sax, P. Weiler, T. Vorherr J. Peptide Sci, 2003, 9, 36-46. 




acyl migration reaction of O-acyl isopeptides seems to be 
slow. 
In table 5.1 are reported the relative purities of 139 
obtained with the synthesis a-d performed. From these results 
it is possible to infer that the best purity (62.87%) is reached 
with the synthesis b in which ChemMatrix resin and the O-
acyl isodipeptide 140 are used. In addition, comparing the 
purities obtained with the synthesis b and d, ChemMatrix 



















     
Scheme 5.7: Conversion of (Boc)Trp to the N-carboxylated species in acid 



































Table 5.1: Purities of 139 obtained with the synthesis a-d. 
 






5.5 Cyclization via NCL of kalata B1-
Nbz(Me)  
After the Fmoc/t-Bu synthesis of  kalata B1-Nbz(Me) 
(139), the next step, according to the synthetic scheme 5.4, is 
the cyclization of 139 via a NCL reaction. 
We tried to purify 139 with a C18 semipreparative column 
(C18 X Bridge, 5 µm × 19mm × 150 mm), but, due to the 
hydrophobic nature of the peptide, a purification yield of only 
30% was experimented. So, we decided to perform the 
following cyclization reaction on 139 crude.  
In scheme 5.9 it is reported the cyclization reaction carried 
out on compound 139. It was conducted at pH 7-7.2 in high 
dilution conditions under nitrogen and making use of 4-
mercaptophenol (130) as catalyst, which is less expensive 
than (4-carboxymethyl)thiophenol (129), tris(2-
carboxyethyl)phosphine to prevent the oxidation of the thiole, 
and a phosphate buffer containing guanidinium 
hydrochloride. This last is a typic denaturing agent which is 
able to break a preferential conformation of the linear peptides 




generating a mixture of rotamers, some of which are prone to 
the reaction. The pH must be neutral due to the fact that at 
basic pH the thiole oxidation is more favourite and at low pH 
the terminal amine could be protonated and the reaction could 
not occur.   
The reaction mixture was purified making use of a C4 
semipreparative column (C18 Symmetry 300, 5 µm × 10 mm × 











Scheme 5.9: Cyclization via NCL of the linear peptide 139. The ligation 
buffer is a phosphate buffer containing guanidinium hydrochloride. 
5.6 Folding of  kalata B1  
  A folding reaction of kalata B1 in reduced form (147) 
was required to obtain kalata B1 (10). We successfully 
performed a test reaction on 147 but unfortunately there was 
not a sufficient quantity of 147 to scale up the reaction. As 
shown in scheme 5.10, the compound 147 was oxidized at pH 
8.5 using a specific folding buffer (50% v/v isopropyl alcohol 
in ammonium bicarbonate solution) in presence of reduced 







The final molecule (10) was obtained with 100% relative 
purity (HPLC analysis) and was analyzed via Maldi-TOF 
confirming the formation of the three disulfide bonds.  Due to 
the very small amount it was not possible to register the NMR 
spectrum. In absence of NMR data it is not possible to verify 
whether the connectivity of the three disulfide bonds in the 
synthesized cyclotide 10 is the same of the native kalata B1. 
Anyway, Craik reported that carrying out a reductive 
defolding of the native kalata B1 and subsequently an 
oxidative refolding in the conditions before reported, only the 
highly stable native structure was observed.
118
 So, it is 
reasonable to affirm that the synthesis of kalata B1 with an 

















Scheme 5.10: Folding of kalata B1 in reduced form (147). The folding 
buffer is 50% v/v isopropyl alcohol in ammonium bicarbonate solution. 
                                                 
117 N. L. Daly, R. J. Clark, D. J. Craik J. Biol. Chem., 2003, 278, 6314-6322.  
118 N. L. Daly, S. Love, P. F. Alewood, D. J. Craik, Biochemistry, 1999,  38, 10606–10614. 





In this chapter, the synthesis of kalata B1 linear 
precursor (139) with four different approaches (a-d), 
according to the innovative Fmoc/t-Bu strategy for the 
generation of peptide-thioesters, was reported. The best one 
revealed to be the synthesis b performed with the O-acyl 
isodipeptide unit (Boc-Thr(Fmoc-Gly)-OH) (140) on 
ChemMatrix rink amide resin. 
In addition, the synthesis of kalata B1 in reduced form (147) 
was successfully performed using a NCL reaction. 
Finally, a test folding reaction on 1mg of 147 produced kalata 
B1 (10) with 100% relative purity (HPLC analysis). The 
formation of the three disulfide bonds was confirmed via 
Maldi-TOF.  
5.8 Experimental section   
5.8.1 General procedures 
Reagents purchased from commercial sources were used 
without further purification. All reactions involving air or 
moisture sensitive reagents were carried out under a dry argon 
atmosphere. CH2Cl2 was distilled from CaH2. Glassware was 
flame-dried (0.05 Torr) prior to use. When necessary, 
compounds were dried in vacuo over P2O5 or by azeotropic 
removal of water with toluene under reduced pressure. 
Starting materials and reagents purchased from commercial 




suppliers were generally used without purification. Reactions 
were monitored by TLC on silica gel plates (0.25 mm) and 
visualized by UV light or by spraying with  ninhydrin 
solutions or drying with iodine. Flash chromatography was 
performed on Silica Gel 60 (particle size: 0.040–0.063 mm) 
and the solvents employed were of analytical grade. 
Analytical HPLC was performed on a Waters instrument 
comprising a Waters 2695 (Waters, MA, USA) separation 
module, an automatic injector, a photodiode array detector 
(Waters 996 or Waters 2998), and a Millenium
32
 login system 
controller. The columns used were a Sunfire
TM
 C18 reversed-
phase analytical column (3.5 μm × 4.6 mm × 100 mm) with 
linear gradients of ACN (0.036% TFA) into H2O (0.045% 
TFA) over 8 min or a Xbridge
TM
 C18 reversed-phase 
analytical column (5 μm × 4.6 mm × 150 mm) with linear 
gradients over 30 min. UV detection was at 220 and 254 nm 
and the system was run at a flow rate of 1.0 mL/min. Semi-
preparative RP-HPLC was carried out on a Waters instrument 
comprising two solvent delivery pumps (Waters Delta 600), 
an automatic injector (Waters 2700 Sample Manager), a 
Waters 2487 dual wavelength absorbance detector, an 
automatic sample collector (Waters Fraction Collector II), a 
Masslynx v3.5 system controller and two different columns, 
obtained also from Waters: a Xbridge
TM 
BEH OBD C18 
reversed-phase column (8.5 μm × 19 mm × 150 mm) and a 
Symmetry300
TM
 C4 reversed-phase column (5 μm × 10 mm × 
150 mm). Linear gradients of ACN (0.5% TFA) into H2O (1% 




TFA) with flow rates of 15 mL/min or 6 mL/min were used. 
HPLC-MS analysis was performed on a Waters instrument 
comprising a separation module (Waters 2695), an automatic 
injector, a photodiode array detector (Waters 2998), a Waters 
micromass ZQ spectrometer and a Masslynx v4.1 system 
controller. The column used was a Sunfire C18 reversed-
phase analytical column (3.5 μm × 2.1 mm × 100 mm). 
Ultraviolet detection was at 220 and 254 nm, and linear 
gradients of ACN (0.07%  formic acid) into H2O (0.1% 
formic acid) were run at 0.8 mL/min over 8 min. Mass spectra 
were recorded on a MALDI-TOF Applied Biosystem 4700 
with a N2 laser of 337 nm using SA matrix [10 mg/mL of SA 
in ACN−H2O−TFA (1:1:0.1)]. Sample preparation: a mixture 
of sample solution (1 μL) and matrix (1 μL) is prepared, 
placed on a MALDI-TOF plate and dried by air. Yields refer 





NMR) pure materials.  















C at 75.5 MHz) spectrometers. Chemical shifts 
(δ) are reported in ppm relatively to the residual solvent peak 
(CHCl3, δ = 7.26, 
13
CDCl3, δ: = 77.0; CD2HCN: δ = 1.98; 
13
CD3CN: δ = 1.80, in the case of solvent mixtures, the 
considered residual peak was that of the most abundant 
deuterated solvent). The multiplicity of each signal is 
designated by the following abbreviations: s, singlet; d, 




doublet; t, triplet; q, quartet; m, multiplet; b, broad. Coupling 
costants (J) are quoted in Hz. 
5.8.2  Synthesis of  140  
Synthesis of  143 
Benzyl bromide (7.5 ml, 63 mmol) was added to a stirring 
solution of N-(t-butoxycarbonyl)-L-threonine (3.0 g, 14 
mmol) and potassium carbonate (1.9 g, 14 mmol) in DMF (91 
ml). The resulting mixture was stirred at room temperature 
overnight, concentrated in vacuo, diluted with AcOEt and 
washed successively with water (×2), brine. The organic layer 
was dried over Na2SO4 and the solvent was removed in 
vacuo. The resulting oil was purified by silica gel column 
chromatography (hexane/AcOEt, from: 98/2 to 7/3) to yield 
143 (2.7 g, 57 %). 
 Compound 143 
HPLC: tR: 6.8 min; conditions: 0 → 100% B in 8 min (A, 
0.036% TFA in water, B, 0.045 % TFA in acetonitrile); 
Sunfire
TM
 C18 reversed-phase analytical column (3.5 μm × 4.6 
mm × 100 mm); flow: 1 mL min
−1
, 220 nm. 
ES-MS:  310.0 m/z [M+H
+
]. 
Synthesis of  144 
EDC.HCl (1.15 g, 6.0 mmol) was added to a stirred solution 
of  143 (1.7 g, 5.0 mmol), Fmoc-L-glycine (1.8 g, 6.0 mmol), 
and DMAP (122 mg, 1.0 mmol) in DCM (50 ml) at 0 
°
C. The 




mixture was slowly warmed to room temperature over 2h, 
stirred additionally overnight, diluted with EtOAc, and 
washed with water, 1 M HCl, water, saturated NaHCO3 and 
brine. The organic layer was dried over Na2SO4 and the 
solvent was removed in vacuo. The resulting oil was purified 
by silica gel column chromatography (hexane/AcOEt, from 
98/2 to 6/4) affording 144 (2.3 g, 80 %).  
 Compound 144 
HPLC: tR: 9.1 min; conditions: 0 → 100% B in 8 min (A, 
0.036% TFA in water, B, 0.045 % TFA in acetonitrile); 
Sunfire
TM
 C18 reversed-phase analytical column (3.5 μm × 4.6 
mm × 100 mm); flow: 1 mL min
−1
, 220 nm. 




Pd/C (210 mg) was added to a stirring solution of  144 (2.2 g, 
3.7 mmol) in EtOAc (80 mL), and the reaction mixture was 
vigorously stirred under a hydrogen atmosphere overnight. 
The catalyst was filtered off through celite. The solvent was 
removed in vacuo and the crude product was purified by silica 
gel column cromatography, at first with hexane:AcOEt 2:1 
and then the final product was washed out by methanol to 
give pure 140 (1.3 g, 70 %). 
 Compound 140 
1
H-NMR: (300 MHz, CDCl3) δ: 7.76-7.30 (8H, m, ArH), 
5.56 (1H, m, CHOCO), 5.45 (1H, m, NH), 5.27 (1H, m, NH), 
4.51 (1H, m, CHNHBoc), 4.39 (2H, d,  J = 6.8 Hz, 




CH2Fmoc), 4.21 (2H, t, J = 6.8 Hz, CHFmoc), 3.94 (2H, m, 
CH2NHFmoc), 1.45 (9H, s, C(CH3)3), 1.34 (3H, d, J = 6.2 Hz, 
CH3). 
HPLC: tR: 7.6 min; conditions: 0 → 100% B in 8 min (A, 
0.036% TFA in water, B, 0.045 % TFA in acetonitrile); 
Sunfire
TM
 C18 reversed-phase analytical column (3.5 μm × 4.6 
mm × 100 mm); flow: 1 mL min
−1
, 220 nm. 
ES-MS: 399.08 m/z [(M-Boc)+H
+
]. 
5.8.3  Solid phase synthesis of kalata B1-
Nbz(Me) 
For the synthesis of kalata B1-Nbz(Me) (139) two different 
resins were used: PCAS H-Rink-amide ChemMatrix 0.52 
mmol/g, Ernst- Simon Tentagel SNH2 0.48 mmol/g. Fmoc 
aminoacids and the dipeptide Fmoc-Gly-Thr(ψ(Me,Me)pro)-
OH (141) were purchased from Iris-Biotech. The linker 
Fmoc-Dbz(Me) (132) was previously synthesized in 
Albericio’s laboratory. Fmoc aminoacids used were: Fmoc-
Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Trt)-OH, 
Fmoc-Glu(Ot-Bu), Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Pro-
OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-
Trp(Boc)-OH, Fmoc-Val-OH. The valine next to cysteine in 
loop 6 was selected as the suitable initiation point for the 
synthesis.   
General protocol. Synthesis were performed manually on a 
0.05 mmol scale.  




In the case of H-Rink-amide ChemMatrix resin washings with 
DCM 1% TFA, DMF 1% TFA, DMF were previously 
performed in order to remove residues of free amine. 
Aminoacids were coupled using a 10-fold excess (0.50 
mmol). A solution of HBTU 0.5 M (0.50 mmol, 190 mg) in 
DMF (1mL) was added to the Fmoc protected aminoacid, 
then was added DIPEA (0.55 mmol, 95 µl) and the aminoacid 
was activated for 30 sec prior the coupling. The resin was 
bubbled with N2. A single treatment of 1 h was used for the 
first three residues of the sequence (Gly, Dbz(Me), Val) and a 
double treatment of 1 h for the following residues. Dipeptides 
141, 142 were coupled using a 5-fold excess (0.25 mmol), a 
solution 0.5 M of HATU (0.25 mmol, 95 mg)  in DMF (1mL) 
containing DIPEA (0.3 mmol, 52 µl)  respectively for 1h and 
2h. Boc-Cys(Trt)-OH was used in the final coupling step. The 
Fmoc group was deprotected with 20% piperidine/DMF (v/v, 
1 mL) for 10 min. Couplings were checked using the 
ninhidrin test. 
The resin was washed with DMF (6 × 1 mL) at the end of 
each coupling. After peptide elongation, the resin was washed 
with DCM and p-nitrochloroformate solution (101 mg, 
0.5mmol, 0.5 M in DCM) was added. The resin was bubbled 
with N2 for 2 h. Then, it was washed with DCM and treated 
with DIPEA 0.5 M (436 µl) in DMF (2.5 mL) for 1 h and, 
finally, washed with DMF and DCM. The peptidyl-resin was 
dried under vacuum and the peptide was cleaved from the 
resin in the case of methodologies b-d with the reagent 




cocktail: 92.5% TFA, 2.5% H2O, 2.5% EDT, 2.5% 1,2-
dimethyl indole (2.5 mL) for 1.30 h. In the case of 
methodology a, the following reagent cocktail was used: 94% 
TFA, 2.5% H2O, 2.5% EDT, 1% TIS (2.5 mL) for 1.30 h . 
The TFA solution containing the peptide was concentrated 
under vacuum to a minimal volume, added over cold Et2O 
and precipitated by centrifugation. The supernatant was 
removed and the residue was dissolved in 20 mL of 
ACN/H2O (1:1) 0.045% TFA (HPLC buffer) and lyophilized.  
 Compound 139 
Calculation of yield for methodology a 
Resin substitution value: 0.52 mmol /g. 
Synthesis scale: 0.05 mmol. 
Peptide molecular weight = 3150 g/mol. 
Peptide weight: 40 mg. 
% yield : 25%. 
Peptide weight for methodologies b-d  
Crude peptide weight for methodology b: 147 mg. 
Crude peptide weight for methodology c: 160 mg. 
Crude peptide weight for methodology d: 150 mg. 
Crude peptides contained 1,2-dimethyl indole.   
Relative purity for methodologies a-d 
HPLC purities were calculated from integration of the trace at 
220 nm. Analytical HPLC chromatograms are illustrated in 
section 5.4. 
Relative purity for methodology a: 57.0%. 




Relative purity for methodology b: 62.9%. 
Relative purity for methodology c: 55.6%. 
Relative purity for methodology d: 56.4%. 
Purification via RP-HPLC 
The purification of the crude peptide via RP-HPLC on a C18 
reversed-phase semi-preparative column (Xbridge
TM 
BEH 
OBD C18 reversed-phase column (8.5 μm × 19 mm × 150 
mm)) was performed with 10% yield. tR: 37.4 min.; 
conditions: 5 → 70% B in 80 min (A: 0.05% TFA in water, 
B: 0.1% TFA in acetonitrile), degassing (helium): 30 
mL/min, flow: 15 mL min
−1
, 220 nm.  
ES-MS: 1050.9 m/3z [M+3H
+
]. 
HPLC: tR: 15.4 min (methodology a), 15.1 min (methodology 
b), 15.4 min (methodology c), 15.1 min (methodology d); 
conditions: 0 → 70% B in 30 min (A, 0.036% TFA in water, 
B, 0.045 % TFA in acetonitrile); Xbridge
TM
 C18 reversed-
phase analytical column (5 μm × 4.6 mm × 150 mm); flow: 1 
mL min
−1
, 220 nm. 
5.8.4  Cyclization by NCL of kalata B1-
Nbz(Me)  
A “one pot” buffer for peptide cyclization/ligation was 
prepared using 50 mM of 4-mercaptophenol, 20 mM of tris(2-
carboxyethyl)phosphine hydrochloride (TCEP.HCl) and 6 M 
guanidinium hydrochloride in a 200 mM phosphate buffer. 
The pH was adjusted to be between pH 7.0-7.2. Buffer was 
degassed under N2 for 15 min before the reaction.  Kalata B1-




Nbz(Me) (0.8 µM, 13.5 mg) was incubated in 5 ml of the 
“one pot” buffer overnight. Later, the reaction mixture was 
purified via RP-HPLC to afford 147 (37%, 4.4 mg).  
  Compound 147 
The crude residue was purified by RP-HPLC on a C4 
reversed-phase semi-preparative column (Symmetry300
TM
 
C4 reversed-phase column (5 μm × 10 mm × 150 mm)). tR: 
32.0 min.; conditions: 5 → 70% B in 80 min (A: 0.05% 
TFA in water, B: 0.1% TFA in acetonitrile), degassing 
(helium): 30 mL/min,  flow: 6 mL min
−1
, 220 nm. 
MALDI-TOF: 2898.0 uma. 
HPLC: tR: 15.7 min; conditions: 0 → 70% B in 30 min (A, 
0.036% TFA in water, B, 0.045 % TFA in acetonitrile); 
Xbridge
TM
 C18 reversed-phase analytical column (5 μm × 4.6 
mm × 150 mm); flow: 1 mL min
−1
, 220 nm. 
5.8.5  Folding of kalata B1 
Oxidative folding reaction of 147 (1 mg) was performed at 
room temperature overnight in 50% isopropyl alcohol (v/v) in 
0.1 M ammonium bicarbonate, pH 8.5 and 1 mM reduced 
glutathione. 
 Compound 10 
MALDI-TOF: 2892.0 uma. 
HPLC: tR: 18.9 min; conditions: 0 → 70% B in 30 min (A, 
0.036% TFA in water, B, 0.045 % TFA in acetonitrile); 






 C18 reversed-phase analytical column (5 μm × 4.6 
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